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I. PREFACE 
  
  
Preface 
 
Changing type 1 diabetes natural clinical history 
 
 
Type 1 diabetes mellitus is an autoimmune chronic disease that has undergone 
drastic changes on its clinical natural history in the last decades. 
 
Until the early XX century, the diagnosis of diabetes would mean a fatal 
outcome in few weeks or months. The evidence of hyperglycemia associated 
with abrupt polyuria, polydipsia, polyphagia and weight loss in a child or a 
young person determined a diagnosis of failure of insulin secretion, metabolic 
catabolism and death.  
 
The introduction of treatments with exogenous insulin was the first important 
change in the natural clinical history of diabetes. Subjects affected by diabetes 
experienced then a hope of treatment and life. The main initial concern of 
physicians and scientists was to avoid important episodes of hypo or 
hyperglycemia, which could lead to hypoglycemic coma or diabetic 
ketoacidosis. Different classes of insulins were tested and used with success, 
offering better life expectancy for the affected persons. 
 
In parallel with the provided increase of life expectancy, chronic complications 
related to diabetes were prone to appear. Those patients who, at that moment, 
benefit from the exogenous insulin, but maintained many episodes of 
hyperglycemia and glycemia fluctuations, developed chronic complications 
leading to blindness, renal failure, limbs amputations and/or cardiovascular 
complications as heart attack or stroke.  
 
Aware of the consequences of hyperglycemia, researchers started to design 
studies promoting a more strict control of glucose levels, with the intention of 
minimizing chronic complications related to diabetes. Studies for type 1 
diabetes (T1D) like DCCT, published in 1993 (The Diabetes Control and 
Complications Trial Research Group, 1993) and its follow-up EDIC (Nathan et 
al., 2005), and others alike for type 2 diabetes (T2D) (UK Prospective Diabetes 
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Study, UKPDS Group 1998), proved the reduction of complications rates and 
marked a new change in the natural clinical history of diabetes. 
 
Recently, tighter glycemic control became possible with the help of new 
insulins, insulin infusers, glucose sensors and nutrition research. The incidence 
of retinopathy, nephropathy, neuropathy and their consequent serious 
outcomes as blindness, end renal stage disease and lower limb amputations, 
reduced in the past two decades, as described in the US patients with diabetes 
(Gregg et al., 2014). The excess risk of mortality in individuals over 20 years old 
with diabetes (T1D and T2D) if compared with the risk of individuals without 
diabetes has decreased over time in both Canada and the UK, as shown in data 
recently published (M Lind et al., 2013). This may be, in part, due to the earlier 
diagnosis, as well as to improvements in diabetes care (M Lind et al., 2013). In 
patients with T1D, a reduction of all-cause mortality and also of specific 
cardiovascular mortality could be verified, especially if associated with a good 
glycemic control; these rates, nevertheless, are still the double of the ones seen 
in subjects without diabetes (Marcus Lind et al., 2014). 
 
Physical activity is considered as a health promoter procedure for general 
population and a therapeutic tool for prevention and/or treatment of several 
chronic diseases, like T2D, cardiovascular disease or cancer. Persons with T1D 
are stimulated to participate in exercise training programs and competition 
events. Nowadays, with the current knowledge, several elite athletes with T1D 
are able to compete in the same categories that the ones without diabetes, but 
requiring for that a strict balance among insulin adjustments, carbohydrate 
intake and physical activity characteristics.  
 
Many questions may be formulated at the present time: are persons with T1D 
being beneficiated from physical activity as persons without diabetes? Do the 
subjects with T1D present the same physical conditions for exercise 
performance than the non-diabetic ones? Do they present different metabolic 
response when performing a session of exercise? Does physical activity 
improve lipoprotein profile generating cardiovascular benefits for the subjects 
with T1D? What are the characteristics of muscular composition of patients with 
4
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T1D, and are they different from subjects without diabetes? What are the 
factors that could be interfering? 
 
These questions are discussed in the present thesis. Some answers were 
achieved and some other questions emerged. Nowadays, the availability of new 
technological approaches, the improvements on basic research, and the 
possibility to integrate the information of basic research with clinical research 
are improving the knowledge in biomedical science. A better understanding of 
physiopathology can be obtained, and with it, a better care, a better quality of 
life, and longer life expectancy can be offered to persons who have type 1 
diabetes.   
5
 
  
 
 
 
 
II. INTRODUCTION 
  
  
Introduction 
 
 
 
 
1. Diabetes mellitus 
 
 
1.1. Definitions and epidemiology  
 
Diabetes is a group of metabolic diseases characterized by hyperglycemia 
resulting from defects in insulin secretion, insulin action, or both. The chronic 
hyperglycemia of diabetes is associated with long-term damage, dysfunction, 
and failure of different organs, especially the eyes, kidneys, nerves, heart, and 
blood vessels (American Diabetes Association, 2014a). Type 2 diabetes (T2D) 
is the more prevalent type of diabetes, and presents a worldwide increasing 
incidence associated with rising rates of obesity and with the worsening of 
lifestyle, which comprises diet habits and sedentary lifestyle (International 
Diabetes Federation, 2013). Type 2 diabetes is characterized by different 
degrees of insulin resistance with relative insulin deficiency. Many different 
countries are suffering the increasing incidence of this type of diabetes, in which 
the prevalence rates can reach, for example, 12.3% in U.S.A. population 
(National Center for Chronic Disease Prevention and Health Promotion, 2014) 
or more than 20% in some Western Pacific Islands (International Diabetes 
Federation, 2013). The differences on these rates depend on ethnology, weight 
changes and lifestyle (Figure 1). 
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
 
Figure 1: IDF (International Diabetes Federation) Diabetes Atlas of global diabetes 
prevalence. Sixth edition – 2014 update (Mena, Sea, & Lucia, 2014).  
 
In Spain, the Di@abet.es Study (Soriguer et al., 2012) provided actualized data 
of prevalence of diabetes in people 18 years old and older. The Di@bet.es 
Study was a national, cross-sectional, population-based survey conducted 
during 2009–2010. The study identified that approximately 13.8% of the 
population had diabetes (7.8% with known and 6% with unknown diabetes) and 
14.8% had prediabetes, counting for a total of 28.6% of the studied population 
with some carbohydrate metabolic disturbance (Figure 2). A previous review 
study in 2007 (Valdés, Rojo-Martínez, & Soriguer, 2007), established that the 
prevalence in Spain was between 10 and 15%. That data was obtained from 
different regional registers and counted with different diagnostic criteria. Even 
then, the authors called attention to the increase in diabetes prevalence that 
was taking place over the years.  
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Figure 2: Official slide from diabetes prevalence in Spain from Di@bet.es Study. IFG: 
impaired fasting glucose. IGT: impaired glucose intolerance. IC: confidence interval (Soriguer et 
al., 2012) 
 
Some other specific and less frequent types of diabetes are genetic defects of 
β-cell function (like maturity onset diabetes of young, or MODY); genetic defects 
of insulin action, like specific resistance pathologies; disease of exocrine 
pancreas, as chronic pancreatitis; some endocrinopathies, like Cushing 
Syndrome or acromegaly; drugs, like glucocorticoids; or a particular population 
that presents diabetes during gestation (gestational diabetes). 
 
The second more prevalent type of diabetes is the type 1 diabetes (T1D). 
According to American Diabetes Association (ADA) 2015’s statement (American 
Diabetes Association, 2015b), it accounts for 5–10% of all types of diabetes. 
This type of diabetes was previously encompassed by the terms insulin-
dependent diabetes or juvenile-onset diabetes, due to the usual onset on early 
ages and early insulin requirements. It is a result of a cellular-mediated 
autoimmune destruction of the β-cells of the pancreas. The usual markers of 
Di@bet.es Study
1,7-2,7%2,2%IFG + IGT
8,2-10,2%9,2%Impaired glucose tolerance (IGT)
2,9-4%3,4%Impaired fasting glucose (IFG)
5,4-6,7%6%DM unknown
6,97- 8,59% 7,8%DM known
12,8-14,7%13,8%Total Diabetes Mellitus (DM)
IC 95%Prevalence
Source: Prevalence of diabetes mellitus and impaired glucose regulation in Spain: the Di@bet.es Study, Diabetologia (2011)
Study supported by CIBER in Diabetes and Associated Metabolic Disorders-CIBERDEM (ISCIII, Ministry of Science and Innovation, 
Spain) and Spanish Society of Diabetes-SED. More information www.ciberdem.org/estudiodiabetes
Almost 30% of the study population have some carbohydrate metabolism disturbances:
Spain: 5 field work regions
5,072 participants
aged > 18 years
100 clusters
(health centres or
the equivalent)
Data adjusted for age, sex and field work regions
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this immune destruction of the β-cell include autoantibodies to insulin (IAAs), 
autoantibodies to anti-glutamic acid decarboxylase (GAD), autoantibodies to the 
tyrosine phosphatases IA-2 and IA-2β, and the more recently described 
antibodies to zinc transporter 8 - ZnT8 (ZnT8As) (Lampasona et al., 2010; 
Vermeulen et al., 2011). Type 1 diabetes is defined by the presence of one or 
more specific antibodies. In addition, the disease has strong HLA associations, 
with linkage to the DQA and DQB genes, and these HLA-DR/DQ alleles can be 
either predisposing or protective. 
 
Type 1 diabetes has many different prevalences depending on the population 
studied, which could be attributed to genetics and/or to the environment 
(Patterson et al., 2012). According to a recent review (Canivell & Gomis, 2014), 
the incidence of T1D is increasing worldwide at the rate of 3-5% per year. The 
annual increase rate of T1D was 5.4% in children aged 0-4 years between 1989 
and 2003, and the trends predict doubling the incidence in this age group by 
2020. In International Diabetes Federation (IDF) 2013’s reports, the estimation 
rate of overall annual increase of T1D is around 3% in children under 15 years 
old, increasing more abruptly in some Central and Eastern European countries, 
where the disease is less common (International Diabetes Federation, 2013). 
 
In a recent publication, Barreiro and colleagues (Barreiro et al., 2014) could 
estimate the incidence of T1D in Spain, using different studies with their 
regional incidences. The regional incidences in children under 15 years old 
oscillated from 11.5 cases/100,000 inhabitants/year in Asturias to 27.6 
cases/100,000 inh/year in Castilla - la Mancha. From the data obtained in that 
study, there was not an increment of incidence of T1D in the last 20 years in 
some autonomic communities (Catalonia, Extremadura, Galicia, Madrid 
Community, Basque Country), different from other regions (Andalucía, Aragón, 
Cantabria, Navarra Community and Murcia Region) that presented a raise of 
incidences, especially in the last 5-10 years. Just a few Spanish regions have 
estimative of prevalences, that varies from 0.95 cases/1,000 inh (Badajoz) to 
1.53 cases/1,000 inh (Cantabria). The study estimated a mean annual 
incidence of T1D is 17.69 cases/100,000 inh/year in Spain, but observed the 
12
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importance of a better register for new cases and encouraged the register in the 
regions where these data are not available.  
 
 
1.2. Physiopathology of type 1 diabetes 
 
Type 1 diabetes is the result of β-cell destruction of pancreatic islets of 
Langerhans, vast majority in consequence of autoimmunity (American Diabetes 
Association, 2015b). Autoimmune destruction of β-cells has distinct genetic 
predispositions and is also related to environmental factors that are still poorly 
defined. Persons affected by T1D are also prone to develop associated 
autoimmune disorders such as Graves' disease, Hashimoto's thyroiditis, 
Addison's disease, vitiligo, celiac disease and others (ADA 2015). 
 
As reviewed by Jaberi-Douraki M and colleagues (Jaberi-Douraki, Liu, 
Pietropaolo, & Khadra, 2014), the disease is triggered by various factors in 
genetically predisposed individuals. It is mediated by autoreactive β-cell specific 
helper CD4+ and cytotoxic CD8+ T lymphocytes that infiltrate the islets and 
destroy up to 90% of the total β-cell population. The destruction of β-cells 
ultimately leads to the reduction of insulin secretion and eventually the induction 
of abnormally high levels of blood glucose in these individuals. The activation 
and recruitment of T-cells to the islets, along with the increased release of 
proinflammatory cytokines, finally drive β-cell destruction and increase the 
workload on surviving β-cells. This, in turn, is suggested to elevate stress in the 
endoplasmic reticulum (ER), the compartment where various proteins including 
insulin are synthesized, exacerbating β-cell loss (Figure 3).



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Figure 3. Scheme showing the various components of the autoimmune response in T1D. 
Trigger stimulus leads to the activation of various classes of islet-specific CD4+ and CD8+ T-
cells (i.e., Th-lymphocytes, regulatory T-cells and autoregulatory T-cells as well as B-cells). 
High avidity cytotoxic T-lymphocytes destroy β-cells by either secreting harmful cytokines, or by 
inducing apoptosis via cell-to-cell contact. Mature B-cells release islet specific autoantibodies 
that may appear prior to disease onset. Figure extracted and modified from Jaberi-Douraki 
(Jaberi-Douraki et al., 2014) 
 
 
In this type of diabetes, the rate of β-cell destruction is variable, being faster in 
some individuals, especially in the younger ones. Some patients, particularly 
children and adolescents, may present ketoacidosis as the first manifestation of 
the disease. Others have modest fasting hyperglycemia, associated with classic 
symptoms of polyuria, polydipsia, weakness and weight loss that can rapidly 
change to severe hyperglycemia and/or ketoacidosis in the presence of 
infection or other stress. Still others, particularly adults, may retain residual β-
cell function sufficient to prevent ketoacidosis for many years. Once the disease 
is stablished, there is little or no insulin secretion, as manifested by low or 
undetectable levels of plasma C-peptide (American Diabetes Association, 
2014a).  
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1.3. Microvascular complications in type 1 diabetes 
 
Chronic complications related to diabetes are primarily the micro and 
macrovascular diseases. The main targets of microvascular disease are eyes, 
kidneys and nervous system (American Diabetes Association, 2014b). 
 
Diabetic retinopathy is a highly specific vascular complication of both T1D and 
T2D, with prevalence strongly related to the duration of diabetes (American 
Diabetes Association, 2015d). In addition to the duration of diabetes, the most 
important risk factors for retinopathy include chronic hyperglycemia, associated 
nephropathy and hypertension. Studies like DCCT could demonstrate that an 
intensive diabetes management with the goal of achieving near-normoglycemia 
could prevent and/or delay the onset and progression of diabetic retinopathy 
(The Diabetes Control and Complications Trial Research Group, 1995b). 
 
Diabetic nephropathy occurs in 20–40% of patients with diabetes and is the 
single leading cause of end stage renal disease. Persistent albuminuria in the 
range of 30–299 mg/24h has been shown to be an early stage of diabetic 
nephropathy in T1D. Persistent albuminuria is a well-established marker of 
increased cardiovascular disease (CVD) risk (American Diabetes Association, 
2015d). Intensive diabetes management with the goal of achieving near-
normoglycemia has been shown to delay the onset and progression of 
increased urinary albumin excretion in patients with T1D (The Diabetes Control 
and Complications Trial Research Group, 1995a). 
 
Diabetic neuropathy is a heterogeneous chronic related complication, whose 
symptoms vary according to the class of fibers involved (American Diabetes 
Association, 2015d). The most common is the distal polineuropathy with 
symptoms that involve small fibers, and the symptoms include pain, 
dysesthesias and numbness. The major clinical manifestations of diabetic 
autonomic neuropathy include resting tachycardia, exercise intolerance, 
orthostatic hypotension, constipation, gastroparesis, erectile dysfunction, 
sudomotor dysfunction, impaired neurovascular function, and, potentially, 
autonomic failure in response to hypoglycemia. Tight and stable glycemic 
15
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control, implemented as early as possible, has been shown to effectively 
prevent the development of distal polineuropathy and autonomic neuropathy in 
patients with T1D for many years (J. Albers et al., 2010; The Diabetes Control 
and Complications Trial Research Group, 1995c, 1998).  
 
 
 
1.4. Cardiovascular disease in type 1 diabetes  
 
Cardiovascular disease (CVD) is the major cause of morbidity and mortality in 
individuals with diabetes. According to the last Standards of Medical Care from 
ADA (American Diabetes Association, 2015a), in T2D, CVD usually coexists 
with other cardiometabolic risk factors, like hypertension, dyslipidemia and/or 
obesity. In T1D, however, hypertension is often the result of underlying 
nephropathy. It is known that young subjects with T1D that were diagnosed in 
childhood have also a high risk of early subclinical and clinical CVD (Trevor J 
Orchard, Forrest, Kuller, & Becker, 2001; Skrivarhaug et al., 2006). The 
American Heart Association (AHA) categorizes children with T1D in the highest 
level for cardiovascular risk and recommends both lifestyle and pharmacological 
treatment for those with dyslipidemia, in particular, with elevated low density 
lipoprotein (LDL) cholesterol levels (Kavey et al., 2006).  
 
The natural history of CVD in diabetes has been changing in the last decades 
with the identification of the major risk factors associated, like hypertension, 
hyperglycemia, dyslipidemia, obesity and smoking and with the improvement on 
prevention approaches and treatments. Cardiovascular disease was identified 
as an important cause of morbi-mortality in subjects with T1D since the ‘70 
decade, and was mainly associated with nephropathy, end stage renal disease 
and hypertension, as referred before (Christlieb et al., 1981; Krolewski et al., 
1987).  
 
A Pittsburg register from 1984 (Dorman et al., 1984) reported a sevenfold 
excess in mortality risk in patients with T1D when compared with the rates 
expected from U.S. population of the same age. The main cause of death was 
16
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related to renal disease in younger subjects with an important increment in CVD 
in the ones that were older than 30 years. Krolewski and colleagues (Krolewski 
et al., 1987) studied the coronary artery disease (CAD) in Joslin Clinic patients. 
They observed that CAD mortality increased with age and was the main cause 
of death at ages 45-59 years. In the cumulative mortality analysis, the rates 
indicate that, by age 55, about 35% of the group had died from CAD and that 
the risk for women was similar to that for men. The study contrasted these 
results with the Framingham Heart Study, a population-based survey published 
in the same period (Lerner & Kannel, 1986), where the mortality of nondiabetic 
subjects at that age was 8% for men and 4% for women. 
 
The DCCT (The Diabetes Control and Complications Trial Research Group, 
1993) study represented a milestone in the treatment and evolution of chronic 
complications related to diabetes. The DCCT revealed a significant reduction of 
microvascular complications in the group that were treated more intensively 
(multiple insulin doses, with mean HbA1c ~ 7%) and also verified a trend toward 
a lower risk of CVD. The 9-year follow-up study from the DCCT, the 
DCCT/EDIC Study (Nathan et al., 2005), showed that participants previously 
randomized to the intensive arm had a significant reduction of 57% in the risk of 
nonfatal myocardial infarction, stoke or CVD death compared to those that were 
previously assigned as standard group, despite the two groups presented 
similar glycemic control in the follow-up trial (Figure 4).  
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Figure 4 – First ocurrence of nonfatal myocardial infarction, stroke, or death from 
cardiovascular disease. Figure extracted from DCCT/EDIC Study (Nathan et al., 2005) 
 
 
 
In 2006, Orchard and colleagues (Trevor J Orchard et al., 2006) reviewed the 
causes and the risk factors associated with CAD in T1D. Some complications 
related to diabetes, as nephropathy and autonomic cardiac neuropathy, as well 
as the pro-inflammatory state and alterations in lipoprotein profile, especially 
concerning T2D, were pointed as risk factors. The topic of discussion of the 
review was the weak relationship between glycemic control and CAD events in 
the studies that involved subjects with T1D. They indicate that DCCT/EDIC 
advocates a very strong benefit for early, intensive glycemic management, 
although it is still unknown to what degree this finding is mediated via other 
pathways. They finish the review by stating the importance of rigorous glycemic, 
lipid and blood pressure control, while better strategies are yet to be found. 
  
Giannini and colleagues (Giannini, Mohn, Chiarelli, & H, 2011), some years 
later, also reviewed different aspects of macrovascular disease in T1D, focusing 
in the importance of recognition of the risk factors and in the importance of 
actions for prevention and treatment early in the childhood. The authors point 
out the severity degrees of atherosclerosis, intima media thickness of the 
18
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carotids and aorta, as well as endothelial dysfunction, present in the 
macrovascular pathophysiology of T1D. In more recent studies, it has being 
evidenced that fluctuations of glycemic control in patients with T1D are 
implicated in endothelial dysfunction, lower flow-mediated brachial dilatation 
and higher carotid and femoral intima-media thickness, and are imputed as 
aggravators for preclinical atherosclerosis (Ceriello et al., 2012; Giménez et al., 
2011). 
 
Despite advances in diabetes care, UK mortality rates in the past decade 
continued to be higher in patients with T1D than in those without diabetes 
(Soedamah-Muthu et al., 2006). A nationwide study from Scotland in 2012 
(Livingstone et al., 2012) examined major CVD and deaths in T1D. The age-
adjusted incidence rate ratio for first CVD event associated with T1D versus non 
diabetes was higher in women (RR 3.0: 95% CI 2.4-3.9 p <0.001) than men, 
while all-cause mortality associated with diabetes was comparable in men (RR: 
2.6) and women (RR: 2.7). In Spain, in a cross-sectional study from medical 
records in the years 1990-2010, it was identified an overall increased rates of 
CVD of in subjects with T1D (OR 2.32) (Ortega et al., 2015).  
 
In a more recent follow-up, from 1998 to 2011 in Sweden, patients with T1D 
presented a reduction of all-cause mortality and also of specific cardiovascular 
mortality, especially if associated with a good glycemic control, when compared 
with previous studies. Another study from Canada and UK also identified a 
reduction of risk mortality in individuals over 20 years old recently (Lind et al. 
2013). Nowadays, the prevalence of CVD in countries like Sweden, 
nevertheless, is still the double of the one seen in subjects without diabetes, 
and the prevalence increases with the worsening of the glycemic control and 
with the presence of nephropathy, as pointed by Lind and colleagues in 2014 
(Lind et al., 2014). These numbers indicate that relative risk for CVD is still high 
in the population with T1D, but it is declining with the passing of the years. This 
may be in part due to the earlier detection of risk factors, as well as to 
improvements in diabetes care. 
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As already referred above, there are also evidences of higher rates in coronary 
heart disease in women with diabetes (Peters, Huxley, & Woodward, 2014). A 
statement from AHA/ADA regarding CVD in T1D calls the attention to the usual 
lower rates of CVD in premenopausal women, compared to men, that are 
erased in the case of T1D (de Ferranti et al., 2014). These aspects in women 
with T1D again drive our attention to the necessity of better understanding the 
CV risk factors in order to propose better approaches.    
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2. Physical activity  
 
2.1. Effects and benefits of physical activity in general population 
 
Several studies show the importance of physical activity for both prevention and 
treatment of many established atherosclerotic cardiovascular risk factors, once 
cardiovascular disease (CVD) as the leading cause of morbidity and mortality 
worldwide (Eckel et al., 2014).  Statements published by many organizations 
like the Council on Clinical Cardiology (Thompson et al., 2003), by American 
College of Cardiology and American Heart Association (Eckel et al., 2014) , as 
well as the World Health Organization (Lee et al., 2012; World Health 
Organization, 2014), highlighted the importance of physical activity, or 
structured exercise, for the management of risk factors for CVD, including 
hypertension, insulin resistance and glucose intolerance, dyslipidemia (elevated 
triglyceride and/or low high-density lipoprotein cholesterol concentrations) and 
obesity. Physical activity is also advised for the prevention of breast and colon 
cancer, for lowering the risk of depression and for the improvement of well-
being in the general population.  
 
Children and adolescents may also benefit from the promotion of healthy 
lifestyles. Different physical activity programs are encouraged with the objective 
of improving skeletal health, cardiorespiratory fitness, psychological health and 
blood lipid profile in different environments like school, home or institutions 
(Trost & Loprinzi, 2008). Health care and governmental institutions accredit the 
importance of physical activity for the promotion of health and prevention of 
diseases, and many programs of incentive are constantly being promoted 
(World Health Organization, 2014). 
 
The importance of physical activity for the protection against cardiovascular 
mortality was recognized and published in some interesting studies in the 60’s. 
For example, one of the first observational studies on physical activity was 
performed in England (Heady, Morris, Kagan, & Raffle, 1961), and showed that 
drivers, that had a sedentary activity, had the double events of cardiac mortality 
when compared to their colleagues conductors, that had an active work.  
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Some important trials also verified the effect of lifestyle programs (diet and 
exercise) for the prevention of T2D in in-risk populations (Diabetes Prevention 
Program Research Group, 2009; Knowler et al., 2002; Pan et al., 1997; 
Ramachandran et al., 2006; Tuomilehto et al., 2001). One of the classical 
studies, the Diabetes Prevention Program (DPP) showed that lifestyle 
intervention was even superior than drugs like metformin on the prevention of 
the development of T2D (Knowler et al., 2002) (Figure 5).  
 
In the case of established T2D, physical activity acts as a promoter of good 
glycemic control, reflected mainly in HbA1c. In addition, physical activity is able 
to reduce other risk factors like hypertension, obesity, insulin resistance and 
atherogenic lipid profile, in the way that physical activity can prevent and treat 
risk factors for cardiovascular disease in T2D (Boulé, Haddad, Kenny, Wells, & 
Sigal, 2001; Boulé, Kenny, Haddad, Wells, & Sigal, 2003; Cuff et al., 2003; 
Ibañez et al., 2005; Snowling & Hopkins, 2006; Thomas, Elliott, & Naughton, 
2006).  
 
 
Figure 5. Cumulative incidence according to study group.  Participants presented pre-
diabetes and were random in three different group of intervention. The incidence of diabetes 
differed significantly among the three groups. Figure extracted from Knowler et al. (Knowler et 
al., 2002) 
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2.2. Effects and benefits of physical activity in type 1 diabetes 
 
The beneficial effect of physical activity on glycemic control of patients with T1D 
is not so well recognized. The delicate balance among the characteristics of 
physical activity, the carbohydrate intake and the doses of insulin leads to a 
dynamic and permanent control in these patients. Studies about the benefits of 
glycemic control in T1D are controversial, and also complex to perform.  
 
It is common to identify debates about the benefits of physical activity in 
glycemic control in this population. A multicenter study, that included 23,251 
adolescents with T1D, identified a positive correlation between physical activity 
and lower levels of glycated hemoglobin (Herbst, Kordonouri, Scheab, Schmidt, 
& Holl, 2007), association recently confirmed by a study that took place in 
Sweden (Beraki, Magnuson, Särnblad, Aman, & Samuelsson, 2014). On the 
other hand, other studies did not find this correlation (Zinman, Zuniga-Guajardo, 
& Kelly, 1984), probably because the variables were studied following different 
designs, especially considering the different prescriptions of insulin and 
carbohydrate supplementation. Three recent meta-analysis published in 2013 
(A. Kennedy et al., 2013) and in 2014 (Quirk, Blake, Tennyson, Randell, & 
Glazebrook, 2014; Yardley, Hay, Abou-Setta, Marks, & McGavock, 2014) 
concluded that nowadays there are insufficient well-designed studies to confirm 
the effect of exercise training on glycated hemoglobin in subjects with T1D. 
Nevertheless, these meta-analysis indicate that the results are promising to 
confirm the benefits on glycemic control, as well as they encourage physical 
activity for its other known benefits.  
 
In a different systematic review, Chimen and colleagues (Chimen et al., 2012) 
identified several studies with different designs showing the benefits of physical 
activity for patients with T1D in other aspects different from the glycemic control. 
They recognized reduction of insulin requirements, insulin resistance, 
endothelial function, cardiovascular disease, mortality and improvements on 
physical fitness, muscle strength and wellbeing, as well as controversies about 
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the role of physical activity for lipids, blood pressure and microvascular 
complications. 
 
Concerning the difficulties on the routinely management of the triad physical 
activity, carbohydrate intake and insulin doses, there is a known limitation for 
the practice of exercise in this group of patients, that it is the fear of 
hypoglycemia. It has been shown (Valerio et al., 2007) that children and 
adolescents with T1D get less exercise that children and adolescents without 
diabetes of the same age. In parallel with that, patients who have a better 
knowledge of the disease are those who practice more exercise (Brazeau, 
Rabasa-Lhoret, Strychar, & Mircescu, 2008).  
 
There are established physical activity recommendations for T1D and T2D, 
published by ADA (American Diabetes Association, 2015c), in which “all 
children should be encouraged to engage in at least 60 min of physical activity 
each day; and adults should be advised to perform at least 150 min/week of 
moderate-intensity aerobic physical activity (50–70% of maximum heart rate), 
spread over at least 3 days/week with no more than 2 consecutive days without 
exercise”.  
 
The demonstration that patients with T1D have an increased cardiovascular risk 
(CVR) when compared with non-diabetic population, as exposed above 
(Krolewski et al., 1987; Mason, Jenkins, Best, & Rowley, 2006), that an 
adequate glycemic control can reduce cardiovascular complications, such as 
myocardial infarction or stroke (Nathan et al., 2005), and that physical activity 
can reduce CVR factors (Chimen et al., 2012) make us contemplate the idea 
that the application of a good exercise program adapted to the dietary and 
insulin requirements may be useful to delay or reduce cardiovascular events in 
these patients. 
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2.3. Glucose uptake in muscle contraction 
 
 
Molecular and metabolic effects of exercise are partially known, and the field of 
studies of physiology of exercise is growing and taking relevance in different 
areas of medicine.  
 
Richter and Hargreaves (Richter & Hargreaves, 2013) wrote an interesting 
review about glucose uptake following muscle skeletal contraction and the 
relation with glucose transporter type 4 (GLUT4), based on experimental and 
human experiments. During exercise, the coordinated increase in skeletal 
muscle blood ﬂow, capillary recruitment, GLUT4 translocation to the 
sarcolemma and T-tubules, and metabolism are all important for glucose uptake 
and oxidation. One important effect of muscle contraction is to promote the 
migration of the vesicles of glucose transporter GLUT4 to the membrane of the 
muscular cell, facilitating the glucose uptake. The activation of AMPK enzyme 
seems to be important in the signaling of this process by increasing the muscle 
glucose transport (GLUT1 and GLUT4) as well as in the induction of 
mitochondrial biogenesis (J. W. Kennedy et al., 1999; McGee & Hargreaves, 
2006). The activation of AMPK enzyme also could be confirmed by an AMPK 
activator, the 5-aminoimidazole-4-carboxamide-1-D-ribofuranoside (AICAR), 
that provoked similar effects of glucose uptake and GLUT4 than exercise in rats 
(Jessen et al., 2003)  
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Figure 6. Schematic muscle contraction and insulin pathways for GLUT4 translocation to 
the surface of the cellular membrane.  
 
 
 
The effect of muscular contraction has an additional effect with the insulin 
signaling to GLUT4 translocation. Insulin, by different pathways, also promotes 
this migration of vesicles of GLUT4 to cellular membrane (Figure 6). As a 
clinical consequence of physical activity, it is possible to testify an improvement 
on glycemic control in T2D (Boulé et al., 2001, 2003) and reductions of the 
requirements of insulin doses in T1D (Beraki et al., 2014). In Figure 7 it is 
represented an experimental study that evaluated the muscle glucose transport 
by the effect or insulin, muscle contraction or both.
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
Figure 7. Rates of glucose transport in different conditions. Glucose transport were 
evaluated in whole gastrocnemius from lean animals were measured following basal (resting 
without insulin), contraction, insulin, or contraction followed by insulin (Contraction + Insulin) 
stimulation. Contraction increased glucose transport (*p < 0.05). Values are means ± SE. 
Adapted from Thyfault et al. (Thyfault et al., 2007).  
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3. Skeletal muscle composition and glucose metabolism 
 
 
The skeletal muscle is one of the most important organs for the glucose 
metabolism and is directly related to insulin resistance and sensitivity 
(DeFronzo, Tobin, & Andres, 1979; Petersen et al., 2007), for this reason, it is 
important to review some muscle characteristics. In humans, two main fiber 
types are described with their particular characteristics and body distribution. 
Type I fibers are characterized by long period utilization, and also called slow-
twitch or oxidative fibers. These fibers, in normal conditions, have a high 
capacity for fatty acid oxidation and insulin-stimulated glucose transport, 
present more mitochondria and GLUT4 content than type II fibers, and are 
mainly implicated in aerobic actions. By the opposite, type II fibers as type IIA 
(fast-twitch oxidative), and especially type IIX (fast-twitch oxidative-glycolytic), 
showed less intramyocellular lipid (IMCL) amounts, are more glycolytic, present 
lower mitochondrial and GLUT4 content, and are mainly implicated in anaerobic 
actions (Egan & Zierath, 2013; Schiaffino & Reggiani, 2011) (See Table 1 and 
Figure 8). 
 
 
It is well recognized that elite athletes from resistance sports, like marathon or 
triathlon, have proportionally more type I fibers than control subjects, as well as 
sprint athletes, like 100-200 m runners, that present proportionally more type II 
fibers (Baguet et al., 2011; Wilson et al., 2012). There is a current discussion 
whether the athletes endowed with greater percentages of fast or slow twitch 
fibers, or the correlations between fiber types and performance be accounted 
for by exercise training. Some studies could not confirm the association of 
training with the modification of fiber type, but others point to a probable 
plasticity and fibers shift, especially between fibers type IIA and type IIX (Wilson 
et al., 2012). 
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Table 1 – Contractile, metabolic and morphological characteristics of human 
skeletal muscle fibers** 
 
 
 
 SO, slow oxidative; ST, slow-twitch; FOG, fast oxidative-glycolytic; FT, fast-twitch; fast-glycolytic; MHC, 
myosin heavy chain; IMTG, intramuscular triglycerides 
    *mmol kg-1 wet weight. 
 **Adapted from Brendan Egan and Juleen R. Zierath (Egan & Zierath, 2013).  
 
 
 
 
 
 
Short duration, maximal 
effort
Moderate duration, high 
intensityProlonged low intensityExercise-type predominance
4.27.1[IMTG]*
89.283.177.8[Glycogen]*
14.814.512.6[Phosphocreatine]*
HighIntermediate-highLowGlycolitic potential
LowIntermediate-highHighOxidative potential
Metabolic and Substrate properties
13 ± 7.632.2 ± 9.154 ± 12.2Percent distribution in whole muscle
560061105310Fiber size (cross-sectional area)
LowIntermediateHighMitochondrial density
3.24.04.2Capillary density (capillaries per fiber)
Morphological Properties
>75% VO2max>40% VO2maxAll intensitiesRecruitment threshold
3080Time to peak tension (msec)
White/lowRed/intermediateRed/highAppearance/myoglobin content
LowIntermediateHighEndurance capacity
StrongIntermediateWeakForce production (power output)
Fast twitch, glycolytic, fast 
fatigable
Fast twitch, oxidative-glycolytic, 
fatigue resistant
Slow twitch, high oxidative, 
fatigue resistant
Contractile and metabolic 
characteristics
MHC2XMHC2AMHC1Myosin heavy chain isoform
FG, FTbFOG, FTaSO, STAlternative nomenclature
General Properties
Type IIbType IIaType I
Type II
29
Introduction 
 
 
 
 
 
 
 
Figure 8. Skeletal muscle fiber typing in serial sections of biopsies from the vastus 
lateralis muscle in a patient with T1D. Immunostaining with fast myosin heavy chain (FAST). 
As an example, 13 fibers were identified and typed in each serial section: fibers 1 – 4 are slow 
fibers (type I), fibers 5-13 are fast fibers (type II). Figure extracted from Fritzsche K et 
al.(Fritzsche et al., 2008) 
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3.1. Muscular insulin resistance 
 
 
Some metabolic conditions, such as T2D and obesity, have been importantly 
associated with muscular insulin resistance. Imbalances of muscular 
composition, fatty acids intramyocellular accumulations and mitochondrial 
dysfunction have been implicated in muscular dysfunction (Petersen, Dufour, 
Befroy, Garcia, & Shulman, 2004). The accumulation of IMCL has been 
proposed as an important predictor of insulin resistance (White, Ferguson, 
McCoy, Kim, & Castellano, 2006). The mitochondrial dysfunction, related to 
reduction of mitochondrial content, mitochondrial biogenesis and/or electron 
transport chain content, induces a reduction of the oxidative capacity, and is 
associated with lipid accumulation and reduction of insulin action (Befroy et al., 
2007; Montgomery & Turner, 2015; Morino, Petersen, & Shulman, 2006; 
Petersen et al., 2004). In subjects with T2D and obesity, it was observed an 
excess of IMCL accumulation (He, Watkins, & Kelley, 2001; Kelley, Goodpaster, 
Wing, & Simoneau, 1999). Other studies showed IMCL accumulation even in 
lean insulin resistant T2D offspring (Jacob et al., 1999; Gianluca Perseghin et 
al., 1999) in the muscles tibialis anterior (higher content of fiber type II, less 
insulin sensitive) and especially in soleus (higher content of fiber type I, insulin 
sensitive), when analyzed by 1H NMR (proton nuclear magnetic resonance). 
 
Some studies identified, through biopsies of vastus lateralis muscle, a less 
content of type I fibers in T2D and obese subjects, less GLUT4 expression, 
and/or less oxidative enzyme capacity especially in type I fibers when compared 
to control subjects (Gaster, Staehr, Beck-Nielsen, Schrøder, & Handberg, 2001; 
He et al., 2001; Oberbach et al., 2006; Stuart et al., 2013). 
 
A condition called metabolic inflexibility was referred by several authors 
(Aucouturier, Duché, & Timmons, 2011; Battaglia, Zheng, Hickner, & Houmard, 
2012; Russell, Kraemer, & Nelson, 2013; Storlien, Oakes, & Kelley, 2004). 
Metabolic inflexibility is characterized by impaired ability to switch from fat to 
carbohydrate as substrate from the fasted-to-fed transition. Patients with T2D 
and/or obesity are less able to shift between substrates, demonstrating different 
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degrees of metabolic inflexibility, fact that is associated with an excessive 
ectopic lipid accumulation and in lipid intermediates such as diacylglycerol and 
ceramide, resulting in intracellular lipotoxicity. An interesting study was 
performed by Kelley and collaborators (Kelley et al., 1999), in which lean and 
obese subjects received insulin infusion; it could be observed differences in 
insulin sensitivity and fat oxidation between both groups of subjects, suggesting 
that the triglyceride accumulation in skeletal muscle in obese subjects derives 
from reduced capacity for fat oxidation and, with this, a parallel insulin 
resistance.  
 
It is worthy to mention that studies that analyzed high performance athletes 
showed a paradoxical increase in IMCL. In athletes, it is described that IMCL is 
associated with the increase of VO2peak (maximal aerobic capacity); in 
untrained individuals, however, the higher IMCL content predicted the lower 
insulin sensitivity (Machann, Häring, Shick, & Stumvoll, 2004). One study 
showed that IMCL could increase in sedentary subjects when they participated 
in an exercise training program in parallel with the improvement of insulin 
sensitivity (Dubé et al., 2008). It has been proposed by Coen and Goodpaster 
(Coen & Goodpaster, 2012) that the athlete’s paradox represents a 
convergence of two separate areas of research, one linking IMCL to fuel 
metabolism and the other linking IMCL to insulin resistance, as exemplified in 
Figure 9. This paradoxical situation indicates the need of a better understanding 
of the IMCL role and require of a better characterization of muscular 
components associated with the clinical profile.  
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Figure 9. Role of intramyocellular lipid (IMCL) during exercise and in obesity. During 
exercise, fatty acid (FA) acyl CoA is oxidized by mitochondria to synthesize adenosine 
triphosphate (ATP). FA acyl CoA is also subdivided to lipid droplets (LDs), where it is esterified 
to triglyceride (TG). TG can subsequently be lyophilized to release FAs for mitochondrial 
oxidation. In obesity, because of lower energetic demand, most FA acyl CoA is directed to LDs. 
IMCL in LDs can then turn as alternate for ceramide and diacylglycerol. FA CoA oversupply to 
mitochondria during low energetic demand results in incomplete β oxidation and reactive 
oxygen species (ROS) production. Adapted from Coen and Goodpaster, 2012 (Coen & 
Goodpaster, 2012) 
 
 
 
3.2. Muscular composition and type 1 diabetes 
 
In subjects with T1D there is little information about specific muscle fiber 
composition. One study identified a decrease of the slow-twitch oxidative and 
increase of the fast-twitch fibers fractions by biopsies in vastus lateralis muscle 
in subjects with T1D when compared with subjects with normal glucose 
tolerance; and the same study also showed significantly higher glycolytic 
enzyme activities in all fiber types, which were correlated with HbA1c (Fritzsche 
et al., 2008). Another study (G Perseghin et al., 2003) verified higher 
accumulations of IMCL in calf muscles of adult population with T1D, mostly if 
there was an inadequate glycemic control, indicating also an assignment of this 
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organ and probable changes on its functions.  
 
Recently it is been recognized that subjects with T1D could present different 
degrees of insulin resistance (Bergman et al., 2012; Liu et al., 2009). Insulin 
resistance was tested through hyperinsulinemic-euglycemic clamps in 
teenagers with T1D and in non-diabetic controls. It was evidenced that 
teenagers with T1D presented higher insulin resistance and lower 
cardiovascular fitness (determined by VO2peak) than their counterparts, and it 
was also identified that insulin resistance was inversely correlated with 
VO2peak. The same study also analyzed the intra and extramyocellular lipid 
contents (IMCL and EMCL) in soleus and tibialis anterior muscles from both 
groups of subjects, however no differences were identified between them 
(Nadeau et al., 2010). 
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4. Lipoproteins  
 
 
4.1. Lipoproteins in general population 
 
A correct equilibrium of lipoprotein profile is directly related to cardiovascular 
health. Dyslipidemia is one of the most important risk factors involved in 
cardiovascular disease (CVD) (American Hearth Association, 2002) in addition 
to cigarette smoking, hypertension, family history of premature coronary heart 
disease, age and diabetes. It is recognized that low-density lipoprotein (LDL) 
plays a major role in the promotion, development and progression of 
atherosclerosis through mechanisms that involve endothelial dysfunction, 
activation of inflammatory pathways and lipid oxidation and accumulation 
(Morris, Ballantyne, Birtcher, Dunn, & Urbina, 2014). Besides the LDL, 
triglycerides and triglycerides-rich lipoprotein also play an important role as risk 
for cardiovascular disease (Miller, Ginsberg, & Schaefer, 2008; Morris et al., 
2014; Nordestgaard & Varbo, 2014).  
 
Another lipoprotein, the high-density lipoprotein (HDL), is considered as an 
effective biomarker for predicting cardiovascular risk protection, and its role was 
reviewed by Raver and Hovingh (Rader & Hovingh, 2014). Many prospective 
studies have confirmed that HDL-cholesterol (HDL-C) is a strong, consistent, 
and independent predictor of incident cardiovascular events (myocardial 
infarction, ischemic stroke). Strong data also consider HDL-C as a predictor of 
incident cardiovascular events in the setting of secondary prevention in 
individuals who have already been diagnosed with cardiovascular disease.  
 
Lipoproteins are complex particles composed of different proteins which 
transport fat molecules. The fats carried include cholesterol, triglycerides and 
phospholipids; the amounts of each can vary considerably. Lipoproteins 
classically are classified by molecular size and density and are ordered from 
largest to smallest as: chylomicrons, very low-density lipoprotein (VLDL), 
intermediate-density lipoprotein (IDL), low-density lipoprotein (LDL), and high-
density lipoprotein (HDL) (See Figure 10). The most abundant apolipoproteins 
35
Introduction 
 
of HDL particles are apo A-I and apo A-II; the LDL particles, by contrary, 
present the apolipoprotein B-100.  
 
 
 
 
Figure 10. Structure, diameters and density of lipoproteins. In the left, lipoprotein structure; 
and in the right, the different lipoproteins displaced by diameters and densities. Adapted from 
Ridker P., 2014 (Ridker, 2014). 
 
 
One important aspect, more recently recognized, is the size of the lipoprotein 
particles and subfractions, which can be determined through different methods, 
and especially by nuclear magnetic resonance (NMR) lipoprotein analysis 
(Mallol, Rodriguez, Brezmes, Masana, & Correig, 2013). The size of LDL 
particles (LDL-P) varies such that particles with more triglycerides and fewer 
cholesteryl esters result in smaller and denser LDL (Ridker, 2014). Different 
studies evidence that elevated plasma concentrations of small dense LDL are 
correlated with high plasma triglycerides and low HDL levels, and also that 
reduced size and increased density of LDL have been associated with 
increased coronary heart disease (CHD) risk, (Diffenderfer & Schaefer, 2014; 
Morris et al., 2014).  
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The classical determination of LDL-cholesterol (LDL-C) is a measure of the 
cholesterol content of LDL-P. The determination of LDL-C can vary significantly 
between individuals and in response to drug or lifestyle intervention; it has been 
shown, however, that LDL-P could be better than LDL-C in predicting incident 
events (Toth et al., 2014). As well as for LDL-C, the conventional determination 
of HDL-cholesterol (HDL-C) is a measure of the cholesterol content of HDL-
particle (HDL-P). In a similar way to LDL-P, HDL-P have been studied, and it 
could be evidenced that the amount and sizes of HDL-P are also helping on 
elucidating its role. An independent association with other cardiovascular risk 
for coronary artery disease was identified and it could be a good marker for 
cardiovascular risk protection (Harchaoui et al., 2009). 
 
Recent findings are changing some concepts about the HDL functionality, 
concerning its components and sizes (Hovingh, Rader, & Hegele, 2015; Soran, 
Hama, Yadav, & Durrington, 2012). In HDLs, it has been identified distinct 
molecule species of lipids, as well as several proteins compounds, 
characteristics that confer antioxidative, anti-inflammatory, cytoprotective, 
vasodilatory, antithrombotic and anti-infection actions (Rached, Chapman, & 
Kontush, 2015; Soran et al., 2012). The exact role of HDLs, however, is not yet 
completely known since the direct clinical effect of cardioprotection has been 
recently questioned. One of the points of reflection is that drugs that increased 
HDL concentrations failed to prove direct CV protection (Hovingh et al., 2015), 
despite the known association of HDL levels and cardioprotection.  
 
 
4.2. Lipoproteins and physical activity 
 
Physical activity is considered as a protective factor against CVD and also a 
promotor of beneficial effects on lipid and lipoprotein profiles in general 
population. For instance, HDL-C and LDL-C, as well as changes in LDL and 
HDL subfractions and particle sizes, have been identified in several studies as 
modifiable in result of physical activity interventions (Halverstadt, Phares, 
Wilund, Goldberg, & Hagberg, 2007; Spate-Douglas & Keyser, 1999; Trejo-
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Gutierrez & Fletcher, 2007), along with other observational prospective studies 
(Mora, Cook, Buring, Ridker, & Lee, 2007). 
 
The study of different particle compositions and sizes of lipoproteins are helping 
in the knowledge about the influence of physical activity. Sedentary behavior 
was associated with small VLDL-particles (VLDL-P), large LDL-P and TG while 
high and moderate activities were positively associated with large HDL-P, 
average HDL-size, Apo A1 and HDL-C, in a recent study that evaluated healthy 
subjects that registered their physical activity (Aadland, Andersen, Anderssen, 
& Kvalheim, 2013). The same study identified that, for women, the association 
between physical activity with large HDL-P and average HDL size was quite 
strong, whereas a weaker association was detected for conventional HDL-C. An 
example of an interesting study of endurance exercise was the one published 
by Halverstadt and colleagues (Halverstadt et al., 2007) that proposed a 
training for 24 week in subjects between 50 and 75 years-old and analysed 
lipoprotein and lipid profile using both conventional and NMR measures. That 
study showed a significant decrease in total cholesterol, triglycerides and LDL-
C, and also an increase in HDL-C subfractions (HDL3-C and HDL2-C - smaller 
and bigger, respectively). It was also identified a decreased of large and small 
VLDL-P, total, medium, and very small LDL-P and small HDL-P. Mean VLDL-P 
size also decreased significantly and mean HDL-P size increased significantly 
with exercise training. These changes were independent of baseline body fat 
and body fat changes with training. 
 
The American Heart Association and the American College of Cardiology 
(AHA/ACC) stablished guidelines on lifestyle management to reduce CVR 
(Eckel et al., 2014). These guidelines are based on evidences from important 
trials and meta-analysis that studied the effect of diet and physical activity in 
order to modify lipids and to promote blood pressure reduction. Associated with 
diet guidance, there are recommendations for adults to engage in aerobic 
physical activity to reduce LDL-C and non–HDL-C that would be: 3–4 sessions 
per week, lasting on average 40 min per session, and involving moderate- to 
vigorous-intensity physical activity. The same statement indicates that aerobic 
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physical activity alone or resistance exercise training, compared to control 
intervention, have no consistent effect on HDL-C.  
 
As already pointed out in the section above, HDL particles are highly 
heterogeneous. Independent variables can exert effects on the lipoprotein 
profiles, like genetics, diet and several environmental factors. These different 
influences could explain some discrepancies on the results of different 
interventional physical activity studies and individual responses to exercise. 
Some recent studies are evidencing effects of genetics on HDL changes 
(Blazek, Rutsky, Osei, Maiseyeu, & Rajagopalan, 2013). This genetic variability 
and polymorphisms have been studied in different steps of the pathway of HDL 
particles, like in Apo-I, ATP-binding cassette transporter A1 (ABCA1), 
lipoprotein lipase (LPL), hepatic lipase, cholesterol ester transfer lipoprotein 
(CETP) and others (Blazek et al., 2013; Hovingh et al., 2015), and may 
condition to distinct responses to physical activity interventions. 
 
 
4.3. Lipoproteins in type 1 diabetes 
 
As already reviewed above, patients with T1D have a higher prevalence of CVD 
and cardiovascular mortality than subjects without diabetes in the same age. In 
the last years, the rates of CVD in T1D are decreasing, but are still far from non-
diabetic population. The identification of risk factors for CVD is crucial for the 
prevention and the treatment of this condition. 
 
American Diabetes Association (ADA) (American Diabetes Association, 2015a) 
states that patients with T2D have an increased prevalence of lipid 
abnormalities, contributing to their high risk of CVD, and that less evidence of 
this association exists for T1D. ADA stablishes that, although the data are not 
definitive, similar lipid-lowering goals for both groups of patients with T1 or T2D 
should be considered, particularly if they have other CVR factors. This 
recommendation is also corroborated by the joint of ADA and American Heart 
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Association (AHA) in the specific case of T1D, published in 2014 (de Ferranti et 
al., 2014).  
 
This publication from AHA/ADA also calls the attention to the fact that the lower 
rates of CVD in premenopausal women, when compared to men, are erased in 
the case of T1D (de Ferranti et al., 2014), as already mentioned in item 1.4 
(Cardiovascular disease in T1D), and the causes are yet to be clarified. There 
are some evidences that indicate that lipoprotein profile in premenopausal 
women with diabetes is less cardioprotective than in women without diabetes. 
According to Masding and colleagues (Masding, Stears, Burdge, Wootton, & 
Sandeman, 2003), after testing a meal containing a stable isotope in women 
with and without T2D, the premenopausal advantage in clearance of dietary 
lipid is not seen in premenopausal diabetic women. They suggest that this is 
likely to promote an atherogenic lipoprotein profile and may contribute to the 
loss of cardiovascular disease protection seen in diabetic women. Another 
study, by Maahs and colleagues, analyzed the lipoprotein profile in men and 
women with and without T1D submitted to hyperinsulinemic-euglycemic clamp. 
Among men, those with T1D had less VLDL and more HDL cholesterol than 
control subjects. In women, however, those with T1D had more LDL cholesterol 
with an apparent shift of cholesterol distribution within LDL to smaller 
(atherogenic) LDL fractions when compared with those without diabetes. 
Moreover, they identified that insulin resistance was associated with a more 
atherogenic lipoprotein cholesterol distribution in all men and in women with 
T1D (Maahs et al., 2010). 
 
The early observations of lipids and lipoprotein profile in patients with T1D 
revealed pro-atherogenic features, such as hypercholesterolemia and 
hypertriglyceridemia, and were particularly associated with poor glycemic 
control (Patti et al., 1995; Vergès, 2009) and nephropathy (Jenkins et al., 2003; 
T J Orchard, Stevens, Forrest, & Fuller, 1998). In the nineties, studies from 
Europe and U.S. identified similar rates of CVD in subjects with T1D in that 
regions, but with different pattern of dyslipidemia: low HDL-C in EURODIAB and 
hypertriglyceridemia in the U.S. group (T J Orchard et al., 1998). 
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More recent studies identified that an adequate metabolic control could improve 
these characteristics. Epidemiological evidences show that lipids and 
lipoproteins are normal in subjects with T1D if good glycemic control is 
maintained and the patient does not have microalbuminuria or clinical 
nephropathy (Jenkins et al., 2003; Lehmann, Kaplan, Bingisser, Bloch, & 
Spinas, 1997). Some studies question the role of glycemic control, as in the 
work of Guy and colleagues (Guy et al., 2009), when it was identified that young 
patients with T1D presented higher levels of small LDL particles than subjects 
without diabetes, independent of their glycemic control. Different findings were 
described by Alberts and colleagues, in which poor glycemic control was related 
to more dense LDL particles (J. J. Albers et al., 2008). On the other hand, 
Caixàs and colleagues observed that, after intensification of insulin treatment 
for the optimization of glycemic control in patients with T1D, VLDL particles, 
triglycerides, total LDL-C and HDL-C reached the levels of the control group, 
while the pattern of small LDL-C was also similar to that of the non-diabetic 
group, with no changes after optimization (Caixàs et al., 1997).
 
Insulin has an important role in lipoprotein metabolism. Vergès and Howard 
(Howard, 1987; Vergès, 2009) review this topic indicating different functions of 
insulin, for example, in the inhibition of hormone-sensitive lipase. The effect is 
an antilipolytic action of insulin, that promotes the storage of triglycerides in the 
adipocytes, while reduces the release of free fatty acids from adipose tissue into 
circulation. Another described effect of insulin is the inhibition of VLDL 
production by the liver. Insulin is also a potent activator of lipoprotein lipase 
(LPL), which promotes the catabolism of triglyceride-rich lipoprotein levels, also 
reducing the plasma triglyceride levels (Figure 11). It is common to identify, in 
the clinical practice, that patients with T1D under inadequate control due to 
insulin deficiency treatment are more prone to present hypertriglyceridemia. 
Low levels of serum triglycerides are evidenced as well when the patient 
presents an adequate glycemic control. 
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Figure 11. Main effects of insulin on lipoprotein metabolism. HDL2 – smaller HDL particles; 
HDL3 – bigger HDL particles. LPL: lipoprotein lipase; HL: hepatic lipase; CETP: Cholesteryl 
Ester Transfer Protein; LCAT: lecithin-cholesterol acyl transferase; FFA: free fatty acids; B/E 
rec.: receptor B/E (LDL receptor); CE: cholesterol esters. 1) Insulin inhibits hormone-sensitive 
lipase. 2) Insulin activates LPL. 3) Insulin inhibits hepatic VLDL production. 4) Insulin increases 
LDL B/E receptor expression. 5) Insulin activates LCAT. 6) Insulin activates HL. Figure 
extracted from Vergès, 2009 (Vergès, 2009). 
 
 
Few information of the effect of physical activity in subjects with T1D is 
available, concerning changes in lipoprotein profile. From the EURODIAB IDDM 
Complications Study, where 3159 patients with T1D were evaluated, it was 
demonstrated a positive relationship with degree of physical activity and HDL-C 
and HDL3-C, and negative for Total-C/HDL-C ratio and triglycerides in men. In 
women, however, both Total-C and LDL-C had a significantly positive 
relationship with the degree of physical activity (Idzior-Walus et al., 2001). That 
study, however, indicated the smoking habit and the central obesity as 
important factors that influenced the lipoprotein profile. In interventional studies 
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of 3 months of aerobic exercise in patients with T1D, it was described an 
increment of HDL-C in one protocol (Rigla et al., 2000) and an increase in the 
HDL3-C associated with a reduction of abdominal fat and blood pressure 
(Lehmann et al., 1997) in another one. An additional study with a protocol of 
endurance training improved the lipid profile in already physically active men 
with T1D, in the ratio HDL-C/LDL-C, independently of effects on body 
composition or glycemic control (Laaksonen et al., 2000).  

As already mentioned above, the exact role of HDLs are not fully understood 
(Hovingh et al., 2015). In the particular case of patients with T1D, the expected 
protection effect of HDLs profile on coronary artery calcification is not so clear 
as in control subjects, as shown in one study that used 1H NMR methodology 
(Colhoun et al., 2002). Nevertheless, a prospective study associated coronary 
artery disease with lower rates of large HDL and higher rates of medium HDL in 
T1D patients, also measured by 1H NMR (Soedamah-Muthu, Chang, Otvos, 
Evans, & Orchard, 2003). These features are bringing new concepts and 
opening new fields of research and could better explain the association of 
lipoprotein profile and cardiovascular disease in patients with T1D. 
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III. HYPOTHESIS AND AIMS 
  
  
Hypothesis and Aims 
 
  
 
Physical activity produces a beneficial effect on general population associated 
with the delay of development of cardiovascular diseases and improvement of 
life quality. It is recognized that structured physical activity improves glycemic 
control in patients with type 2 diabetes and ameliorates cardioprotective 
lipoprotein profile in general population. 
 
Despite the improvements in diabetes care, patients with type 1 diabetes (T1D) 
still have a high incidence of cardiovascular disease and cardiovascular 
mortality, with evidences of affectation even in the youth. In these patients, 
there are contradictory data about the benefits produced by physical activity on 
the metabolic control.   
 
Nowadays, subjects with T1D can achieve a good metabolic control and avoid 
or delay chronic complications, but a possible hyperinsulinemia induced by 
exogenous insulin administration in addition to some degree of insulin 
resistance could result in different metabolic responses to exercise. In this 
sense, the role of physical activity in this condition is poorly known. 
 
Based on these considerations, we hypothesize that physical activity can induce 
beneficial metabolic responses, promoting changes in intramyocellular lipid 
content and inducing modifications in lipoprotein profile in subjects with type 1 
diabetes. 
 
 
 
The aims of this study are: 
 
1. To describe the clinical characteristics and fitness capacity of a cohort with 
type 1 diabetes compared to non-diabetic counterparts.   
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2. To analyze the metabolomic profile induced by acute exercise in subjects 
with type 1 diabetes compared to non-diabetic counterparts. 
 
3. To investigate the muscular lipids content in subjects with type 1 diabetes in 
relation to their level of physical activity. 
 
4. To compare the lipid and lipoprotein profile in serum of subjects with type 1 
diabetes considering their level of physical activity.  
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IV. STUDY POPULATION, METHODS AND 
RESULTS 
  
  
Study 1 
STUDY POPULATION, METHODS AND RESULTS 
 
The studies were based on the aims proposed and will be presented as 4 
studies, as follows.  
 
 
 
 
AIM 1 – STUDY 1 
 
Clinical charactestics and aerobic exercise capacity in subjects with and 
without type 1 diabetes 
 
 
Rationale 
 
Persons with type 1 diabetes (T1D) are encouraged to carry an active life for 
the promotion of health care and wellbeing, as all the population. Regular 
physical activity prevents or delays type 2 diabetes (T2D) in persons with 
prediabetes and, in persons with established T2D, promotes better glycemic 
control (Knowler et al., 2002; J Lindström et al., 2013; Jaana Lindström et al., 
2003; Wing et al., 2013).  
 
In T1D, the effect of physical activity in the improvement of glycemic control is 
controversial (Kennedy et al., 2013; Landt, Campaigne, James, & Sperling, 
1985; Yardley, Hay, Abou-Setta, Marks, & McGavock, 2014; Zinman, Zuniga-
Guajardo, & Kelly, 1984), and available studies are limited by the difficulties on 
the assessments of physical activity or fitness, the small number of patients, or 
control of the variables (Herbst, Kordonouri, Scheab, Schmidt, & Holl, 2007). In 
addition, the management of T1D is particularly complex and dynamic, due to 
the needs of accurate administration of insulin coordinated with the 
carbohydrate intake and physical activity volume, in order to maintain optimal 
glycemic control. Therefore, taking into account the particularities faced in the 
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management of T1D, studies that analyze the fitness characteristics of this 
population are limited.  
 
The enhancement in insulin sensitivity related to physical activity is also on 
debate in T1D. Studies that conducted programs of exercise (Landt et al., 
1985), demonstrated improvement of insulin sensitivity by clamp techniques, 
but could not demonstrate a parallel improvement on blood glucose control. 
Other studies, comparing T1D athletes with sedentary ones, showed decrease 
in required insulin doses, a worse glycemic control and an increased lipid 
utilization in the trained group, without any improvement on insulin sensitivity 
(Ebeling, Tuominen, Bourey, Koranyi, & Koivisto, 1995).  
 
Individuals with T1D may present some impaired ﬁtness-related components 
and alterations in their cardiorespiratory responses to exercise. To assess 
differences in fitness, Nguyen and colleagues (Nguyen et al., 2014) studied 
three groups of children: eight with good glycemic control (stable HbA1c for 9 
months: ≤ 7.5%), eight with poor glycemic control (HbA1c ≥ 9%) and eight 
healthy controls. Children with poor glycemic control presented lower VO2peak 
(maximal oxygen uptake) compared to the control ones (poor-control: 33.2 ± 5.6 
mL/kg/min; control: 43.5 ± 6.3, p < 0.01). Children with T1D and good glycemic 
control presented similar results compared to the other two groups. This study 
also identified a negative correlation between VO2peak and HbA1c (R = - 0.54, 
p<0.001), concluding that a poor glycemic control could compromise aerobic 
muscle capacity. Stettler and colleagues (Stettler et al., 2006) studied the 
influence of eu- or hyperglycemia on exercise capacity. Different from Nguyen 
(Nguyen et al., 2014), they looked for differences in the current glycemic state, 
through eu- or hyperglycemic clamps, and concluded that these different 
conditions do not affect the peak power output in a bicycle ergometer test.   
 
The association of a reduced lung function with diabetes has been described. 
The lung may be another organ adversely affected by diabetes. Komatsu and 
colleagues (William Ricardo Komatsu et al., 2005) described a reduction of 
VO2peak in adolescents with T1D compared to matched controls ones. Some 
years later, the same group of researchers (William R Komatsu, Barros Neto, 
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Chacra, & Dib, 2010) analyzed pulmonary function and exercise capacity in 
persons with T1D and controls. They described a reduction (p < 0.001) in forced 
expiratory volume in the first second (FEV1) in the group of athletes with T1D 
compared to non-athletes and controls (athletes or not); however, the aerobic 
capacity was similar between athletes with T1D and control athletes. Other 
studies did not identify differences in respiratory capacity when compared with 
control population, but showed a reduction in VO2peak in subjects with T1D 
when compared with controls (Benbassat et al., 2001). Niranjan and colleagues 
(Niranjan, McBrayer, Ramirez, Raskin, & Hsia, 1997), in a cross-sectional 
study, analysed 14 control subjects, 9 subjects with T1D and chronically 
elevated levels of HbA1c; and other 9 subjects with T1D with chronically near-
normal levels of HbA1c. The authors evidenced that chronically hyperglycemic 
patients presented an impaired maximal work load and oxygen uptake that were 
associated with restrictions of lung volume, lung diffusing capacity, and stroke 
index during exercise. The patients in normoglycemic control showed less 
impairment than the hyperglycemic patients, but some parameters were 
different from the control group. In the same study, patients with T1D (both 
groups) presented lower VO2peak than control subjects, but a not commented 
and important aspect was the older age of the patients when compared with the 
control participants. 
 
Insulin resistance is a condition described especially in T2D. Insulin resistance 
is associated with a clinical condition called Metabolic Syndrome, that is 
characterized by the clinical features of hypertension, abdominal obesity, 
hyperglycemia, high triglycerides and low HDL-cholesterol, and recognized as a 
risk factor for cardiovascular disease (American Hearth Association, 2002; 
International Diabetes Federation, 2006). Type 1 diabetes is a different entity, 
but shares many clinical characteristics with T2D like hyperglycemia and the 
association with cardiovascular disease, and micro- and macrovascular 
complications. Different degrees of insulin resistance are also being accepted 
as an additional condition in patients with T1D (Chillarón et al., 2011; Llauradó 
et al., 2012). Searching for a clinical approach to identify insulin sensitivity on 
T1D, Williams and colleagues (Williams, Erbey, Becker, Arslanian, & Orchard, 
2000) described the eGDR (estimated glucose disposal rate) from euglycemic-
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hyperinsulinemic claps performed in T1D patients. The equation was defined in 
24 patients with T1D (male-to-female ratio 12/12) from the Pittsburgh 
Epidemiology of Diabetes Complications Study, with mean age 35.5 years, BMI 
27 kg/m2, HbA1 9.9%, and unspecified ethnicity. This equation uses clinical 
characteristics for the approximation of insulin sensitivity that involve waist/hip 
ratio, hypertension and glycated hemoglobin. Higher levels of eGDR correspond 
to higher insulin sensitivity. Several studies have been using this index to 
approach insulin resistance or sensitivity in patients with T1D (Chillarón et al., 
2009; Girgis, Scalley, & Park, 2012; Llauradó et al., 2012; Olson et al., 2002).  
 
The objective of this analysis was to evaluate patients with T1D, on their 
habitual physical activities, and study possible impairment of fitness and clinical 
characteristics.  
 
 
Subjects and procedures 
 
Subjects 
 
To study clinical characteristics and fitness of type 1 diabetes (T1D), we 
compared a group of 129 subjects affected by T1D with 136 subjects without 
diabetes (controls). 
 
The subjects with T1D were outpatients derived from Hospital Clinic de 
Barcelona. The individuals that were studied as controls came from the staff of 
Hospital Clínic de Barcelona and Laboratory of Diabetes and Obesity 
(IDIBAPS). All the people that joined this evaluation received written and verbal 
explanations about the procedures and signed an informed consent for 
participation in the study. This study was approved by Ethics and Research 
Committees of Hospital Clinic de Barcelona (CEIC nº Register: 2009/4933). 
 
The study was performed at Diabetes Research Clinical Unit, a research 
division of IDIBAPS and Hospital Clínic de Barcelona. One of the research 
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interests of this Unit is the study of exercise and physical activity related to 
diabetes; and, for that, we had the collaboration of several people that accepted 
the invitation and volunteered to participate in the study. These people 
presented different levels of fitness and different physical activity habits, both in 
T1D and control groups.  
 
Men and women, age between 18 and 55 years old, without cardiorespiratory 
pathologies or osteomuscular limitations were included in the study. Subjects 
with T1D with advanced chronic complications related to diabetes and/or 
cardiovascular disease were excluded. Patients with incipient retinopathy, 
albuminuria lower than 300 mg/24h and/or initial peripheral neuropathy, defined 
by slight reduction of vibratory sensitivity (values lower than 25 V in 
biothesiometer measurement, but higher than 15 V) (Duke et al., 2007), were 
allowed to participate.  
 
It was defined as type 1 diabetes all the patients with diagnostic in childhood or 
adolescence, classical history of weight loss, polydipsia, polyuria, and that 
needed treatment with insulin immediately after the diagnosis or some few 
weeks later. Some patients, moreover, had registers of positive autoantibodies 
(anti-GAD and/or anti-IA2). Hypertension was defined as systolic blood 
pressure ≥ 135 mmHg and/or diastolic blood pressure ≥ 90 mmHg and/or in use 
of anti-hypertensive drugs. The anti-hypertensive drugs were from the classes 
of angiotensin converting enzyme inhibitors or antagonist receptors angiotensin 
II and/or diuretics. Dyslipidemia was defined as triglycerides ≥ 150 mg/dl and/or 
LDL-C ≥ 130 mg/dl and/or HDL-C < 50 mg/dl for women or < 40 mg/dl for men. 
The chronical use of statins was also a criterion for dyslipidemia (American 
Hearth Association, 2002; International Diabetes Federation, 2006). 
 
Procedures   
 
a. Anamnesis, physical evaluation and anthropometry 
  
Initially, all the participants answered questions about medical history, familial 
history, habitual physical activity, practice of exercise or habitual sport, and 
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answered the International Physical Activity Questionnaire, short form (IPAQ) 
(“International Physical Activity Questionnaire,” n.d.). 
  
IPAQ is an easy and reproducible questionnaire, used in many countries, which 
facilitates comparison among different populations. Individuals were asked to 
report the number of days and the duration of the vigorous, moderate, and 
walking activities they had undertaken during the previous week (Sjöström, Oja, 
Hagströmer, Smith, & Bauman, 2006). These data were quantified, and an 
estimated MET (Metabolic Equivalent of Task) was attributed to each activity. 
One MET was defined as the energy spent sitting quietly (equivalent to [4.184 
kJ] • kg-1 • h-1). Estimated MET-min per week in this questionnaire, taking the 
different intensities of the activity components into account, were calculated by 
multiplying reported weekly minutes spent in different activities by 8 METs for 
vigorous, by 4 METs for moderate, and by 3.3 METs for walking activities, 
respectively. Energy expenditure per individual was obtained by adding the 
MET-minutes of the three activity components. According to IPAQ score, each 
individual was assigned to one of three categories: high, moderate, and low 
physical activity (“International Physical Activity Questionnaire,” n.d.). Those 
individuals who did not reach a minimum of minutes and/or days per week of 
vigorous, moderate or walking activities, following IPAQ classifications, met the 
criteria for ‘low’ physical activity levels and were thus considered as sedentary 
individuals (Guthold, Ono, Strong, Chatterji, & Morabia, 2008; “International 
Physical Activity Questionnaire,” n.d.; Sjöström et al., 2006) (Annex 1). 
 
Baseline clinical characteristics such as height, weight, BMI, waist and hip 
circumferences, and total and fat body composition were obtained. Body 
composition was evaluated by different methods. The first one was the skinfold 
thickness measurements (Jackson and Pollock equations) (Image 1); the 
second, bioimpedance, that was obtained though multifrequency bioimpedance 
(MediSystem, Sano Care Human Systems) and abdominal impedance (Tanita 
ViScan AB-140) (Image 2); and the third, total body and abdominal composition, 
measured by densitometry using DXA (Lunar iDXA body composition, GE 
Healthcare) (Image 3) (Alvero Cruz, Diego Acosta, Fernández Pastor, & 
Romero, 2005a, 2005b, 2005c).  
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Image 1 - The skinfold thickness measurements  
 
1.a. Skinfold measurement  
 
 
 
 
1.b. Skinfold anatomic references 
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1.c. Skinfold caliper (Holtain, U.K.) 
 
  
 
 
 
Image 2 - Bioimpedance assessment  
2.a. Multifrequency bioimpedance (MediSystem, SanoCare Human Systems) 
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2.b. Abdominal impedance (Tanita ViScan AB-140) 
 
 
 
 
 
 
Image 3 - Total body composition measured by densitometry using DXA  
3.a. DXA densitometer (GE Healthcare, Lunar iDXA) 
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3.b. Example of general image acquisition  
 
 
 
 
 
3.c. Example of abdominal and gynecoid segments acquisition 
 
 
 
Abdominal segment 
Gynaecoid segment 
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Arterial blood pressure was measured using a blood pressure monitor (Hem-
703 C, Omron, Barcelona, Spain) after several minutes of rest. After some 
minutes in supine position, blood pressure was verified; immediately after the 
measurement, the subject was asked to assume the seated position and blood 
pressure was verified again 1 minute later. The difference of 20 mmHg or more 
between both systolic blood pressure measurements was defined as orthostatic 
hypotension (Vinik, Maser, Mitchell, & Freeman, 2003). Patients had cardiologic 
evaluation by clinical examination, rest electrocardiogram (ECG) and ECG by 
cycle-ergometer test. 
 
All subjects were also evaluated for peripheral neuropathy by symptoms, 
physical examination and biothesiometry exploration on first toes and 
metatarsal heads localizations (Bio-thesiometer, Bio-Medical Instrument 
Company, Newbury, OH, U.S.). Subjects with T1D were included in the study if 
presented no symptoms of peripheral polineuropathy and no more than slight 
alteration on biothesiometry exploration (vibratory perception lower than 25 
volts) (J. B. Dyck & Dyck, 1999; Schmid, Neumann, & Brugnara, 2003; Tesfaye 
et al., 2010). 
 
From medical registers, we had access to albuminuria results and 
ophthalmological examination from patients with T1D. All patients included in 
the study presented normal albuminuria or persistent albuminuria values below 
300 mg/24h, and normal retinal exam or incipient retinopathy. Patients with 
persistent albuminuria above 300 mg/24h, or severe nonproliferative or 
proliferative retinopathy were excluded (American Diabetes Association, 2015). 
 
 
b. Physical Fitness Evaluation 
Maximal oxygen uptake or peak (VO2peak) was determined by using a maximal 
progressive incremental exercise test on a friction-braked cycle-ergometer 
(Monark 828E, Monark Sweden). After a 3 min warm-up period at a power 
output of 25-W, workload was increased by 25-W every minute until exhaustion. 
Oxygen uptake was monitored during exercise using a computerized, open 
circuit gas-collection system (Vmax Spectra, version v12.0, Sensor Medics 
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Corp, VIASYS Healthcare Inc, Yorba Linda, CA, U.S.), and VO2peak was 
determined at the point of highest oxygen consumption over a 15-s period. 
VO2peak was confirmed using established physiological criteria, including a 
respiratory exchange ratio above 1.15, oxygen uptake reaching a plateau 
despite an increased work rate, a heart rate near 95% of the age-predicted 
maximum value, or the incapacity to maintain the marked load (Image 4). 
 
Image 4 - Maximal oxygen uptake in cycle-ergometer 
(Monark 828E, Monark Sweden / Vmax Spectra, version v12.0, Sensor Medics 
Corp, VIASYS Healthcare Inc, Yorba Linda, CA, U.S.) 
 
 
 
 
 
c. Standard biochemical determinations and eGDR 
 
Subjects with type 1 diabetes had usual laboratory determinations: glycemia 
(glucose-oxidase method, Advia 2400 Siemens Diagnostics, Deerfield, IL, U.S.); 
glycated hemoglobin (HbA1c) (high-performance liquid 
chromatography [HPLC]); total-cholesterol (TC), HDL-cholesterol (HDL-C) and 
VO
2
peak  
determination 
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triglycerides (TG) (molecular absorption spectrometry) and LDL-cholesterol 
(LDL-C) (Friedewald equation); and albuminuria (immunoturbidimetric assay). 
 
Estimated glucose disposal rate (eGDR) was calculated by the equation 
originally developed by Williams and colleagues (Williams et al., 2000) for use 
in patients with T1D. This equation result of eGDR is expressed in milligrams 
per kilogram per minute and it has a good correlation with values measured with 
a euglycemic-hyperinsulinemic clamp. The equation was modified to be use 
with HbA1c instead of HbA1 (Wáden et al., 2005):  
eGDR = 24.4 – 12.97*(waist-to-hip ratio) – 3.39*(hypertension) – 0.60*(HbA1c), 
where no hypertension is assigned as 0 or hypertension as 1, based on blood 
pressure ≥ 140/90 and/or antihypertensive medication. 
 
d. Statistical Analysis:  
Mean and standard deviation were used to express the clinical and biochemical 
results obtained. ANOVA or Student test were used to compare continuous 
variables; Mann-Whitney U test for non-parametrical variables; chi-square was 
used for dichotomous variables; and Spearman tests for variable correlations. It 
was assumed as significant difference a p value < 0.05.  
 
 
 
Results 
 
An initial overview of subjects that participated is presented in Table 1.1. One-
hundred twenty-nine patients with type 1 diabetes (T1D) and 136 subjects 
without diabetes (controls – CT) were evaluated. The subjects in both groups 
participated in different training modalities - like running, swimming, cycling, 
tennis, soccer –, or performed habitual walking or recreational bicycling, or even 
no activity at all. All participants presented normal cardiac evaluation and no 
one presented orthostatic hypotension or peripheral vasculopathy. 
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Subjects with T1D presented similar age (36.7 ± 11.6 years in T1D vs. 35.8 ± 
8.8 in CT), similar clinical history of hypertension, dyslipidemia or active 
smoking than control subjects. The groups were also not different when 
compared by body composition, considering body mass index (BMI) or total fat 
percentage by skinfolds, or total and abdominal fat percentage, by 
bioimpedances, or DXA. The proportion of low, moderate and high active 
subjects were not different between groups, as well as estimated energy 
consumption evaluated by METs in IPAQ-SF questionnaire. The groups were 
different on the proportion of men and women, fact that could justify the 
differences in weight, height and VO2peak (Table 1.1). 
 
Subjects with T1D were compared separately by gender (Table 1.2). Men and 
women presented the main differences in the field of body composition, 
analyzed by different methods: BMI, skinfolds, bioimpedance and DXA. 
Moreover, women were less active than men (IPAQ classification p= 0.003) and 
presented lower VO2peak (32.3 mL/kg/min ± 10.3 vs. 23.3 ± 7.2, p < 0.001). In 
biochemical analysis, women presented higher levels of HDL cholesterol and 
higher eGDR index.  
 
Aware of these differences in weight, height, body composition and VO2peak 
(Tables 1.1 and 1.2), men and women were analyzed separately. Table 1.3 
presented data from women, and in Table 1.4, data from men. Women with T1D 
presented similar age, body composition, physical activity levels and 
cardiorespiratory capacity than control women. 
 
Men with T1D presented similar body composition and physical activity than 
control men (Table 1.4). In the T1D group, men were older (37.6 ± 11.4 vs. 34.5 
± 6.7 years, p = 0.028) and presented a lower cardiorespiratory capacity (32.3 ± 
10.3 vs. 38.5 ± 11.6 mL/kg/min, p = 0.001) when compared with control ones. 
Age was studied as a covariate, and with this correction, the VO2peak 
difference between the diabetes and control groups remained different (p = 
0.003). 
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Table 1.1 – Overview of clinical characteristics of all subjects 
Total 
(265) 
Type 1 diabetes 
(129) 
Controls 
(136) 
p 
 
Sex (Men / Women) 
 
98 / 31 
 
75 / 61 
 
< 0.001 
Age (years) 36.7 ± 11.6 35.8 ± 8.8 ns 
Hypertension (n) 31 10 < 0.001 
Dyslipidemia (n) 28 8 < 0.001 
Active smoking (n) 32 34 ns 
BODY COMPOSITION    
   Weight (kg) 74.8 ± 12.3 70.8 ± 12.6 0.01 
   Height (m) 1.74 ± 0.07 1.71 ± 0.09 0.008 
   BMI (kg/m2) 24.6 ± 3.2 24 ± 2.9 ns 
   Waist (cm) 84.4 ± 11 81.8 ± 10.1 ns 
   WHR (Waist/hip ratio) 0.84 ± 0.07 0.82 ± 0.07 ns 
   Total fat % (skinfolds) 18.9 ± 7.6 18.6 ± 7.4 ns 
   Total fat % (bioimpedance) 21.2 ± 6.9 21.1 ± 7.4 ns 
   Abdominal fat % (bioimpedance) 10.3 ± 6 9.9 ± 11.4 ns 
   Total fat % (DXA) 26.1 ± 8.7 27.7 ± 8.8 ns 
   Abdominal fat % (DXA) 30.1 ± 12.3 31.5 ± 11.6 ns 
PHYSICAL FITNESS    
   Physical Activity 
   (low / moderate / high) 
29 / 47 / 53 37 / 47 / 52 ns 
   IPAQ – SF (METs/week) 2411 ± 1934 2492 ± 2192 ns 
   VO2peak (mL/kg/min) 30.3 ± 10.6 33.4 ± 11.8 0.031 
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Table 1.2 – Clinical and biochemical characteristics of men and women with 
type 1 diabetes 
 
 T1D 
(129) 
men 
(98) 
women 
(31) 
p 
    
Age (years) 37,6 ± 11,4 33,2 ± 11,5 ns 
Evolution of diabetes (years) 16.4 ± 10.2 13.4 ± 9.6 ns 
Hypertension (n) 26 5 ns 
Dyslipidemia (n) 19 9 ns 
Active smoke (n) 20 12 ns 
CHRONIC COMPLICATIONS    
     Retinopathy (n) 17 3 ns 
     Nephropathy (n) 4 1 ns 
     Neuropathy (n) 9 1 ns 
     Macrovascular disease (n) 0 0 - 
Doses of insulin (Total Units/day) 47.8 ± 18.1 32.8 ± 14.7 <0.001 
Units of insulin / body weight (U/kg) 0.61 ± 0.22 0.51 ± 0.21 0.026 
BODY COMPOSITION    
   BMI (kg/m2) 24.9 ± 2.8 23.1 ± 3.2 <0.001 
   Waist (cm) 86.5 ±10.6 77.5 ±9.3 <0.001 
   WHR (Waist/hip ratio)  0.86 ±.06 0.77 ±.05 <0.001 
   Total fat % (skinfolds) 16.6 ± 6.6 26.1 ± 5.9 <0.001 
   Total fat % (bioimpedance) 19.4 ± 5.9 27.4 ± 6.6 <0.001 
   Abdominal fat % (bioimpedance) 11.1 ± 6.4 7.4 ± 2.9 <0.001 
   Total fat % (DXA) 23 ± 7.3 34.5 ± 6.6 <0.001 
   Abdominal fat % (DXA) 28 ± 12.4 36.2 ± 10.1 <0.001 
PHYSICAL FITNESS    
   Physical Activity (low / moderate / high) 21 / 29 / 48  8 / 18 / 5 0.003 
   SF-IPAQ (METs/week) 2459 ± 1759 2120 ± 1285 ns 
   VO2peak (mL/kg/min) 32.3 ± 10.3 23.3 ± 7.2 <0.001 
BIOCHEMICAL ANALYSIS    
   Glycemia (mg/dl) 159.1 ± 69.4 166.5 ± 49.2 ns 
   Total cholesterol (mg/dl) 177.5 ± 33.7 194.1 ± 34.8 ns 
   LDL cholesterol (mg/dl) 110 ± 24.1 118.8 ± 26.7 ns 
   HDL cholesterol (mg/dl) 53 ± 11.8 62.6 ± 12.2 0.004 
   Triglycerides (mg/dl) 72.5 ± 33.8 63.4 ± 32.1 ns 
   Glycated hemoglobin (%) 7.2 ± 1 7.5 ± 1.2 ns 
   Creatinine (mg/dl) 0.98 ± 0.26 0.79 ± 0.09 0.008 
   eGDR (mg/kg/min) 8 ± 1.9 9.2 ± 2 0.019 
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Table 1.3 - Clinical characteristics in women with type 1 diabetes and controls 
 
WOMEN 
(92) 
Type 1 diabetes 
(31) 
Controls 
(61) 
p 
 
Age (years) 
 
33.2 ± 11.5 
 
37.6 ± 11 
 
ns 
BODY COMPOSITION    
   Weight (kg) 64.1 ± 10.8 61.5 ± 8.9 ns 
   Height (m) 1.65 ± 0.06 1.63 ± 0.06 ns 
   BMI (kg/m2) 23.5 ± 3.8 22.9 ± 2.8 ns 
   waist (cm) 77.5 ± 9.5 77.1 ± 9.7 ns 
   WHR (waist/hip ratio) 0.77 ± 0.05 0.78 ± 0.07 ns 
   Total fat % (skinfolds) 26.1 ± 5.9  23.3 ± 7 ns 
   Total fat % (bioimpedance) 27.4 ± 6.6 24.3 ± 8.9 ns 
   Abdominal fat % (bioimpedance) 7.3 ± 2.8 3.7 ± 5.3 ns 
   Total fat % (DXA) 34.5 ± 6.6 33.5 ± 7.9 ns 
   Abdominal fat % (DXA) 36.2 ± 10.1 34.9 ± 12.5 ns 
FISICAL FITNESS    
   Physical Activity  
   (low / moderate / high) 
8 / 18 / 5 20 / 28 / 13 ns 
   SF-IPAQ (METs/week) 2120 ± 2285 1841 ± 1634 ns 
   VO2peak (mL/kg/min) 23.3 ± 7.2 26.8 ± 8.8 ns 
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Table 1.4 – Clinical characteristics in men with type 1 diabetes and controls 
 
MEN 
(173) 
Type 1 diabetes 
(98) 
Controls 
(75) 
p 
 
Age (years) 
 
37.6 ± 11.4 
 
34.5 ± 6.7 
 
0.028 
BODY COMPOSITION    
   Weight (kg) 78.1 ± 10.8 78.3 ± 9.9 ns 
   Height (m) 1.76 ± 0.06 1.77 ± 0.06  ns 
   BMI (kg/m2) 25 ± 3 24.9 ± 2.7 ns 
   Waist (cm) 86.5 ± 10.6 85.9 ± 8.4 ns 
   WHR (waist/hip ratio) 0.86 ± 0.06 0.86 ± 0.05 ns 
   Total fat % (skinfolds) 16.6 ± 6.6 15 ± 5.4 ns 
   Total fat % (bioimpedance) 19.3 ± 5.9 18.7 ± 4.8 ns 
   Abdominal fat % (bioimpedance) 11.2 ± 6.4 11.9 ± 14.2 ns 
   Total fat % (DXA) 23 ± 7.3 23 ± 6.3 ns 
   Abdominal fat % (DXA) 28 ± 12.4 28.6 ± 10 ns 
PHYSICAL FITNESS    
   Physical Activity  
   (low / moderate / high) 
21 / 29 / 48 17 / 19 / 39 ns 
   SF-IPAQ (METs/week) 2459 ± 1759 3044 ± 2477 ns 
   VO2peak (mL/kg/min) 32.3 ± 10.3 38.5 ± 11.6 0.001 
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A remarkable number of highly active men was included in this study, fact that 
permitted a specific analysis of this subgroup of subjects, with the intention of 
understanding better this difference in cardiorespiratory capacity in T1D men. 
Table 1.5 shows the data of 48 patients with T1D and 39 controls. Both groups 
presented similar age, body composition and estimated energy consumption 
evaluated by METs in IPAQ-SF questionnaire, but, despite these similitudes, a 
lower cardiorespiratory capacity in T1D group was verified when compared with 
the control one (36.4 ± 10.2 vs. 42.8 ± 12.5 mL/kg/min, p = 0.016). 
 
We also studied a possible effect of an incipient chronic complication related to 
diabetes in the group of men with T1D. Chronic complications allowed in this 
study were incipient retinopathy, presence of persistent albuminuria (≥ 30 
mg/24h and ≤ 300 mg/24h) and/or initial peripheral neuropathy (values lower 
than 25 V in biothesiometer measurement, but higher than 15 V). Clinical and 
laboratorial characteristics of patients with T1D were also explored in this 
analysis (Table 1.6). In this specific analysis, 8 subjects presented incipient 
retinopathy, 2 presented persistent albuminuria, and 4 presented initial 
peripheral neuropathy (12 subjects with any combination). The group with any 
chronic complications was older (38.4 ± 8.9 vs.30.6 ± 9.9 years old, p = 0.02) 
and presented more years of evolution of the diabetes (22.1 ± 12.3 vs. 11.2 ± 7, 
p=0.01). Despite of these differences, in our group of patients, early chronic 
complications did not influence the cardiorespiratory capacity (Table 1.6). 
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Table 1.5 – Clinical characteristics of high active men with type 1 diabetes and 
controls 
 
MEN 
(87) 
Type 1 diabetes 
(48) 
Controls 
(39) 
   p 
 
Age (years) 
 
32.6 ± 10.2 
 
35.5 ± 6.5 
 
ns 
 
Hypertension (n) 
 
8 
 
5 
 
ns 
 
Dyslipidemia (n) 6 4 ns 
Active smoking (n) 10 8 ns 
BODY COMPOSITION    
   BMI (kg/m
2
) 24.8 ± 2.7 25 ± 2.5 ns 
   Waist (cm) 84.8 ± 9.7 85.3 ± 8 ns 
   WHR (waist/hip ratio) 0.85 ± 0.05 0.85 ± 0.05 ns 
   Total fat  % (skinfolds) 14.7 ± 6.4  13.2 ± 4.8 ns 
   Total fat % (bioimpedance) 18.8 ± 5.8 18.3 ± 4.6 ns 
   Abdominal fat % (bioimpedance) 9.3 ± 5.4 9.3 ± 4 ns 
   Total fat % (DXA) 20.4 ± 6.8 20.9 ± 5.2 ns 
   Abdominal fat % (DXA) 23.5 ± 12 25.4 ± 9.2 ns 
PHYSICAL FITNESS    
   SF-IPAQ (METs/week) 3793 ± 1425 4473 ± 2551 ns 
   VO
2
peak (mL/kg/min) 36.4 ± 10.2 42.8 ± 12.5 0.016 
  
70
Study 1 
Table 1.6 – Clinical characteristics of high active men with type 1 diabetes 
concerning incipient chronic complications related to diabetes 
 
 
High active men with T1D 
(48) 
Any chronic  
incipient 
complication 
(12) 
Without 
chronic 
complications 
(36) 
   p 
 
Age (years) 
 
38.4 ± 8.9 
 
30.6 ± 9.9 
 
0.02 
 
Evolution of diabetes (years) 
 
22.1 ± 12.3 
 
11.2 ± 7 
 
0.01 
 
Hypertension (n) 
 
3 
 
5 
 
ns 
 
Dyslipidemia (n) 0 5 ns 
Active smoking (n) 1 8 ns 
Units of insulin (U/day) 42.5 ± 9.6 48.1 ± 19.8 ns 
BODY COMPOSITION    
   BMI (kg/m
2
) 25.1 ± 2.4 24.7 ± 2.9 ns 
   Waist (cm) 85.5 ± 7.9 84.6 ± 10.4 ns 
   WHR (waist/hip ratio) 0.83 ± 0.04 0.85 ± 0.05 ns 
   Total fat  % (skinfolds) 17.5 ± 4.6 13.7 ± 6.7 ns 
   Total fat % (bioimpedance) 20.5 ± 2.4 18.3 ± 6.5 ns 
   Abdominal fat % (bioimpedance) 9.1 ± 3 9.3 ± 6.1 ns 
   Total fat % (DXA) 21.4 ± 5.3 20.1 ± 7.3 ns 
   Abdominal fat % (DXA) 23.6 ± 8.7 23.5 ± 13 ns 
PHYSICAL FITNESS    
   SF-IPAQ (METs/week) 3615 ± 1577 3852 ± 1390 ns 
   VO
2
peak (mL/kg/min) 38.5 ± 10.5 35.5 ± 10.1 ns 
eGDR (mg/kg/min)  8.4 ± 1.3 8.3 ± 1.8 ns 
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We also compared highly and less active men with T1D (Table 1.7). We could 
identify that highly active men were younger than less active (35.5 ± 10.2 vs. 
43.9 ± 9.6 years old, p < 0.001), presented less years of evolution of diabetes, 
had less hypertension and less dyslipidemia. In almost all parameters of body 
composition, less active men presented higher percentage of total and 
abdominal fat. In the biochemical analysis, the only parameter that presented a 
difference between groups was fasting glycemia (high 144 ± 55 mg/dl vs. low 
192 ± 83, p = 0.014). EGDR was higher in the highly active group (8.3 ± 1.6 
mg/kg/min vs. 7 ± 2.1, p = 0.024).  
 
EGDR correlations with continuous physical activity variables in T1D are 
presented in Table 1.8 (all T1D subjects), Table 1.9 (men with T1D) and Table 
1.10 (women with T1D). EGDR did not correlate with the physical activity 
variables, named VO2peak or METs by IPAQ-SF. A negative correlation of 
eGRD with total fat percentage (by DXA) in men was found. Considering that 
the data of waist/hip ratio takes part of the formula for the estimation of insulin 
sensitivity (eGDR), it is a coherent result. Other correlations that could be 
verified were the percentage of total fat inversely with physical fitness 
(VO2peak) or with physical activity amount (METs).      
 
We looked for a possible correlation between fitness (VO2peak) and glycemic 
control (HbA1c), but it was not significant. 
 
Finally, we compared the different methods for the determination of body fat 
composition. The total fat percentage estimated by DXA was positively 
correlated with total fat percentage by bioimpedance (p > 0.001, R = 0.741) and 
with total fat percentage by skinfolds (p < 0.001, R = 0.892). For abdominal fat 
percentage, the determination by DXA was positively correlated with abdominal 
by bioimpedance (p < 0.001, R = 0.651).  
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Table 1.7 - Clinical characteristics of men with type 1 diabetes, comparing high 
physical activity with low physical activity  
 
Men with T1D 
(69) 
High physical 
activity 
(48) 
Low physical 
activity 
(21) 
 
 p 
     
Age (years) 32.5 ± 10.2 43.9 ± 9.6 < 0.001 
Evolution of diabetes (years) 14  ± 9.8 19.4 ± 9.2 0.03 
Hypertension (n) 8 10 0.014 
Dyslipidemia (n) 5 8 0.011 
Active smoking (n) 9 3 ns 
Units of insulin (U/day) 46.8 ± 17.9 54.4 ± 17.3 ns 
BODY COMPOSITION     
   BMI (kg/m2) 24.8 ± 2.7 26.2 ± 3.7 ns 
   Waist (cm) 84.8 ± 9.7 92.7 ± 12.7 0.013 
   WHR (waist/hip ratio) 0.85 ± 0.05 0.9 ± 0.07 0.01 
   Total fat  % (skinfolds) 14.7 ± 6.4 19.8 ± 6.4 0.005 
   Total fat % (bioimpedance) 18.8 ± 5.8 20.8 ± 7.9 ns 
   Abdominal fat % (bioimpedance) 9.3 ± 5.4 16.5 ± 7.4  < 0.001 
   Total fat % (DXA) 20.4 ± 6.8 28.3 ± 6.1 < 0.001 
   Abdominal fat % (DXA) 23.5 ± 12 36.7 ± 9.1 < 0.001 
PHYSICAL FITNESS    
   SF-IPAQ (METs/week) 3793 ± 1425 488 ± 387 < 0.001 
   VO2peak (mL/kg/min) 36.4 ± 10.2 25.1 ± 7.3 < 0.001 
BIOCHEMICAL ANALYSIS    
   Fasting glycemia (mg/dl) 144 ± 55 192 ± 83 0.014 
   HbA1c (%) 7.2 ± 1.1 7.2 ± 1.2 ns 
   Total cholesterol (mg/dl) 172 ± 37 184 ± 34 ns 
   HDL-cholesterol (mg/dl) 52.9 ± 13.7 53.2 ± 8.6 ns 
   LDL-cholesterol (mg/dl) 104.9 ± 30 116.6 ± 24 ns 
   Triglycerides (mg/dl) 69.2 ± 31.5 70.7 ± 48.3 ns 
eGDR (mg/kg/min) 8.3 ± 1.6 7 ± 2.1 0.024 
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Table 1.8 – Correlations eGDR with physical fitness variables and total fat 
percentage in type 1 diabetes (men and women) 
 
 METs a VO2peak eGDR 
 
Total Fat % (DXA) 
 
R = - 0.46 
 
R = - 0.614 
 
R = - 0.146 
 p < 0.001 p < 0.001 p = 0.19 
    
METs a  R = 0.517 R = 0.186 
  p < 0.001 p = 0.078 
    
VO2peak (mL/kg/min)   R = 0.076 
   p = 0.48 
a IPAQ-SF in METs/week 
 
 
Table 1.9 - Correlations eGDR with physical fitness variables and total fat 
percentage in men with type 1 diabetes  
 
 METs a VO2peak eGDR 
 
Total fat % (DXA) 
 
R = - 0.389 
 
R = - 0.419 
 
R = - 0.393 
 p < 0.001 p < 0.001 p = 0.002 
 
METs a 
 
- 
 
R = 0.472 
 
R = 0.23 
  p < 0.001 p = 0.055 
 
VO2peak (mL/kg/min) 
  
- 
 
R = 0.124 
   p = 0.323 
a IPAQ-SF in METs/week 
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Table 1.10 - Correlations eGDR with physical fitness variablesand total fat 
percentage in women with type 1 diabetes  
 
 METs a VO2peak eGDR 
 
Total fat % (DXA) 
 
R = - 0.471 
 
R = - 0.581 
 
R = - 0.291 
 P < 0.001 p < 0.001 p = 0.201 
 
METs a (per week – SF-IPAQ) 
 
- 
 
R = 0.451 
 
R = 0.33 
  p < 0.001 p = 0.88 
 
VO2peak (mL/kg/min) 
  
- 
 
R = 0.153 
   p = 0.066 
a IPAQ-SF in METs/week 
 
 
 
Discussion 
 
The present analysis is based on an observational study of patients with T1D 
and subjects without diabetes that volunteered to participate in this evaluation. 
The patients that were included in the final analysis did not present advanced 
chronic complications related to diabetes. In the group with diabetes there was 
a higher proportional presence of men than in the control group. Some clinical 
characteristics were found to be different between the groups with or without 
diabetes: a higher prevalence of hypertension and dyslipidemia and a lower 
VO2peak, a marker of physical fitness level. 
 
VO2peak may be conditioned by some factors like age, gender, genetics and 
physical training (Powers & Howley, 2015). Thus, we separated the subjects by 
gender (Tables 1.3 and 1.4) to review the variables in more detail. The analysis 
of women showed no differences between the ones with T1D and the control 
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ones. On the other hand, men with T1D presented lower VO2peak than the 
ones without diabetes, even after the adjustment for age. We are aware about 
the small number of subjects, especially women, and a possible different 
physical training between the subjects. Due to that, we specifically compared 
highly active men with and without T1D (Table 1.5), and VO2peak presented 
sustained lower rates in T1D. A lower VO2peak in subjects with T1D was 
already observed by some studies (William Ricardo Komatsu et al., 2005; 
Nguyen et al., 2014), but not confirmed by others (Benbassat et al., 2001; 
William R Komatsu et al., 2010), as stated in the Rationale. The glycemic 
control is referred as a factor that could influence VO2peak, but no association 
was found in our study, probably due to the adequate glycemic control 
presented by the subjects that participated in this analysis reflected by glycated 
hemoglobin (HbA1c) of 7.2 ± 1 % in men and 7.5 ± 1.2 in women.  
 
EGDR in an easy clinical index to estimate insulin sensitivity in subjects with 
T1D. In the present analysis, the difference of eGDR index between men and 
women must be interpreted carefully because one of the elements of the 
equation of eGDR is waist/hip ratio (WHR), and women constitutionally present 
lower values of WHR (Table 1.2).  
 
It is described that eGDR is associated with microvascular complications 
(Chillarón et al., 2009; Girgis et al., 2012), subclinical atherosclerosis (Olson et 
al., 2002) and low grade inflammation (Llauradó et al., 2012) and it also predicts 
coronary artery disease (Orchard et al., 2003; Orchard, Costacou, Kretowski, & 
Nesto, 2006). In the present study, we analyzed just a few patients with any 
chronic complication (n = 12), but they did not present difference in the eGDR 
index compared to the ones without complications (Table 1.6). It is 
demonstrated that sedentary patients had lower eGDR (Wáden et al., 2005) 
than active ones, and we could obtain similar results when we compared highly 
active with less active men (Table 1.7), identifying that low active subjects 
presented higher prevalence of hypertension and higher waist/hip ratio (criteria 
for eGDR) and a probable higher insulin resistance. 
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Finally, we did not obtain correlations of physical fitness (VO2peak) and physical 
activity levels (METs) with eGDR (Tables 1.8, 1.9 and 1.10), but VO2peak with 
total body fat percentage.   
 
The results suggest a lower physical fitness of men with T1D when compared 
with control men. Despite the careful characterization of the participants in 
relation to clinical data, body composition, metabolic control and chronic 
complications, we believe that studies with a higher number of subjects must be 
performed to confirm these results.  
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AIM 2 – STUDY 2 
 
Metabolomics approach for analyzing the effects of exercise in subjects 
with type 1 diabetes mellitus 
 
In the second study, we proposed to analyze the metabolic response to an 
acute exercise in subjects with T1D, in order to understand the main metabolic 
aspects of this response and to verify if there were differences compared to 
subjects without diabetes. 
 
For this, we worked with the Metabolomics Platform from Universitat Rovira i 
Virgili, which performed a non-target metabolomic analysis from the serum of 
the subjects. This metabolomics analysis was explored by two approaches:  1H-
NMR and GC-MS.  
 
To avoid gender interference in the results, we invited just men to participate. 
The volunteers were invited from the ones that had already participated in the 
baseline evaluation in de Diabetes Research Clinical Unit, from the series 
explained in Study 1. Ten men with T1D and 11 men without diabetes 
participated in the Study 2. 
 
The exercise proposed was 30 minutes of cycle-ergometer at 80% maximal 
aerobic capacity, calculated from of each individual VO2peak, already 
determined in the first evaluation.  The tests were performed at first hour in the 
morning, in fasting state. Participants with T1D were oriented to do not inject 
fast-action insulin in the morning. Capillary blood determinations were 
performed before, during and after the 30 min of the exercise test in subjects 
with T1D. Blood samples were taken before and just after the 30 minutes of 
exercise from all subjects. 
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The results are described in the following publication: 
Brugnara L, Vinaixa M, Murillo S, Samino S, Rodriguez MA, Beltran A, et al. 
(2012) Metabolomics Approach for Analyzing the Effects of Exercise in Subjects 
with Type 1 Diabetes Mellitus. PLoS ONE 7(7): e40600. 
doi:10.1371/journal.pone.0040600  
 
IF (2012): 3.73; Q1; D2 
Referred by 16 publications on October 2015. 
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Abstract
The beneficial effects of exercise in patients with type 1 diabetes (T1D) are not fully proven, given that it may occasionally
induce acute metabolic disturbances. Indeed, the metabolic disturbances associated with sustained exercise may lead to
worsening control unless great care is taken to adjust carbohydrate intake and insulin dosage. In this work, pre- and post-
exercise metabolites were analyzed using a 1H-NMR and GC-MS untargeted metabolomics approach assayed in serum. We
studied ten men with T1D and eleven controls matched for age, body mass index, body fat composition, and
cardiorespiratory capacity, participated in the study. The participants performed 30 minutes of exercise on a cycle-
ergometer at 80% VO2max. In response to exercise, both groups had increased concentrations of gluconeogenic precursors
(alanine and lactate) and tricarboxylic acid cycle intermediates (citrate, malate, fumarate and succinate). The T1D group,
however, showed attenuation in the response of these metabolites to exercise. Conversely to T1D, the control group also
presented increases in a-ketoglutarate, alpha-ketoisocaproic acid, and lipolysis products (glycerol and oleic and linoleic
acids), as well as a reduction in branched chain amino acids (valine and leucine) determinations. The T1D patients presented
a blunted metabolic response to acute exercise as compared to controls. This attenuated response may interfere in the
healthy performance or fitness of T1D patients, something that further studies should elucidate.
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Introduction
Type 1 diabetes mellitus (T1D) is a lifelong metabolic disorder
of usual acute onset in children, adolescents and young adult
people. Over time, micro and macro vascular co-morbidities
develop in patients with T1D which are closely related to
metabolic control [1]. In addition to these complications, the
management of T1D is particularly complex and challenging. It is
well known that, in order to maintain optimal glycemic control,
T1D patients need accurate administration of insulin coordinated
with a balanced diet and an adequate level of physical activity.
Exercise plays a crucial role in the prevention and treatment of
several chronic diseases, including glucose intolerance states, type
2 diabetes [2–4] and diseases of the cardiovascular system [5,6].
Moreover, it has been demonstrated that exercise improves the
quality of life in the general population [7]. However, the
beneficial effects of exercise in patients with T1D are not fully
proven, given that exercise may occasionally induce acute
metabolic disturbances, mainly related to insulin treatment.
Nevertheless, children and adolescents with T1D are encouraged
to exercise regularly as a means of improving social integration
and cardiovascular health [8]. Thus, a better understanding of the
effects of exercise on the metabolic response in T1D patients will
allow clinicians to prescribe exercise to their patients with greater
clarity.
Metabolomics enables the systematic assessment of the abun-
dant changes of low molecular weight compounds present in
biological samples, using high-throughput sample analysis tech-
niques (GC-MS, NMR or HPLC-MS) and computer-assisted
multivariate pattern-recognition techniques [9]. Metabolomics is
enriching our current understanding of both the physiologic and
physiopathologic processes underlying diabetes mellitus [10–12].
Moreover, recent metabolomic-based studies have described the
first metabolic signatures of exercise in human plasma [13–15].
For example, Lewis et al [13] described the metabolic changes in
tricarboxylic acid cycle, fatty acid oxidation and lypolisis in the
plasma of healthy subjects exposed to different intensities and
durations of exercise.
Most of the in vivo studies investigating the metabolic pathways
of T1D have been performed under strictly controlled conditions
using hyperinsulinemic euglycemic clamp techniques [16,17] or in
situations of insulin withdrawal [12]. Although these studies have
provided invaluable new insights into the metabolic disturbances
present in T1D, the experimental conditions used are dissimilar to
everyday life. To the best of our knowledge, no study to date has
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applied a metabolomics approach prior to and following exercise
in subjects with T1D. We hypothesize that (a) an acute bout of
exercise will result in changes in the systemic metabolic profile and
that (b) these parameters will be different in patients with T1D in
comparison to healthy controls. The aim of this study is to analyze
the metabolic changes induced by a short-term session of acute
exercise performed by T1D patients and their corresponding non-
diabetic counterparts. A comprehensive 1H-NMR and GC-MS
untargeted metabolomics approach was applied to serum samples
taken from all participants.
Methods
Participants
Ten recreationally active male patients with T1D, recruited by
the Department of Endocrinology (Hospital Clinic, Barcelona),
and eleven non-diabetic controls matched for sex, age, body mass
index (BMI) and similar physical activity, recruited from a
research institute (IDIBAPS, Barcelona), were enrolled in the
study.
The T1D patients participating in the study had diabetes for a
total of 1468.4 years, undetectable C-peptide levels and good
glycemic control, as determined by glycated hemoglobin A1c.
Total body composition was measured by densitometry using
DXA (Lunar iDXA body composition, GE Healthcare). Patients
with chronic complications related to diabetes were excluded. All
patients presented microalbuminuria values below 30 mg/L,
normal retinal exam by direct and indirect retinoscopy, normal
peripheral neurologic evaluation by clinical exploration and
biothesiometry (Bio-thesiometer, Bio-Medical Instrument Com-
pany, Newbury, OH, U.S.), and normal. resting 12-lead electro-
cardiogram (ECG) and normal exercise testing by upright cycle-
ergometer (25 W/3 min) [18]. At the time of testing, none of the
T1D participants were taking any form of prescription medication,
except for long-acting basal insulin analogue glargine (Sanofi-
Aventis, U.S.) and fast-acting insulin analogue aspart (Novo
Nordisk, Denmark).
Experimental Procedures
All subjects were required to visit the Diabetes and Exercise
Research Unit of the Hospital Clı´nic on two separate occasions.
On the first visit, all subjects were fully briefed and familiarized
with the experimental procedures. Baseline clinical characteristics
such as height, weight, BMI and total and fat body composition
where also obtained, and each subject was required to complete an
evaluation of current physical activity using the International
Physical Activity Questionnaire [19]. Maximal oxygen uptake
(VO2max) was determined by using a maximal progressive
incremental exercise test on a friction-braked cycle-ergometer
(Monark 828E, Monark Sweden). After a 3 min warm-up period
at a power output of 25-W, workload was increased by 25-W every
minute until exhaustion. Oxygen uptake was monitored during
exercise using a computerized, open circuit gas-collection system
(Vmax Spectra, version v12.0, Sensor Medics Corp, VIASYS
Healthcare Inc, Yorba Linda, CA, U.S.), and VO2max was
determined at the point of highest oxygen consumption over a 15-s
period. VO2max was confirmed using established physiological
criteria, including a respiratory exchange ratio above 1.15, oxygen
uptake reaching a plateau despite an increased work rate, and a
heart rate near 95% of the age-predicted maximum value.
On the second visit, conducted at the same time (8:30am) a
week later, subjects performed an acute bout of 30 minutes of
intense exercise at 80% VO2max (individually calculated during
the preliminary session) on a cycle-ergometer. Subjects performed
3 to 6 minutes of warm-up until achieving a fixed cardiac
frequency. Prior to exercise, all participants fasted overnight for a
12 hour period, following a balanced meal consisting of
approximately 55% carbohydrates, 30% fat, and 15% proteins.
Furthermore, T1D patients had received their last short-acting
insulin injection before dinner at 8 p.m. and their long-acting
insulin injection at 10 p.m. All subjects were asked to avoid
strenuous exercise and alcohol consumption the day prior to the
acute exercise protocol.
Blood determinations. Fasting blood samples were obtained
before and after the short-term intensive exercise intervention.
Glycemia (glucose-oxidase method, Advia 2400 Siemens Diag-
nostics, Deerfield, IL, U.S.) and insulinemia (quimioluminiscent
method, Siemens Healthcare Diagnostics, Tarrytown, NY, U.S.)
were determined in serum samples. For the metabolomic
measurements, serum was obtained once blood had been allowed
to clot at room temperature for 30 min and after centrifugation at
4uC at 5000 rpm for 10 min. Samples were kept at - 80uC until
further metabolomic analysis.
Serum 1H-NMR metabolomics. Serum samples were
thawed, vortexed and allowed to stand for 10 min prior to
NMR analysis. For NMR measurements 430 ml of serum were
transferred into 5 mm NMR tubes. A double tube system was
used: an internal tube (o.d. 2 mm, supported by a Teflon adapter)
containing the reference substance (sodium 3-trimethylsilyl [2, 2,
3, 3-d4] propionate (TSP) 9.9 mmol/l, MnSO4 0.47 mmol/l in
99.9% D2O) was placed coaxially into the NMR sample tube (o.d.
5 mm). This double tube system was kept at 4uC in the sample
changer until analysis was performed. Spectra were acquired at a
1H observation frequency of 600.20 MHz at a temperature of
300 K using an Avance III-600 Bruker spectrometer equipped
with an inverse TCI 5 mm cryoprobeH. The Carr-Purcell-
Meiboom-Gill (cpmg, spin-spin T2 relaxation filter) pulse sequence
with a fixed spin-spin relaxation delay of 200 ms was applied to
acquire 1H-NMR spectra for all serum samples, in order to
minimize the broad signals arising from lipoprotein and albumin
in the NMR spectra. For each sample, 128 transients were
collected into 32 K data points using a spectral width of 12 kHz
with a relaxation delay of 2 s and an acquisition time of 1.36 s. A
line-broadening function of 0.3 Hz was applied to all spectra prior
to Fourier transform.
Serum GC-MS metabolomics. A second aliquot of serum
(100mL) was used for GC-MS analysis according to Agilent’s
specifications [20]. Each aliquot was spiked with 20 ml internal
standard solution (1 mg.mL-1 succinic-d4 acid; Sigma-Aldrich).
After protein precipitation using 900 ml of cold methanol/water
(8:1 v/v), samples were centrifuged for 10 minutes at 4uC. 200 mL
of the supernatant were transferred to a GC autosampler vial and
spiked with 20 ml of myristic acid-d27 (Sigma Aldrich), used as the
internal standard for retention time lock (RTL system provided in
Agilent’s ChemStation Software), and lyophilized overnight (Lyo-
trap freeze dryer). Samples were methoximated by incubating
lyophilized serum residues in 50 ml of methoxyamine in pyridine
(0.3 mg/mL) for 16 hours at room temperature. Silylation was
subsequently done using 30 mL of N-methyl-N-trimethylsilyltri-
fluoroacetamide with 1%trimethylchlorosilane (MSTFA +1%
TMCS, Sigma) for 1 hour at room temperature. Samples were
automatically injected into a GC–MS system (HP 6890 Series gas
chromatograph coupled to a mass selective detector model 5973)
equipped with a J&W Scientific DB 5-MS+DG stationary phase
column (30 m 6 0.25 mm i.d., 0.1 mm film) (Agilent Technolo-
gies). The injector temperature was set at 250uC, and the helium
carrier flow rate was kept constant at 1.1 mL/min. The column
temperature was held at 60uC for 1 min, then increased to 325uC
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at a rate of 10uC/min and held at 325uC for 10 min. The detector
operated in the electron impact ionization mode (70 eV) and mass
spectra were recorded after a solvent delay of 4 min with 2.46
scans per second (mass scanning range of m/z 50–600; threshold
abundance value of 50 counts). The source temperature and
quadrupole temperature were 230 and 150uC, respectively.
Ethics
Written informed consent was obtained from all subjects prior
to participation. The experimental protocol was approved by the
Research and Ethics committees of the Hospital Clı´nic de
Barcelona, in accordance with the Declaration of Helsinki.
Data Analysis and Statistical Methods
The acquired CPMG 1H-NMR spectra were phased, baseline-
corrected and referenced to the chemical shift of the a-glucose
anomeric proton doublet at 5.23 ppm. Pure standards compound
reference in BBioref AMIX (Bruker) was used; HMDB and
Chenomx databases were used for metabolite identification. After
baseline correction, intensities of each 1H-NMR region identified
in the CPMG 1D-NMR spectra were integrated using the AMIX
3.8 software package (Bruker, GmBH). Each region was normal-
ized to the ERETIC (Electronic REference To access In vivo
Concentrations) signal [21].
Raw GC/MS files were exported into the platform-independent
netCDF (*.cdf) and loaded into XCMS software (version 1.6.1)
based on R-program version 2.4.0 (R-Foundation for statistical
computing, www.Rproject.org), where peak peaking, integration
and alignment in the time domain were performed. Integrated
intensities of each m/z-retention time pair (MZRT) were obtained
for each one of the samples used in the study. These intensities
were normalized to internal standard succinic acid-d4. The
AMDIS program (Automated Mass Spectral Deconvolution and
Identification System, National Institute of Standards and
Technology, Gathersburg, MD, U.S.A.) was run for peak
annotation, and both the Fiehn GC/MS Metabolomics RTL
Library and NIST mass spectral databases were used for
identification. Table S1 shows detailed identification parameters
for both GC-MS and 1H-NMR determined metabolites.
Baseline metabolic differences between T1D and control groups
were evaluated using the Mann-Witney U run test. Effects of
exercise intervention on the independent control and T1D groups
were assessed using the Wilcoxon exact rank sum tests. Repeated
measures ANOVA were used to determine diabetes6exercise
interactions. A statistically significant interaction indicates that
control and T1D responded differently to the acute exercise
protocol for a given metabolite. To account for multiple testing, q-
values were computed for all systematic univariate tests outlined
above by applying the FDR (False Discovery Rate) procedure
described by Storey et al [22]. In all cases statistical significance
was set at q#0.1.Data (pre-) processing, data analysis, and
statistical calculations were performed with Matlab (Matlab
version 6.5.1, Release 13, The Mathworks, 2003).
Results
Clinical and Biochemical Baseline Characteristics
Anthropometric and fitness data are summarized in Table 1. In
ten patients with T1D and eleven controls matched for age,
height, weight, and body mass index (BMI), no differences were
found in relation to the percentage of body fat composition and
cardio respiratory capacity evaluated by VO2max.
At baseline (Table 2), subjects with T1D presented higher
glucose and insulin levels than controls. Moreover, untargeted 1H-
NMR and GC-MS metabolomic profiling results showed elevated
levels of the tricarboxylic acid cycle intermediates (TCAIs) malate
and citrate in T1D. Glycerol was also increased in the T1D group,
whereas lysine levels were significantly lower as compared to the
control group.
Metabolic Changes Induced by Short-term Intensive
Exercise
Figure 1A shows a comparison of the mean net percent
variation following exercise in the individual T1D and control
groups for glucose and insulin. After 30 minutes of intensive
exercise, glucose levels varied differently according to diabetic
condition. The T1D group, hyperglycaemic at baseline, showed
significant glucose depletion with acute exercise unlike their
control counterparts. Insulin levels also varied differently with the
exercise according to diabetic condition. While insulin levels rose
Table 1. Clinical characteristics of T1D patients and control
population.
Control T1D
p-
values
Subjects 11 10 ns
Age (years) 32.568.8 35.168.4 ns
Evolution of diabetes (years) – 1468.4 –
Height (m) 1.7660.06 1.7660.05 ns
Weight (kg) 75.968.6 75.665.8 ns
BMI (kg/m2) 24.762.6 24.361.7 ns
Fat percentage (%, by DXA) 23.965.7 21.766.5 ns
IPAQ (METs min/week) 25506995 26306241 ns
VO2max (mL/kg/min) 3469.1 3566.5 ns
Units of insulin glargine – 3167.9 –
Values are reported as mean values 6 SD.
ns: not significant.
doi:10.1371/journal.pone.0040600.t001
Table 2. Baseline analytical differences of T1D patients and
control population.
Control
(n = 11)
T1D
(n=10) q-values
Biochemical determinations
Glucose (mg/dl) 90.2762.25 202.7624.36 5.5261024
Insulin (UI/L) 6.9661.31 18.6264.64 0.022
C-peptide (ng/ml) – undetectable –
Glycated hemoglobin (%) – 6.961 –
Metabolomics analysis (arbitrary units)
Lysine 0.03960.0036 0.02560.0029 0.023
Glycerol 0.03960.0022 0.04560.0039 0.064
Citrate 0.00660.0004 0.00860.0005 0.052
Malate 0.00160.0001 0.00260.0002 0.083
Values are reported as mean values 6SEM. Selected quantitative ions relative to
internal standard areas are used in the case of GC-MS measurements. Selective
1H-NMR regions relative to ERETIC digital signals are used in the case of NMR
measurements. Two-sided p-values are calculated using Mann-Witney test.
Statistical significance was set as q,0.1.
doi:10.1371/journal.pone.0040600.t002
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significantly with exercise in the T1D group, control exercisers
showed a net decrease of insulin, which did not account for
statistical significance. Although after short-term acute exercise
both T1D and control groups showed a significant net increase in
circulating levels of gluconeogenic precursors (alanine and lactate),
this increase was less pronounced in the T1D group (Figure 1B). In
addition to alanine and lactate, pyruvate increased significantly
with exercise in the control group but not in the T1D group.
A significant enrichment in TCA cycle intermediates citrate,
malate, fumarate, and succinate was observed after acute exercise
in the peripheral blood of both control and T1D groups (Figure 2).
However, a-ketoglutarate levels significantly increased only in the
case of control exercisers. In general terms, there was less
accumulation of TCA cycle intermediates in serum in the T1D
group. No changes in other TCAIs were identified (isocitrate,
succinil-coA and oxalacetate), nor was any interaction observed
between the groups of T1D and controls in the metabolites that
increased following exercise.
Exercise significantly increased glycerol and oleic and linoleic
acid concentrations in the control group exclusively. This effect
was attenuated in the T1D group (Figure 3A). There was no
interactive effect observed between the T1D and control groups in
these products of lipolysis. Branched chain amino acids (valine and
leucine) were lower following short-term acute exercise in the
control group (Figure 3B). These changes were paralleled by
significantly increased levels of alpha-ketoisocaproic acid (2-KIC)
in the same group. This increase was shown to be a diabetes-
dependent trend (p-interaction diabetes6exercise = 0.05) but not
statistically significant after FDR correction at the established
conventional significance level (q#0.1). Worth mentioning is
lysine, which also showed a diabetes-dependent effect with the
exercise.
Metabolite identification parameters are presented in support-
ing table (Table S1).
Discussion
The principal aim of this study was to analyze the metabolomic
profile at rest and after a short period of intense exercise in patients
affected by T1D to provide a comprehensive insight into the
physiological effects of exercise on this particular population.
Based on serum sample analysis, we have compared the metabolic
response to short term acute exercise in T1D and healthy subjects
using an untargeted metabolomics approach (GC-MS and 1H-
NMR). Our findings revealed similar metabolic events in T1D
patients and their control matched exercisers, although the T1D
patients showed an attenuation of overall metabolic response after
intense short-term exercise.
As it is commonly known, in order to increase energy supply
during intense short-term exercise, glycogen breakdown is induced
Figure 1. Relative changes in insulin and glucose and in gluconeogenic precursors in response to acute exercise. Relative changes in
insulin and glucose (A) and in gluconeogenic precursors (B) in response to 30 minutes of acute exercise (80% VO2max). Percentage of variation was
calculated for each individual as the levels of a certain metabolite after exercise minus the levels of the same metabolite prior to exercise relative to
the former. Data are shown as mean6sem of net percent variation for T1D and control groups. A positive value of percentage of variation indicates
that metabolic levels have increased in mean with exercise, whereas a negative mean denotes the opposite. *Indicates a significant variation in
metabolic levels with exercise (Wilcoxon rank-summed test for the comparison of a particular metabolite level prior to and after exercise in the
independent T1D and control exercisers, q,0.1). #Indicates a significant diabetes6exercise interaction for a particular metabolite (Repeated-
measures ANOVA, q,0.1). Insulin and glucose data correspond to biochemical measurements, whereas lactate, alanine, and pyruvate were evaluated
in 1H-NMR spectra according to Table S1.
doi:10.1371/journal.pone.0040600.g001
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to provide the substrate for activating anaerobic glycolysis,
resulting in the accumulation of pyruvate and lactate in plasma.
Recently, Lewis et al [13] confirmed these results by using LC-
MS-based metabolomics in a non-diabetic population. Our data,
using a different metabolomic approach based on 1H-NMR and
GC-MS techniques, showed that the non-diabetic group presented
an increase in serum lactate and pyruvate concentration after
exercise, indicating that glycolysis was activated, as previously
reported by other groups [13,23]. However, the T1D patients
elicited only an increase in lactate levels having blunted the
pyruvate response, suggesting that exercise induces a reduced
activation of glycogenolysis and glycolysis in the T1D group as
compared to the control group. Given the inhibitory effect of
insulin on glycogen breakdown, the higher insulin levels observed
in the T1D group could explain in part the attenuated
glycogenolytic response.
Our analysis demonstrated a significant increase in TCAIs
(malate, citrate, succinate, fumarate and a-ketoglutarate) in the
control subjects in response to exercise. These results are in
accordance with a previous metabolomics-based study investigat-
ing the plasma signature of exercise [13], in which accumulated
levels of malate, fumarate and succinate were reported following
60 minutes of exercise in a healthy cohort. Other studies have
demonstrated that an increase in the total concentration of TCAIs
is necessary to enhance and maintain TCA cycle flux during
strenuous exercise [24]. In addition, a positive correlation has been
demonstrated between the total concentration of TCAIs and the
estimated TCA cycle flux in human skeletal muscle taken from
muscle biopsies during exercise [25]. In the case of patients with
T1D, our results also pointed to a less significant accumulation of
TCAIs after exercise, which might also compromise the TCA flux
rates. Given that many of the reactions that lead to a net influx of
TCAIs are directly or indirectly dependent on the level of pyruvate
and that elevated concentrations of pyruvate appear to be
necessary for the anaplerosis pathway [25], we suggest that the
insufficient increase in pyruvate concentrations in T1D subjects
might have an impact on TCA cycle replenishment. In this sense,
our findings of an attenuated enrichment of TCAIs in the serum of
T1D patients in response to a short period of intense exercise
indicate that the activation of the TCA cycle flux rates might be
affected. This suggests that the T1D group has a compromised
oxidative aerobic system as compared to the control group, as the
T1D group did not show a significant turnover of TCA
metabolites.
Concerning lipolysis, our data demonstrated that the healthy
controls showed an increase in free fatty acids and glycerol in
response to exercise, however, this response was attenuated in the
T1D group. The increase in lipolysis after acute exercise had been
previously reported in healthy individuals [13,26]. Under condi-
tions of hyperinsulinemia induced by clamp techniques, a
suppression of the intramuscular and subcutaneous adipose tissue
lipolysis was demonstrated in healthy volunteers [27,28]. In
another study performed in obese men, a delay in the lipolytic
activation was observed together with an increase in plasma
insulin levels following 30 minutes of acute resistance exercise, a
finding that the authors attributed to an increase in insulin levels
Figure 2. General significant enrichment in TCA cycle intermediates (TCAIs) in peripheral blood after acute exercise. Monitored using
GC-MS (malate, fumarate, a-ketoglutarate) and NMR (citrate and succinate). Data are mean6sem of net percent variation with exercise. *Indicates a
significant variation in metabolic levels with exercise (Wilcoxon rank-summed test for the comparison of a particular metabolite level prior to and
after exercise in the independent T1D and control exercisers, q,0.1).
doi:10.1371/journal.pone.0040600.g002
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[26]. The increased insulin levels found in the T1D group in our
study could have a role in the attenuated lipolytic action observed
following exercise.
Our results demonstrated that control exercisers presented a
significant reduction in leucine levels. It is well established that
exercise increases energy expenditure, resulting in the promotion
of amino acid catabolism in general and, in particular, in the
oxidation of branched chain amino acids, mainly leucine [13,29].
In parallel to the reduction of leucine, we observed an increase in
circulating levels of 2-KIC, which is the first step in leucine
degradation. This increase in 2-KIC is in concordance with a
previous reported study on the metabolomic profiling performed
on urine samples of men following acute exercise [15]. Our results
suggest that the effect induced by exercise on protein catabolism
was attenuated in the diabetic patients, in agreement with other
authors who have previously demonstrated a decrease in protein
catabolism in T1D patients [17]. Moreover, there are evidences
confirming that elevated insulin levels induced by infusion in
healthy men promote muscle protein anabolism by inhibiting
protein breakdown [30] and elicit the ability to stimulate glucose
uptake and alanine transport, thus suppressing protein degrada-
tion in skeletal muscle [31]. Taking all these data into consider-
ation, we propose that the high insulinemia levels induced by
exogenous insulin administration in our T1D group could be the
cause of reduced protein breakdown, as demonstrated by the
minor alterations observed in the levels of leucine and 2-KIC
following exercise.
Of special note, we detected an increase in insulin serum levels
in all the T1D patients after 30-minute of acute exercise. This
increase may explain in part the attenuation in the metabolomic
response of all energetic substrates. Pharmacokinetic studies have
shown that the peak action of insulin glargine is usually within the
first 3 or 4 hours after injection [32], and in our protocol, samples
were taken 10 hours later. One possible explanation for the
increased insulin concentration detected in the serum of our T1D
group could be that intense exercise induces the lipolysis of
Figure 3. Relative changes in lypolysis (A) and BCAA metabolism (B) with acute exercise. Data are mean6sem of net percent variation.
*Indicates a significant variation in metabolic levels with exercise (Wilcoxon rank-summed test for the comparison of a particular metabolite level
prior to and after exercise in the independent T1D and control exercisers, q,0.1). #Indicates a significant diabetes6exercise interaction for a
particular metabolite (Repeated-measures ANOVA, q,0.1).
doi:10.1371/journal.pone.0040600.g003
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subcutaneous adipose tissue where insulin is stored and rapidly
released into the circulation. In line with this hypothesis, Davison
et al [33] previously reported an exercise-induced lipolysis effect
by monitoring the release of liposoluble vitamins from the
subcutaneous tissue into the bloodstream, an effect which may
be responsible for the increased insulin levels observed in our T1D
patients.
Although we speculate that high insulin levels induced by
exogenous treatment may be responsible for the attenuated
response of metabolites to acute exercise, alternative explanations
must also be considered. For example, the possible presence of
insulin resistance (IR), an important condition described in T1D
patients, cannot be ignored. Some authors have considered that
supra-physiologic levels of exogenous insulin [34] and hypergly-
cemia per se [35] could be responsible for IR in T1D patients.
Insulin, not the rate of glucose disposal per se, regulates glycogen
synthesis, meaning that the low level of glycogen synthase activity
found in insulin-resistant states is a consequence of impaired
insulin action, rather than reduced glucose disposal. Nevertheless,
this assumption has been challenged in a more recent study in
which adult patients with T1D exhibited both impaired glucose
utilization and impaired insulin-induced non-esterified fatty acid
suppression [36]. In addition, these patients showed IR in hepatic
and skeletal muscle tissue, despite good glycemic control [37].
Another report [38] demonstrated that T1D adolescents had
significantly impaired functional exercise capacity and decreased
insulin sensitivity as compared to non-diabetic adolescents. In spite
of their IR and reduced cardiovascular fitness, T1D youth showed
paradoxically normal intramyocellular lipid content (IMCL). This
finding contradicts the previously well- established theory that
IMCL accumulation is a marker for insulin resistance in both T1D
and T2D [39,40].
Metabolic flexibility defined as the ability to switch from fat to
carbohydrate oxidation is usually impaired during a hyperinsulin-
emic clamp in insulin-resistant subjects. Thus, the phenomena of
metabolic inflexibility mainly described in T2D and other insulin-
resistant states could explain some of the alterations occurring in
the machinery of lipid and glucose metabolism [41,42]. In
addition, the inability to modify fuel oxidation in response to
changes in nutrient availability has been implicated in the
accumulation of intramyocellular lipids as well as in insulin
resistance. Exercise represents a paradigm which requires a highly
regulated coordination between fuel supply and oxidative
machinery. The assumption that metabolic inflexibility may affect
energy metabolism under exercise conditions in T1D patients
remains to be elucidated.
Several studies involving T2D patients and their offspring have
demonstrated the presence of mitochondrial dysfunction [43,44].
In T1D patients, mitochondrial dysfunction has also been
described, contributing to abnormalities in the TCA cycle and
fatty acid metabolism. A recent report [45] verified that the
mitochondrial capacity of untrained women with T1D correlates
positively with glycemic control. The hypothesis that mitochon-
drial abnormalities may be a primary cause of metabolic
inflexibility and insulin resistance has been offered. Significant
differences in mitochondrial number, structure and function have
been described between insulin-resistant and insulin-sensitive
subjects, but the causal link still remains unknown [46].
Although our study was not designed to analyze IR or metabolic
flexibility, these factors might have influenced the metabolomic
spectrum described in our T1D patients. In addition, the presence
of hyperglucagonemia and impaired glucagon counterregulation,
as reported in several studies [47], could affect lipolysis,
gluconeogenesis and protein metabolism. Finally, other situations
not present in our patients should be taken into account, such as
autonomic dysfunction, which influences lypolitic responsiveness
[48], cardiac dysfunction, which has been documented in T1D
patients as affecting exercise responses [49,50], and abnormal
blood flow during exercise, which could affect muscular vascular
function, contributing toward metabolic disturbances [51].
In summary, we report that T1D patients have an attenuated
metabolic response as compared to their healthy control counter-
parts after a short period of acute, intense exercise. We speculate
that exercise could mobilize the subcutaneous exogenous insulin
depot in adipose tissue. Furthermore, our data suggest that high
insulinemia levels might play a role in the attenuated response in
lipolysis, proteolysis, glycogenolysis, and oxidative metabolism
observed in T1D patients following exercise. Whether the
attenuation of metabolic response to acute and intense exercise
might interfere in the training performance of T1D patients
remains to be elucidated, and additional studies are required.
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Table S1. Metabolite identification parameters 
 
1H-NMR Metabolites δ(ppm) multiplicity Moieties 
Glycerol 3.65 double doublet Half (-CH2-) 
Citrate 2.52 doublet Half (-CH2-) 
Lactate 1.33 doublet -CH3 
Succinate 2.39 singlet (-CH2-) 
Pyruvate 2.36 singlet (-CH2-) 
Alanine 1.46 doublet -CH3 
    
GC-MS Metabolites RT(min) Quantitative ion (m/z)  
Malate  12.87 245  
Lysine  17.02 200  
Fumarate  11.0 245  
-ketoglutarate  13.88 198  
Oleic acid  20.48 339  
Linoleic acid  20.43 337  
-ketoisocaproic acid (2-KIC)  9.13 200  
Leucine  8.33 170  
Valine 9.22 144  
 
Metabolite identification parameters. 
1
H-NMR: proton nuclear magnetic resonance 
spectroscopy; δ: chemical shift; GC-MS: gas chromatography-mass spectrometry; RT: retention 
time 
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AIM 3 – STUDY 3 
 
Muscular lipids content in patients with type 1 diabetes in relation to their 
level of physical activity 
 
In the third study, we proposed to analyze the muscular lipids content in 
patients with type 1 diabetes in relations to their level of physical activity, in 
order to understand components imbalances and/or some influence of insulin 
resistance. 
 
For this study, we had the collaboration of Ana Isabel García and Jaume 
Pomes, from the Department of Radiology of Hospital Clínic de Barcelona; 
Guerau Fernandez and Susana Kalko, from Bioinformatics Core Facility from 
IDIBAPS; and Miguel Angel Rodriguez, Maria Vinaixa and Xavier Correig, from 
the Metabolomics Platform from Universitat Rovira i Virgili, in Reus. 
 
 
Rationale 
  
The skeletal muscle is one of the most important organs for the glucose 
metabolism and is directly related to insulin resistance and sensitivity 
(DeFronzo et al., 1979; Petersen et al., 2007). Some metabolic conditions, such 
as type 2 diabetes (T2D) and obesity, have been importantly associated with 
muscular insulin resistance (IR) (S E Kahn, 2003; Steven E Kahn, Hull, & 
Utzschneider, 2006). In subjects with type 1 diabetes (T1D), despite the 
growing knowledge about IR associated components, there are little information 
on muscle particularities and specific metabolism.   
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Imbalances of muscular composition, fatty acids intramyocellular accumulations 
and mitochondrial dysfunction have been implicated in muscular dysfunction 
(Petersen et al., 2004). The mitochondrial dysfunction, related to a reduction of 
mitochondrial content, mitochondrial biogenesis and/or electron transport chain 
(ETC) content, induces a reduction of the oxidative capacity, and is associated 
with lipid accumulation and reduction of insulin action (Befroy et al., 2007; 
Montgomery & Turner, 2015; Morino et al., 2006; Petersen et al., 2004), and, in 
parallel, the accumulation of intramyocellular lipids (IMCL) has been proposed 
as an important predictor of IR (White et al., 2006). In subjects with T2D and/or 
obesity, it was observed an excess of IMCL accumulation (He et al., 2001; D E 
Kelley et al., 1999) and this condition occurs in muscle with predominantly type I 
muscular fibers (oxidative slow-twitch) (Hwang, Pan, Heydari, Hetherington, & 
Stein, 2001).  
 
In humans, two main muscular fiber types, the type I and the type II, are 
described. The type I fibers, in normal conditions, have a high capacity for fatty 
acid oxidation and insulin-stimulated glucose transport, present more 
mitochondria and GLUT4 content than type II fibers, and are mainly implicated 
in aerobic actions. These fibers are characterized by long period utilization. By 
the opposite, type II fibers, in their subclasses type IIa (oxidative fast-twitch) and 
specially type IIx (glycolytic fast-twitch), show less IMCL amounts, are more 
glycolytic, present lower mitochondrial and GLUT4 content, and are mainly 
implicated in anaerobic actions (Egan & Zierath, 2013; Schiaffino & Reggiani, 
2011). Some studies have identified, by biopsies of vastus lateralis muscle, a 
less content of type I fibers in T2D and in obese subjects, less GLUT4 
expression, and/or less oxidative enzyme capacity especially in type I fibers 
than in lean controls (Gaster et al., 2001; He et al., 2001; Oberbach et al., 2006; 
Stuart et al., 2013). 
 
Recently, it has been recognized that patients with T1D could present different 
degrees of insulin resistance (Bergman et al., 2012; Liu et al., 2009). However, 
there is less information about changes in the muscle fibers, neither dysfunction 
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nor lipid accumulation in this group of subjects. One study identified decrease of 
the slow oxidative and increase of the glycolytic fibers fractions by biopsies in 
vastus lateralis muscle when compared with normal glucose tolerant subjects; 
and the study also showed significantly higher glycolytic enzyme activities in all 
fiber types, which were correlated with a worse glycemic control, expressed by 
HbA1c (Fritzsche et al., 2008). Another study (Gianluca Perseghin et al., 2003) 
verified higher accumulations of IMCL in calf muscles of adult population with 
T1D, mostly if there was an inadequate glycemic control, indicating also an 
assignment of this organ and probable changes on its functions.  
 
Designed interventions of physical activity in patients with T2D, or high-risk 
populations, were able to reduce the IMCL, demonstrating to be effective in the 
increase of mitochondria activity and in insulin sensitivity (Meex et al., 2010). 
Nevertheless, it is not clear if this beneficial effect of physical activity would 
have the same results in patients with T1D. 
 
Proton magnetic resonance spectroscopy (1H MRS) is a specialized non-
invasive approach used for the estimation, in vivo, of certain human muscle 
compounds. Recently, by this technique, it was described that carnosine could 
estimate fiber type composition (Baguet et al., 2011). Carnosine is a dipeptide 
present in high concentrations in skeletal muscle and is involved in many 
physiological processes. This dipeptide has an important role as an intracellular 
buffer and it is more abundant in fast-twitch (type II) muscle type, which has the 
higher capacity to generate energy from anaerobic glycolytic metabolism 
(Baguet et al., 2011; Boldyrev, Aldini, & Derave, 2013). Nowadays, a few 
studies are starting to use this resource for the elucidation of muscular 
composition in different conditions (Baguet et al., 2011; Gualano et al., 2012). 
Creatine is another stable dipeptide in muscle mainly present in type II fibers 
(Rico-Sanz et al., 1999). In parallel, 1H MRS is also a well-established method 
for the determination of IMCL, and even for the differentiation of saturated and 
unsaturated lipids into the cell, whose imbalance has been described as altered 
in processes such as osteoporosis and renal cell carcinoma (Katz-Brull et al., 
2005; Yeung et al., 2005).  
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The aim of this study was to evaluate a possible muscle imbalance in patients 
with T1D through a non-invasive method (1H MRS), for the assessment of 
intramyocellular lipid (IMCL) accumulation and the influence of physical activity 
on these features. The identification of muscular components by a non-invasive 
method in patients with T1D and the comprehension of the associated clinical 
factors could help in the approach and in the better care of these subjects. 
 
 
Research design and Methods 
 
Participants 
 
Sixteen men with T1D, recruited from the Department of Endocrinology 
(Hospital Clinic, Barcelona), and fourteen men without diabetes (control group), 
recruited from staff of Laboratory of Diabetes and Obesity (IDIBAPS), were 
enrolled in the study. From the subjects with T1D, 10 were highly trained 
competitor athletes (marathon, triathlon or cycling) and six were sedentary (less 
than once a week of structured physical activity); and in control group, nine 
were athletes and five were sedentary. The Research and Ethics committees of 
the Hospital Clínic of Barcelona approved the experimental protocol, in 
accordance to the Declaration of Helsinki. Written informed consent was 
obtained from all subjects prior to participation.  
 
The patients with T1D that participated in the study had diabetes diagnosis for 
more than 5 years. Estimated glucose disposal rate (eGDR), an indicator of 
insulin sensitivity in patients with T1D, was calculated (taking into account 
HbA1c, waist/hip ratio and presence of hypertension) (Trevor J Orchard et al., 
2006; Williams et al., 2000, Waden 2005). Patients with chronic complications 
related to diabetes were excluded, except if presented incipient retinopathy. All 
patients presented microalbuminuria values below 30 mg/L; normal peripheral 
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neurologic evaluation by clinical exploration and biothesiometry (Bio-
thesiometer, Bio-Medical Instrument Company, Newbury, OH, U.S.); and 
normal cardiologic evaluation by rest electrocardiogram (ECG) and by cycle-
ergometer test. Hypertension and active smoking habit were registered. None of 
the participants was in use of lipid lowering drugs. At the time of testing, none of 
the participants was taking any form of prescription medication. Patients with 
T1D were in multiple daily injection (MDI) regimen. 
 
 
Procedures 
 
All subjects were invited to perform the tests in the Diabetes Research Clinical 
Unit of IDIBAPS/Hospital Clínic. Baseline clinical characteristics such as height, 
weight, BMI and total body composition where also obtained, and each subject 
was required to complete an evaluation of current physical activity using the 
short version of International Physical Activity Questionnaire, that provided an 
estimation of METs (“International Physical Activity Questionnaire,” n.d.). They 
were also classified as athletes if performed routinely 4 or more sessions (1 or 
more hours) a week of moderate and/or intense exercises like running or 
cycling; and classified as sedentary if performed less than once a week of 
structured physical activity. 
 
In addition to the conventional anthropometric parameters, total body 
composition was measured by densitometry using DXA (Lunar iDXA body 
composition, GE Healthcare). Maximal oxygen uptake (VO2peak) was 
determined by using a maximal progressive incremental exercise test on a 
friction-braked cycle-ergometer (Monark 828E, Monark Sweden) as described 
elsewhere (Brugnara et al., 2012).  
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Blood determinations 
Fasting blood samples were obtained. Standard biochemical analyses were 
determined at Hospital Clinic laboratory: fasting glycemia (glucose-oxidase 
method, Advia 2400 Siemens Diagnostics, Deerfield, IL, U.S.), glycated 
hemoglobin (HbA1c) (high-performance liquid chromatography [HPLC]), 
albuminuria (immunoturbidimetric assay), total-cholesterol (TC), HDL-
cholesterol (HDL-C) and triglycerides (TG) (molecular absorption spectrometry) 
and LDL-cholesterol (LDL-C) (Friedewald equation). 
 
1H MRS studies  
Subjects were scanned using a 3T whole body MRI system (Siemens Trio, 
Erlangen, Germany), positioned the right leg in the magnet bore, using a 
transmit/receive extremity coil and a 4-channel flexible coil for calf and thigh 
musculature, respectively. Axial T1-weighted spin-echo (SE) MR images were 
obtained at the proximal two thirds of the calf and the thigh (TR 450ms, TE 
18ms, slice thickness 5mm, interslice gap 0mm, two acquisitions, 166 x 256 to  
320 x 260 matrix, and field of view 220 to 400 mm). Single voxel point-resolved 
spectral selection (PRESS) spectroscopy pulse sequence (TR 3000ms, TE 
30ms, 128 average in the acquisition with water suppression, 60 average in the 
acquisition without water suppression of the same voxel for each scan, 1024 
data points over 2000 kHz spectral width, TA: 6´) with manual shimming, was 
used to obtain spectra from the soleus (predominant slow-twitch), tibialis 
anterior (predominant fast-twitch) and vastus intermedius (mixed fast-twitch) 
muscles (Edgerton, Smith, & Simpson, 1975; Yang & Yoo, 1986), with very 
careful positioning of the voxel (size 3.6mL to 4.5mL) in muscles without any 
visible intermuscular fat, blood vessels and bone in the images. The PRESS 
box was prescribed on the axial T1-weighted SE images of the calf and thigh in 
the cross-sectional area with greater muscles volumes (Figure 3.1).  
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Figure 3.1. Example of the three muscles studied by 1H MRS and the voxel positioning 
(white square in each muscle).    
 
 
The spectra were analyzed using jMRUI software (v. 4.0 for Java). The 
metabolite peaks were fitted with AMARES using lorentzian line shapes and 
soft constraints for the peak position and linewidth. Area under the curve of 
peak arising at δ ~8 ppm was used to estimate the carnosine and at δ ~3 ppm 
was used to estimate the creatine skeletal muscle levels. The lipid pool was 
obtained with the area under the curve from methylene protons (in saturated 
lipids) within IMCL (at 1.2 ppm) and EMCL (at 1.4 ppm), and olefinic protons (in 
unsaturated lipids, or UFA) within IMCL (at 5.2 ppm) and EMCL (at 5.4 ppm). 
Carnosine, creatine and lipid content were scaled to the water peak at 4.6 ppm 
position of the spectra. (Figure 3.2) 
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Figure 3.2. Example of a muscular espectrum in tibialis anterior from one patient. In the 
upper part of the figure, individual component, the peaks are represented as follows: 1. 
carnosine; 2. olefinic protons EMCL; 3. olefinic protons IMCL; 4. water; 5. creatine; 6. methylene 
protons EMCL; 7. methylene protons IMCL. In the botton part it is represented the original raw 
spectrum.  
 
 
Lipid unsaturation index was calculated according the ratio of the olefinic to 
methylene protons in intramyocellular and extramyocellular compartments 
(signal at 5.2 / 1.2 ppm within IMCL, and 5.4 / 1.4 ppm within EMCL) (Katz-Brull 
et al., 2005), here called as UI_IMCL and UI_EMCL, respectively.  
 
Statistical analysis  
Categorical data are expressed as frequencies and percentages, and 
continuous data as means ± SD or 95% confidence interval (95% CI) following 
normal distribution, and median and interquartile ranges (IQRs) following non 
normal distribution.  
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We ran an exploratory covariance PCA on Partek to identified outliers. 
Statistical differences of clinical as well as muscle data by group, subgroup or 
by exercise were analyzed using Fisher exact test for categorical data and 
ANOVA and FDR Step Up as multiple test correction method for continuous 
data. We also tested exercise as interaction with grouping. We performed 
Wilcoxon test for variables years of DM (years of evolution of diabetes), eGDR 
and HbA1c. We applied Kruskal-Wallis test and post-hoc Dunn test with 
Bonferroni p-adj to detect differences of metabolites between muscles. 
 
Statistical analyses were conducted in R v3.2.2 (R Core Team, 2015) and 
significance was assumed at p ≤ 0.05. 
 
Pearson Correlation and Networks  
To determine the relationship between clinic variables, standard serum 
laboratory, muscular fatty acids, carnosine and creatine, Pearson correlations 
were computed at p-value < 0.05 in subjects with T1D and controls separately, 
and for different muscles.  
Integration of datasets was accomplished with the corrplot and qgraph R 
packages, which constructs and displays correlation networks between 
components (seen in Figure 3.3 with thresholds – in p-value < 0.05, in R > 0.5).  
 
 
RESULTS 
 
Subject characteristics and clinical data 
Clinical data, body composition and standard laboratory analysis of the 
participants in the study are presented in Table 3.1. Subjects with T1D had 
diabetes diagnosis for a mean of 16.5 ± 9 years, were older (p = 0.01), did not 
smoke (p = 0.035), and presented higher glycemia (p < 0.001) and higher HDL-
C (p = 0.042) than control subjects. Six patients with T1D presented incipient 
diabetic retinopathy.  
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The VO2peak and METs were higher in all athletes than in all sedentaries (p < 
0.001, for both parameters), higher in athletes with T1D than sedentary with 
T1D (p < 0.001, for both parameters) and higher in athlete controls than in 
sedentary controls (p < 0.001 and p < 0.05, respectively), confirming a better 
fitness and higher amount of physical activity of athletes in general. Total body 
fat and abdominal fat percentages, estimated by DXA, were lower in athletes 
than in sedentary subjects (p = 0.03, for both measurements). Subjects with 
T1D had higher HDL-cholesterol (p = 0.03) than control ones. The other 
parameters were not statistically different.  
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Table 3.1 – Clinical characteristics of type 1 diabetes and control subjects  
 
T  Student and chi-square tests 
a) p< 0.01 between T1D and CT;  b) p< 0.05 between T1D and CT c)  p < 0.05 between sedentary  and  athletes;  d) p < 0.001 
between sedentary  and  athletes ; e) p <0.001 between T1D sedentaries and athletes; f) p <0.05 between CT sedentaries and 
athletes; g) p <0.001 between CT sedentaries and athletes;  ns – non significant. Obs.: T1D with retinopathy do not present 
clinical differences vs. without retinopathy   
 Type 1 diabetes 
(16) 
Controls 
(14) 
p 
Athlete  Sedentary Athlete Sedentary  
 10 6 9  5  
      
Age (years) 41 ± 8 41 ± 7.5 35.8 ± 7.88 30.8 ± 1.9 a 
Evolution of diabetes (years) 15.5 ± 9.5 18.1 ± 8.6 - - ns 
Body composition      
   Weight (kg) 78  ± 9  83 ± 9.3  76.6 ± 8.2 79.7 ± 10.8 ns 
   BMI (kg/m2) 25 ± 2.5 25.6 ± 2.3 25.1± 2.1 23.4 ± 4.3 ns 
   WHR (waist/hip ratio) 0.86 ± 0.06 0.88 ± 0.04 0.86 ± 0.05 0.86 ± 0.06 ns 
   Total fat (% - by DXA) 20.6 ± 6.9 29.9 ± 4.6 22.3 ± 5.2 26.7 ± 7.9 c 
   Abdominal fat (% - by DXA) 24.6 ± 6.9 37.8 ± 5.3 28.4 ± 10 36.6 ± 12.6 c 
Physical fitness      
    SF-IPAQ (METs/week) 3512  ± 1604 619 ± 427 5940 ± 4032 832 ± 699 d, e, g 
   VO2peak (mL/kg/min) 41.3 ± 10.4 22.4 ± 6.2 46.3 ± 16.1 26.6 ± 7.2 d, e, f 
Other characteristics      
   Hypertension (yes) 1 3 0 0 - 
   Dyslipidemia (yes) 1 1 0 1 - 
   Active smoking (yes) 0 0 2 2 - 
   Incipient retinopathy (yes) 5 1 - - - 
   eGDR 8.52 ± 1.59 7.25 ± 1.6 - - ns 
Laboratory analysis      
   Fasting glycemia (mg/dl) 160 ± 57 141 ± 30.2 91.8 ± 5.8 91.5 ± 12 a 
   HbA1c (%) 7.2 ± 1.1 8.2 ± 1.8 - - ns 
   Total cholesterol (mg/dl) 175.3 ± 34.8 190.5 ± 25.8 190.5 ± 42.2  157 ± 21.2 ns 
   HDL cholesterol (mg/dl) 56.8 ± 5.6 50.1 ± 4.1 49.6 ± 15.9 43.5 ± 20.5 b 
   LDL  cholesterol (mg/dl) 105.6 ± 28.8 125.5 ± 23.3 127.8 ± 39.5 131 ± 71.1 ns 
   Triglycerides (mg/dl) 64 ± 27.5 71.8 ± 24.3 63.3 ± 22.9 111.5 ± 95.4 ns 
   Creatinine (mg/dl) 0.93 ± 0.08 1.01 ± 0.08 0.99 ± 0.16 1.03 ± 0.1 ns 
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1H MRS Studies 
Analyzing the three muscles, when separated by the groups T1D and control, it 
could be evidenced that IMCL (saturated, methylene protons) was higher in 
soleus muscle (2.21±1.21 U.A. for T1D and 2.42±1.62 for controls) when 
compared with tibialis anterior (0.57±0.29 U.A. for T1D and 0.43±0.15 for 
controls) (p = 0.001 for T1D and p < 0.001 for controls) and with vastus 
intermedius (1.1±0.71 U.A. for T1D and 1.04±0.37 for controls) (p = 0.035 for 
T1D and p = 0.018). The estimation of olefinic fatty acids was not different 
among the muscles.  
 
The estimation of carnosine, creatine, IMCL (saturated fatty acids, methylene 
protons), olefinic fatty acids (unsaturated fatty acids, or UFA), UI_IMCL and 
UI_EMCL were not different between the subjects with T1D and control, as well 
as no differences were identified when compared all the subjects differentiating 
them by the physical activity (athlete and sedentary) criteria. All the 
comparisons took in account the three different muscles. 
 
 
Network analysis, data integration 
Figure 3.3 presents the network layouts of the significant relationships observed 
between the clinical variables, carnosine and creatine estimations, 
intramyocellular fatty acids and unsaturated ratios (p < 0.05; R > 0.5), 
determined separately in six networks: subjects with T1D and control ones, and 
their three respective muscles (soleus, tibialis anterior, vastus intermedius). 
In the six networks presented (Fig 3.3: a, soleus in T1D; b, soleus in controls; c, 
tibialis anterior in T1D; d, tibialis anterior in control; e, vastus intermedius in 
T1D; f, vastus intermedius in control), a consistent positive correlation was 
identified in clinical variables of body composition, as follows; BMI, waist/hip 
ratio (WHR), total fat and abdominal fat. EGDR, the index for insulin sensitivity 
in subjects with T1D, presented and inverse correlation with BMI, but with no 
other clinical variable, standard blood lipoproteins, nor with muscle variables.  
VO2peak, variable that indicates the physical fitness, was positively correlated 
with HDL-C in subjects with T1D, but not in control ones. VO2peak was also 
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negatively correlated with abdominal fat in all subjects and, in control ones, also 
with total body fat. In soleus muscle of control subjects, VO2peak was also 
negatively correlated with carnosine.  
LDL-C was positively correlated with abdominal fat and TG with abdominal and 
total fat, as well as HDL-C was inversely connected with body fat composition in 
control subjects. In T1D, TG was associated with abdominal fat, while HDL-C 
was associated with VO2peak.  Serum creatinine had a noted hub role in 
networks of T1D, condition that did not occur in control subjects. Serum 
creatinine participated in different connections, depending on the muscle 
studied.  
Carnosine appears positively associated with total and abdominal fat in soleus 
muscle of both T1D and control groups (Fig 3.3a and b), positively associated 
with BMI and WHR in tibialis anterior muscle in T1D (Fig 3.3c), but had a 
negative correlation with WHR in the same muscle in control subjects (Fig 
3.3d). Interestingly, in soleus muscle, the more oxidative one, carnosine is 
negatively associated with VO2peak, as referred before, but also positively with 
glycemia, LDL-C and negatively with HDL-C, in control subjects.   
A constant positive cluster in almost all networks was identified among 
carnosine, creatine and IMCL. In the case of the muscles from subjects with 
T1D, olefinic fatty acids were also connected in this cluster. It is worth noting 
that there was an inverse correlation between UI_IMCL and UI_EMCL in soleus 
and muscle vastus intermedius muscles of both T1D and control groups.  
In soleus and tibialis anterior muscles from control subjects (Fig 3.3b and d), 
compact lattices corresponding to the main classes of variables may be 
observed with large positive correlations inside the muscular clusters. In the 
case of the same muscles in subjects with T1D (Figure 3.3a and c), lattices 
from the main classes lose density, and cluster especially on body composition 
variables. 
 
In vastus intermedius muscle, that has mixed fast-twitch characteristics, 
different muscle lattices were evidenced, in especial in subjects with T1D.    
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Figure 3.3 - Network models of clinical variables, serum determinations and 
intramuscular variables of subjects with T1D and control subjects, in soleus, 
tibialis anterior and vastus internus. WHR, waist/hip ratio; T.fat, total fat; A.fat, abdominal 
fat; VO2p, VO2peak; glyc, glycemia, TC; total-cholesterol; HDL.C, HDL-cholesterol; LDL.C, LDL-
cholesterol; TG, triglycerides; creat, creatinina; CA, carnosine; CR, creatine; olef, olefinic; IMCL, 
methylene intramyocellular lipids; UI.IM, UI_IMCL; UI.EM, UI_EMCL. a) Soleus in T1D; b) 
Soleus in controls; c)  Tibialis anterior in T1D; d) Tibialis anterior in control; e) Vastus 
intermedius in T1D; f) Vastus intermedius in control. Integration of datasets was accomplished 
with the corrplot and qgraph R packages which constructs and displays correlation networks 
between components (p-value < 0.01 and thresholds R > 0.5). Green lines represent positive 
correlations, and red lines represent negative associations. Green spheres represent clinical 
variables; in orange, standard laboratory analysis; in white, intramuscular variables. Blue circles 
highlight the component VO2peak 
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DISCUSSION 
 
The current study showed that men with T1D presented similar muscle 
compounds than men without diabetes, as well as athletes and sedentary 
subgroups did not presented muscle component differences. This study 
analyzed similar healthy men, having the diabetes or physical activity levels as 
the basic differences. The subjects presented normal body fat compositions 
range by BMI, and, in the ones with T1D, few presented incipient chronic 
complications (retinopathy) and had no other pathology that could confound the 
results. These characteristics were intentionally chosen to seek for a better 
control of both aspects in focus, the T1D and the physical activity.  
 
Gualano and col. (Gualano et al., 2012) described an experiment with subjects 
with T1D, T2D and respective matched controls, using also a 1H MRS, similar 
to the present one. Compared to controls, a lower carnosine content in 
gastrocnemius muscle of patients with T2D was identified and no differences 
were identified in carnosine in soleus muscle, as well as no differences were 
observed in those muscles in patients with T1D. Our findings are comparable to 
that study. We did not identify differences in carnosine content between 
subjects with T1D and controls in the three muscles studied. 
 
Our study brought information about muscular compounds identified by 1H 
MRS and integrated them with clinical and laboratory variables. Considering the 
muscular variables studied, carnosine, as described by Boldyrev (Boldyrev et 
al., 2013), has a buffer activity during high-intensity muscle contractions, when 
the anaerobic glycolysis leads to the production of lactic acid which immediately 
dissociates into protons (H+) and lactate ions, processes more typical of type II 
muscular fibers. Carnosine also has an antioxidant activity mediated by different 
mechanisms involving metal ion chelation, scavenging reactive oxygen species 
(ROS) and peroxyl radicals. Other experimental studies described the potential 
benefits of carnosine for the prevention or delay of diabetic nephropathy or 
retinopathy in animals (Pfister et al., 2011; Riedl et al., 2011). Carnosine, in our 
networks, was positively associated with IMCL in both groups of T1D and 
control.  
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The accumulation of IMCL has been proposed as an important predictor of IR 
(White, Ferguson, McCoy, Kim, & Castellano, 2006); however, it is also 
recognized a paradoxical increase of IMCL in athlete subjects (Moro, Bajpeyi, & 
Smith, 2008). It is referred that high IMCL predicted low insulin sensitivity, but 
mainly in untrained individuals (Machann, Häring, Shick, & Stumvoll, 2004), and 
that IMCL can even increase in obese subjects submitted to an exercise 
program, in parallel with an improvement of insulin sensitivity (Dubé et al., 
2008). Soleus muscle is a typical deep muscle of sustaining that withstands 
prolonged time utilization, and is characterized by high proportion of oxidative 
fibers (type I). These oxidative fibers contain higher concentration of 
mitochondria and GLUT-4, and are the preferential fiber for the accumulation of 
IMCL. In our study, IMCL of soleus muscle was positively correlated with total 
fat in subjects with T1D and positively correlated with waist/hip ratio in control 
subjects, indicating association with inadequate body composition compounds, 
but not with physical fitness. As referred above, the carnosine was positively 
associated with IMCL in our networks; regarding so, it could be speculated that 
in the presence of higher levels of IMCL, and a probable oxidative dysfunction 
(related to IR), more carnosine is expressed as a buffer and/or antioxidant 
agent in glycolytic and other processes. Moreover, our study identified that this 
increased soleus carnosine in soleus muscle of T1D and controls was 
associated with poorer clinical characteristics, like total fat and abdominal fat, 
variables associated with IR.  
 
VO2peak presented a negative correlation with abdominal fat in all subjects and 
with total fat in control subjects, indicating that men that presented a better 
fitness also presented a lower fat accumulations, and probable less risk for IR. 
VO2peak was not associated with any muscular fatty acid compound in our 
study. Nevertheless, an interesting negative association was detected between 
VO2peak and carnosine in soleus muscle of control subjects, suggesting some 
association of better fitness and less carnosine amount and/or expression. This 
association, however, was not present in subjects with T1D. 
 
It is worth to mention that EMCL was not used in this study as an isolate 
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variable because its estimations may vary even with discrete changes in the 
intra-individual coil positioning (Torriani et al., 2005). UI_EMCL ratio, 
nevertheless, has its interest due to an intrinsically balance of the different kind 
of lipids in the extramyocellular space. We could identify in the networks an 
inverse association between unsaturated indexes of intra and extramyocellular 
environment (UI_IMCL and UI_EMCL), suggesting an imbalance: in the 
presence of higher proportion of ratio olefinic/IMCL in the intramyocellular 
space, lower proportion of olefinic/EMCL in the extramyocellular space. This is 
a novel observation, not described previously. 
     
We could not identify muscular differences concerning the different groups of 
athletes and sedentary. Two possible explanations are the small number of 
subjects that participated and the fact that this is a cross-sectional observational 
study. An interventional study would perhaps demonstrate some intra-individual 
changes of lipid content. Another limitation is the type of the 1H MRS study 
acquired, whereas there are other new sequences recently developed, as 2D-
localized correlated spectroscopy (L-COSY), for the determination of the 
unsaturated lipid compounds, differencing monounsaturated fatty acids from 
polyunsaturated fatty acids. On this topic, it has been observed that patients 
with T2D, obese and overweight subjects present altered 
monounsaturated/polyunsaturated ratios, reflecting a dysregulation also in lipid 
metabolism (Velan et al., 2008).   
 
The use of networks for understanding the interconnections of clinical and 
biochemical variables has been used by other authors and by our group 
(Brugnara et al., 2015; Mäkinen et al., 2009). This approach could give us the 
pattern of the main links between body composition, blood determinations and 
muscle variables, which in a traditional correlation analysis would be difficult to 
integrate. Slight differences could be observed between the patterns of T1D and 
control subjects, fact that could be explained by differences in metabolic status; 
moreover, some links differ among the muscles, which could be explained by 
the differences of fiber compositions and/or intrinsic metabolism. 
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This study demonstrates that patients with T1D with weight in normal range and 
without advanced chronic complications related to diabetes presented similar 
values of IMCL, unsaturated lipid ratios, carnosine and creatine than control 
subjects. However, despite the weight in normal range, slight alterations in BMI 
and/or body fat composition may be enough to establish alterations in IMCL 
amounts. Improvement in body composition, in terms of BMI, waist/hip ratio and 
body fat values, may be determinant for a more favorable muscle components 
profile, and prospective studies in this model of patients will help to elucidate 
the role of muscle components and its functionality.  
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AIM 4 – STUDY 4 
 
 
Improving assessment of cardio-protective lipoprotein profile in type 1 
diabetes by 1H NMR spectrometry 
 
 
In the fourth study, we proposed to analyze the lipoprotein profile in subjects 
with type 1 diabetes, in order to understand lipoprotein subfractions, the main 
clinical aspects involved and if there were differences compared to subjects 
without diabetes. 
 
The volunteers were selected from the ones that already participated in the 
baseline evaluation in de Diabetes Research Clinical Unit, from the series 
explained in Study 1. Thirty persons with T1D and 30 without diabetes 
participated in Study 4. It was performed a careful selection for matching both 
groups concerning gender, age, body mass index (BMI), body fat percentage by 
DXA (dual-energy X-ray absorptiometry) and similar physical activity and 
cardiorespiratory fitness levels (VO2peak). 
 
To obtain a comprehensive profile of lipid and lipoprotein parameters in both 
groups of subjects, two different 1H NMR methods were used. In the first 
analysis, it was possible to estimate the lipoprotein particle concentrations and 
the average particle size for every main fraction, provided by the NMR 
LipoProfile test commercialized by LipoScience, Inc. (Raleigh, USA). The 
second analysis was performed at the Metabolomics Platform (URV), and 1H 
NMR spectroscopy was employed to determine the concentrations of the 
cholesterol and triglycerides content of 9 lipoprotein subclasses and, for this 
purpose, partial least square (PLS) regression was used.  
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The results are described in the following publication: 
Brugnara L, Mallol R, Ribalta J, Vinaixa M, Murillo S, Casserras T, Guardiola M, 
Vallvé JC, Kalko SG, Correig X, Novials A (2015) Improving Assessment of 
Lipoprotein Profile in Type 1 Diabetes by 1H NMR Spectroscopy. PLoS ONE 
10(8): e0136348. doi:10.1371/journal.pone.0136348    
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Abstract
Patients with type 1 diabetes (T1D) present increased risk of cardiovascular disease (CVD).
The aim of this study is to improve the assessment of lipoprotein profile in patients with
T1D by using a robust developed method 1H nuclear magnetic resonance spectroscopy
(1H NMR), for further correlation with clinical factors associated to CVD. Thirty patients with
T1D and 30 non-diabetes control (CT) subjects, matched for gender, age, body composition
(DXA, BMI, waist/hip ratio), regular physical activity levels and cardiorespiratory capacity
(VO2peak), were analyzed. Dietary records and routine lipids were assessed. Serum lipopro-
tein particle subfractions, particle sizes, and cholesterol and triglycerides subfractions were
analyzed by 1H NMR. It was evidenced that subjects with T1D presented lower concentra-
tions of small LDL cholesterol, medium VLDL particles, large VLDL triglycerides, and total
triglycerides as compared to CT subjects. Women with T1D presented a positive associa-
tion with HDL size (p<0.005; R = 0.601) and large HDL triglycerides (p<0.005; R = 0.534)
and negative (p<0.005; R = -0.586) to small HDL triglycerides. Body fat composition repre-
sented an important factor independently of normal BMI, with large LDL particles presenting
a positive correlation to total body fat (p<0.005; R = 0.505), and total LDL cholesterol and
small LDL cholesterol a positive correlation (p<0.005; R = 0.502 and R = 0.552, respec-
tively) to abdominal fat in T1D subjects; meanwhile, in CT subjects, body fat composition
was mainly associated to HDL subclasses. VO2peak was negatively associated (p<0.005;
R = -0.520) to large LDL-particles only in the group of patients with T1D. In conclusion,
patients with T1D with adequate glycemic control and BMI and without chronic complica-
tions presented a more favourable lipoprotein profile as compared to control counterparts.
In addition, slight alterations in BMI and/or body fat composition showed to be relevant to
provoking alterations in lipoproteins profiles. Finally, body fat composition appears to be a
determinant for cardioprotector lipoprotein profile.
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Introduction
Dyslipidemia is one of the most important risk factors involved in cardiovascular disease
(CVD) [1] in addition to cigarette smoking, hypertension, family history of premature coro-
nary heart disease, age and diabetes. CVD is the leading cause of mortality in patients with type
1 diabetes (T1D) [2–4]. Early observations of lipids and lipoprotein profile in patients with
T1D, revealing pro-atherogenic features such as hypercholesterolemia and hypertriglyceride-
mia, were particularly associated with poor glycemic control [5,6] and nephropathy [7,8]. In
the nineties, studies from Europe and US identified similar rates of cardiovascular disease in
T1D subjects, but with different pattern of dyslipidemia: low high density lipoprotein choles-
terol (HDL-C) in EURODIAB and hypertriglyceridemia in the US group [8].
Considering the well-known evidences that intensive treatment for glycemic control in T1D
patients prevents and/or delays micro and macrovascular complications [9,10], international
guidelines of diabetes care were designed mainly to establish goals of good glycemic control
[11]. Nowadays, with the optimization of insulin treatment, it has been possible to corroborate
a decrease in chronic complications related to T1D and also a reduction in cardiovascular mor-
tality [10,12–14]. Furthermore, current epidemiological data have shown evidences that lipids
and lipoprotein profiles are optimal in T1D subjects when they exhibit good glycemic control
in absence of microalbuminuria or clinical nephropathy [7,15].
In parallel, the role of body composition in lipoprotein profile in T1D has been extensively
analyzed [16,17]. In the Diabetes Control and Complications Trial (DCCT) [16], T1D patients
receiving intensive insulin treatment showed greater weight gain than those with conventional
treatment. Excessive weight gain in the intensive treatment group was associated to insulin
resistance, higher blood pressure and worse lipid profile. The deterioration of these clinical
parameters was accompanied by an increase in total triglycerides, total cholesterol, LDL-C,
VLDL, IDL and denser LDL particles, and by a decrease in HDL-C. In the EURODIAB Pro-
spective Complications Study, an increase in triglycerides and total cholesterol was identified
along with a smaller improvement in HDL-C in the group that ameliorated glycemic control,
but in parallel gained more weight, when compared with the group that was not so successful
in glycemic control, but experienced less weight gain [17].
It is also well known that physical activity (PA) has protective effects on lipoprotein profile
in the general population [18,19]. PA is associated with the prevention of cardiovascular dis-
ease and improvements in lipoprotein profile. It is known that HDL and HDL2 (large) lipopro-
teins are firmly associated to protective factors for the risk of CVD in the non-diabetic
population [20]. Few studies have analyzed the effect of increased PA on lipoprotein subfrac-
tions in T1D patients, using conventional methods such as routine clinical biochemistry or
lipoprotein isolation by sequential ultracentrifugation. In T1D patients, an improvement in
HDL/LDL ratio and in ApoB and triglyceride levels [21] was observed after performing a
16-week program of aerobic exercise. Another report also demonstrated an increase in HDL-C
levels after implementing an exercise program in T1D patients [22].
Nuclear magnetic resonance spectroscopy (1H NMR) is, at present, a standard technique
for the determination of advanced lipoprotein profile in serum and/or plasma samples. 1H
NMR is able to measure the particle number and size of several subfractions of lipoproteins
[23], which has been helpful in demonstrating a wider spectrum of CV risk factors in different
populations [24]. Moreover, other 1H NMR approaches based on regression methods also
allow for the determination of the cholesterol and triglycerides concentrations of several lipo-
protein classes and subclasses [25]. Our group has, in the context of other pathologies, already
used this methodology [26,27]. Therefore, the aim of the present study was to analyze and
improve the knowledge of lipoprotein subclasses in T1D patients by using two complementary
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methods based on 1H NMR spectroscopy [28] and by comparing the obtained lipoprotein pro-
files with age-matched, non-diabetic counterparts. From these data, we have detected the clini-
cal factors with the largest correlations with lipoprotein profile in each population.
Participants, Material and Methods
Participants
Thirty patients with T1D, recruited by the Department of Endocrinology and Nutrition of the
Hospital Clinic de Barcelona, and 30 subjects without diabetes, recruited by the staff of the
IDIBAPS Diabetes and Obesity Research Laboratory, were enrolled in the study. Control (CT)
subjects were matched with T1D patients for gender, age, body mass index (BMI), body fat per-
centage by DXA (dual-energy X-ray absorptiometry) and for similar physical activity and fit-
ness levels (VO2peak). The experimental protocol was approved by the Research and Ethics
committees of the Hospital Clínic de Barcelona, in accordance to the Declaration of Helsinki.
Written informed consent was obtained from all subjects prior to participation (CEIC Register
n°: 2009/4933).
T1D subjects participating in the study had diabetes for a mean of 11.9 ± 10.1 years,
undetectable C-peptide levels and acceptable glycemic control, as determined by glycated
hemoglobin A1c (7.05% ± 1.1). Estimated glucose disposal rate (eGDR), an indicator of insulin
resistance in T1D patients, was calculated (taking into account HbA1c, waist/hip ratio and
presence of hypertension) [29,30]. Patients with chronic complications related to diabetes were
excluded, except for five who presented incipient retinopathy. All patients presented microal-
buminuria values below 30 mg/L. Peripheral neurologic evaluation, assessed by clinical explo-
ration and biothesiometry (Bio-thesiometer, Bio-Medical Instrument Company, Newbury,
OH, U.S.), was normal in all subjects. In addition, all of them presented a normal cardiac evalu-
ation, assessed by electrocardiogram (ECG) at rest and during bicycle ergometry test. Hyper-
tension (systolic blood pressure 135 mmHg and/or diastolic blood pressure 85) and active
smoking were registered. Patients with T1D were following multiple daily injections (MDI)
regimens. None of the participants was using lipid-lowering drugs or any other medication.
Material and Methods
All subjects were invited to the Diabetes Research Clinical Unit of IDIBAPS/Hospital Clínic de
Barcelona to perform the tests. Clinical history and baseline clinical characteristics, such as
height, weight, BMI and total body composition, were obtained. Each subject was required to
complete an evaluation of current physical activity using the Short-form of the International
Physical Activity Questionnaire [31], estimating energetic expenditure for vigorous, moderate,
and walking activities, expressed as METs-min/week. They were also classified as sedentary or
physically active, defined as routinely performing three or more sessions of moderate and/or
intense exercise (of one or more hours per session) per week. Participants were questioned
regarding dietary habits using a four-day dietary at-home record (3 workdays and 1 non-work-
day) and the results were analyzed by the program PCN 1.0, CESNID-University of Barcelona
[32].
Total body composition was measured by densitometry using DXA (Lunar iDXA body
composition, GE Healthcare). Maximal oxygen uptake (VO2peak) was determined by using a
maximal progressive incremental exercise test on a friction-braked cycle-ergometer (Monark
828E, Monark Sweden). After a 3 min warm-up period at a power output of 25-W, workload
was increased by 25-W each minute until exhaustion. Oxygen uptake was monitored during
exercise using a computerized, open circuit gas-collection system (Vmax Spectra, version
v12.0, Sensor Medics Corp, VIASYS Healthcare Inc, Yorba Linda, CA, U.S.), and VO2peak was
Lipoprotein Profile in T1D by 1H NMR Spectroscopy
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determined at the point of highest oxygen consumption over a 15-s period. VO2peak was con-
firmed using established physiological criteria, including a respiratory exchange ratio above
1.15, oxygen uptake reaching a plateau despite an increased work rate, and a heart rate near
95% of the age-predicted maximum value.
Blood determinations. Fasting blood samples were obtained for analysis. Glycemia (glu-
cose-oxidase method, Advia 2400 Siemens Diagnostics, Deerfield, IL, U.S.) and glycated hemo-
globin (high-performance liquid chromatography [HPLC]) were determined in the Hospital
Clinic laboratory. For the conventional determination of lipoproteins and metabolomic mea-
surements, serum was obtained once blood had been allowed to clot at room temperature for
30 min and after centrifugation at 4°C at 5000 rpm for 10 min. Samples were kept at -80°C
until further analysis. Standard laboratory methods were used to determine total cholesterol,
triglycerides and HDL cholesterol. LDL cholesterol was calculated by the Friedewald formula.
Remnant lipoprotein cholesterol (RLPc) was measured by immuno-affinity chromatography.
Serum lipoprotein profile. To obtain a comprehensive profile of lipid and lipoprotein
parameters in both groups of subjects, two different 1H NMRmethods were used. In the first
analysis, we obtained the distribution of lipoprotein subclasses as provided by the NMR Lipo-
Profile test commercialized by LipoScience, Inc. (Raleigh, USA). The procedure simultaneously
estimates the lipoprotein particle concentrations and the average particle size for every main
fraction. NMR was performed on plasma samples collected in EDTA tubes and stored at -80°C
[24]. The LipoProfile test measured 15 variables: (a) total VLDL and chylomicron particle con-
centrations (total VLDL-P) and chylomicron; large, medium and small VLDL-P (nmol/L); (b)
total LDL particle concentrations (total LDL-P); IDL particles (IDL-P); large LDL-P; total
small LDL-P (expressed by medium, small and very small LDL particles)–in (nmol/L); (c) total
HDL particle concentrations (total HDL-P); large, medium and small HDL-P particles–in
(μmol/L); and (d) mean particle sizes: VLDL, LDL and HDL size–in (nm).
In the second analysis, performed at the Metabolomics Platform (URV), 1H NMR spectros-
copy was employed to determine the concentrations of the cholesterol and triglycerides content
of 9 lipoprotein subclasses. For this purpose, partial least square (PLS) regression was used to
calibrate the regression models as proposed in published method [25]. NMR spectra were
acquired using the longitudinal eddy-current delay (LED) sequence, and cholesterol and tri-
glycerides concentrations were obtained using high performance liquid chromatography
(HPLC) as reference values. To calibrate these PLS regression models, 61 plasma samples were
used.
In addition, these analyses complemented the information provided by LipoProfile by offer-
ing another 20 determinations: (a) total LDL-C; large, medium and small LDL-C (mg/dL); (b)
total HDL-C; large, medium and small HDL-C (mg/dL); (c) total VLDL-TG (mg/dL); large,
medium and small VLDL-TG (mg/dL); (d) total LDL-TG; large, medium and small LDL-TG
(mg/dL); (e) total HDL-TG; large, medium and small HDL-TG (mg/dL).
Remnant lipoprotein cholesterol (RLPc) was measured in plasma using the method
described by Nakajima et al., using RLP-Cholesterol Assay Kits (Jimro-II, Japan Immuno
research Laboratories, Japan) [33]. The remnant lipoprotein particles were separated from
plasma by immuno-affinity chromatography with a gel containing monoclonal antibodies
raised against epitopes of apoB100 and apoA1.
Statistical analysis. A comprehensive profile of 40 lipid and lipoprotein parameters (20
measured by PLS regression, 15 measured by LipoProfile, and another 5 conventional determi-
nations and remnant lipoprotein cholesterol) were studied in the 60 subjects (30 T1D subjects
and 30 age-matched control subjects).
A linear model analysis of variance (ANOVA) adjusted for 6 covariates (age, gender, active
smoking habits, waist/hip ratio, percentage of total body fat and VO2peak) was used to
Lipoprotein Profile in T1D by 1H NMR Spectroscopy
PLOS ONE | DOI:10.1371/journal.pone.0136348 August 28, 2015 4 / 15
118
compare lipoprotein abundance between T1D versus control subjects. Lipoproteins with p-
values< 0.05 were considered significant.
Pearson Correlation and Networks. To determine the relationship between lipoprotein
abundance and clinic variables, or diet components, Pearson correlations were computed at p-
value< 0.005 in patients and controls separately. In the case of diet components, variable cor-
relations were analyzed in only 19 patients and 19 controls.
Integration of datasets was accomplished with the Cytoscape tool (www.cytoscape.org),
which constructs and displays correlation networks between components (seen in Fig 1 with
thresholds–in p-value< 0.005, in R> ± 0.5 for clinical variables and R> ± 0.7 for lipoprotein-
lipoprotein variables). Besides, heatmaps were plotted for the correlations of all clinical and
lipid and lipoprotein variables using handmade software.
Results
Clinical and dietary data
Table 1 describes the clinical characteristics of the participants. As previously described, the
two groups were similar in terms of gender, age, BMI, physical activity habits (regular physical
activity or nonphysical activity expressed in METs-min/week) and cardiorespiratory fitness
(VO2peak). Moreover, there were no differences in the usual dietary habits of T1D and CT
groups concerning proteins, cholesterol, saturated or unsaturated fat intake. Only a higher
intake of total carbohydrates in the control group (p = 0.047), and a tendency of higher con-
sumption of simple carbohydrates and alcoholic beverages, also in the CT group, were
observed (Table 2).
Main differences between T1D and CT subjects
Certain variables were established as covariates in the ANOVA comparative statistical analysis
between T1D and CT subjects: age, gender, active smoking, waist/hip ratio, total fat percentage
by DXA, and VO2peak. Controlling for these covariates, a moderate number of lipid and lipo-
protein parameters were identified as significantly different between the two groups. T1D sub-
jects presented a lower concentration of small LDL-C, medium VLDL-P particles, large
VLDL-TG, and total triglycerides (p< 0.05) (Table 3). Using the Benjamini & Hochberg [34]
methodology for taking into account the multiple comparisons, no single variable was deemed
significant, as fdr was 0.389552 for all of them. The change in abundance levels was very low in
all cases; we are dealing with a dataset with no clear magnitude fingerprint, and this fact guided
us to search for a correlation signature.
Correlations between lipoprotein profile and clinical variables
Gender. The most important findings resulting from the correlation analysis between
lipoprotein profiles and clinical variables are presented in Tables 4 and 5. Women showed a
positive correlation with HDL size, in addition to a positive correlation to large HDL-TG con-
centration and a negative correlation to small HDL-TG concentration in the T1D group
(Table 4). The positive correlation between large HDL-TG concentration and the female gen-
der was also identified in the control group (Table 5).
Physical activity. Physical activity had a significant negative correlation with cardiorespi-
ratory capacity, as determined by VO2peak, and large LDL-P in the T1D group. There was no
evidence of correlations between physical fitness and other lipoprotein particles (Table 4).
Age. An increase in age showed a positive correlation with the concentration of small
HDL particle (small-HDL-P), only in the control group (Table 5).
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Body composition. The most important findings on lipoprotein profiles as related to
body composition are presented in Tables 4 and 5. In the T1D group, large LDL-P showed a
positive correlation with total body fat, as determined by DXA (R 0.5 and p< 0.005); and
abdominal fat percentage (by DXA) presented a positive correlation to total LDL-C and small
LDL-C (Table 4).
In the control group, large HDL-P and HDL size presented a negative correlation with waist
and waist/hip ratio, while small HDL-P correlated positively with waist/hip ratio. A negative
correlation was also identified between waist and/or waist/hip ratio for the following lipopro-
tein parameters: total HDL-C; large HDL-C; medium HDL-C; large HDL-TG; and conven-
tional determination of HDL-C. The small HDL-TG presented a positive correlation with
waist/hip ratio (Table 5).
Dietary habits and other type 1 diabetes specific factors. It is worth noting that only 19
T1D patients and 19 controls completed the 4-day dietary record. Few differences in dietary
habits were identified between the two groups, mainly in total carbohydrates (g/day) (Table 2).
Associations between different dietary compounds and lipoproteins can be verified in the sup-
plemental tables (S1 and S2 Tables). In addition, neither the time elapsed, expressed as years of
diabetes progression, nor the incipient retinopathy present in five of the patients with T1D,
conditioned the lipoprotein profiles. Furthermore, indicators of diabetes control or insulin
resistance, represented by Hb1Ac and eGDR respectively, were not associated to any lipopro-
tein parameter in the present study.
Fig 1. Networkmodels of lipoproteins and clinical variables in control subjects and in T1D subjects. Control (1A) and T1D subjects (1B). Integration of
datasets was accomplished with the Cytoscape tool (www.cytoscape.org), which constructs and displays correlation networks between components (p-
value < 0.005 and thresholds R > ± 0.5 for clinical variables, and R > ± 0.7 for lipoprotein variables). Continuous lines represent positive correlations, and
dashed lines represent negative associations. Grey spheres represent clinical variables; in red, LDL related lipoproteins; in green, HDL lipoproteins; in blue,
VLDL lipoproteins; and in purple, total triglycerides. Orange circles mark the variables that are reduced in T1D subjects.
doi:10.1371/journal.pone.0136348.g001
Table 1. Clinical characteristics of subjects with type 1 diabetes and controls.
Type 1 diabetes (n = 30) Controls (n = 30)
Gender (women/men) 10 / 20 10 / 20
Age (years) 34.8 ± 9.6 35.8 ± 8.8
Body Composition
BMI (kg/m2) 23.7 ± 2.8 23.2 ± 2.4
Waist (cm) 81.5 ± 9.1 82 ± 8.4
Waist/hip ratio 0.82 ± 0.06 0.82 ± 0.08
Total body fat (%—by DXA) 24.7 ± 9.2 26 ± 8.8
Abdominal fat (%—by DXA) 27.1 ± 11.8 29.8 ± 10.4
Physical ﬁtness
Physically active (yes) 15 21
METs (per week–SF-IPAQ) 3008 ± 2230 2115 ± 1728
VO2peak (mL/kg/min) 33.5 ± 11.3 33.1 ± 9.1
Other characteristics
Hypertension (yes) 5 3
Active smoking (yes) 8 4
Duration diabetes (years) 11.9 ± 10.1 -
Incipient retinopathy (yes) 5 -
HbA1c (%) 7.05 ± 1.1 -
MET: Metabolic Equivalent of Task. 1 MET = 3.5 ml O2kg−1min−1. No statistical differences between groups, based on Chi-square and Student T-test.
doi:10.1371/journal.pone.0136348.t001
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Network analysis
Network layouts of the significant (p< 0.005) relationships observed between the lipoproteins
(R> ± 0.7) and clinical variables (R> ± 0.5) (Tables 4 and 5) are presented in Fig 1, deter-
mined separately in control subjects (Fig 1A) and T1D subjects (Fig 1B).
In control subjects (Fig 1A), compact lattices corresponding to the main classes of variables
may be observed with large positive correlations inside the lipoprotein clusters. In the case of
T1D subjects (Fig 1B), lattices from the main classes lose density, especially in the case of LDL-
lipoproteins and clinical variables. A new sub-cluster of LDL-lipoproteins disconnected from
the rest of components may be observed.
TG is the only biochemical parameter appearing in the networks, and highly connected to
VLDL-lipoproteins in both groups.
For supplementary information about all the correlations of clinical, lipid and lipoprotein
profile, heatmaps are available as supplementary figures for control subjects (S1 Fig) and sub-
jects with T1D (S2 Fig).
Table 2. Diet components by dietary records in subjects with type 1 diabetes and controls.
Type 1 diabetes (n = 19) Controls (n = 19) p
Gender (women/men) 5 / 14 6 / 13 ns
Energy (kcal) 2215 ± 489 2430 ± 641 ns
Total proteins (g/day) 101.2 ± 22.1 100.1 ± 28.9 ns
Total lipids (g/day) 112 ± 27.1 112.5 ± 33.2 ns
Saturated fatty acids(g/day) 33.6 ± 10.3 35.4 ± 14.5 ns
Monounsaturated fatty acids (g/day) 52.4 ± 13.7 51.3 ± 13.5 ns
Polyunsaturated fatty acids (g/day) 15.8 ± 5.5 16.6 ± 5.3 ns
Cholesterol (mg/d) 327.1 ± 122.8 351.7 ± 175.3 ns
Total carbohydrates (g/day) 193.2 ± 61.9 238.1 ± 72.4 0.047
Simple carbohydrates (sugars) (g/day) 83.6 ± 32.3 103.4 ± 37.2 ns (0.089)
Total ﬁber (g/day) 21.9 ± 7.1 22.2 ± 10.3 ns
Alcohol (g/day) 3.7 ± 7 9 ± 10 ns (0.069)
No statistical differences between groups, based on Student T-test, except for total carbohydrate intake.
doi:10.1371/journal.pone.0136348.t002
Table 3. Statistical analysis of covariance contrasting lipid and lipoprotein data from subjects with
type 1 diabetes and control subjects.
Lipoprotein FC * p-value
Medium VLDL-P (medium VLDL particles) a -1.44 0.0216477
Small LDL-C (small LDL cholesterol) b -1.26 0.0289017
Large VLDL-TG (large VLDL, fraction triglyceride) b -1.21 0.0327273
TG (triglyceride) c -1.06 0.0490274
a lipoprotein subfraction determined by LipoProﬁle
b lipoproteins subfraction determined PLS regression
c lipoprotein determined by conventional determinations
Covariates considered: age, gender, active smoking, waist/hip ratio, total fat percentage by DXA and
VO2peak
* FC: Fold change. Negative values correspond to lower concentrations found in T1D.
doi:10.1371/journal.pone.0136348.t003
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Discussion
In the present study, we aim to improve the characterization of lipoprotein particles in patients
with T1D by using two complementary methods based on 1H NMR spectroscopy, in order to
find a better correlation of lipid and lipoprotein parameters with clinical phenotype. In the cur-
rent context of improving diabetes care, patients with T1D selected to participate presented
an adequate metabolic control and BMI, and no developed chronic complications related to
diabetes or other drug except insulin. The subjects with T1D were paired with carefully selected
subjects without diabetes, as control subjects, with the intention of matching their clinical char-
acteristics within the extent possible. Matching was performed concerning gender, age, BMI,
body fat percentage, physical activity and cardiorespiratory fitness, to avoid any interference by
these factors in the differences in lipoproteins between the two groups. Nevertheless, some of
Table 4. Association of clinical characteristics and lipoproteins features in subjects with type 1 diabetes (T1D).
Clinical variables R Gender (+ for women) BMI (kg/m2) Abdominal fat % (DXA) Total fat % (DXA) VO2peak (mL/kg/min)
LipoProﬁle
Large LDL-P - - - 0.505 -0.520
Large HDL-P - -0.627 - - -
HDL size 0.601 - - - -
PLS regression
Total LDL-C - - 0.502 - -
Small LDL-C - - 0.552 - -
Large HDL-TG 0.534 - - - -
Small HDL-TG -0.586 - - - -
Conventional
HDL-C - -0.564 - - -
Summary of the main clinical variables and lipoprotein features that reached R  ± 0.5 and p value < 0.005. Other clinical variables did not reach R  ±
0.5: age, physically active proﬁle, METs, active smoking, HbA1c or eGDR.
doi:10.1371/journal.pone.0136348.t004
Table 5. Association of clinical characteristics and lipoproteins in control subjects.
Clinical variables R Age (years) Gender (+ for women) Waist (cm) Waist/Hip ratio
LipoProﬁle
Large HDL-P - - -0.525 -0.724
Small HDL-P 0.517 - - 0.500
HDL size - - -0.570 -0.719
PLS regression
Total HDL-C - - -0.554 -0.683
Large HDL-C - - -0.600 -0.737
Medium HDL-C - - -0.583 -0.711
Large HDL-TG - 0.524 -0.598 -0.680
Small HDL-TG - - - 0.595
Conventional
HDL-C - - - -0.656
Summary of the clinical variables and lipoprotein features that reached R  ± 0.5 and p value < 0.005. Other clinical variables did not reach R  ± 0.5:
Physically active proﬁle, METs, VO2peak, active smoking, BMI, total fat percentage (DXA), abdominal fat (DXA).
doi:10.1371/journal.pone.0136348.t005
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these variables were identified as intrinsically significant covariates for analysis, requiring spe-
cial attention in the proper evaluation of the lipoprotein profiles.
The main findings of this study were attributed to having diabetes, whereas the effect of
physical activity per se in each population was independent of this status. We observed that the
concentration of small LDL cholesterol subfraction was reduced in T1D as compared to con-
trols. However, this finding is controversial, as it may depend on the method used and the clin-
ical characteristics of the population under study. As noticed, Guy and colleagues [35]
identified that young T1D patients presented higher levels of small LDL particles than subjects
without diabetes, independent of their glycemic control. Different findings were described by
Alberts and cols., in which poor glycemic control was related to more dense LDL particles [36].
On the other hand, Caixàs et al. observed that, after intensification of insulin treatment for the
optimization of glycemic control in patients with T1D, VLDL particles, triglycerides, total
LDL-C and HDL-C reached the levels of the control group, while the pattern of small LDL-C
was also similar to that of the non-diabetic group, with no changes after optimization [37].
Regarding VLDL lipoproteins, we also identified that in T1D subjects the concentration of
medium VLDL-P and large VLDL-TG were reduced as compared to the control group. A pos-
sible explanation could be attributed to treatment with insulin. Patients with T1D were using
subcutaneous insulin treatment, thus hyperinsulinemia pharmacologically induced by insulin
must be taken into consideration. It is known that insulin has an anti-lipolytic action, promot-
ing the storage of triglycerides in the adipocytes while reducing the release of free fatty acids
from adipose tissue into the circulation [5]. Insulin reduces VLDL production by diminishing
circulating free fatty acids, which are substrates for VLDL, but also by a direct inhibitory effect
on the liver [5]. Our patients presented a better glycemic control than those described in other
studies. Furthermore, they exhibited lower levels of triglycerides, which can be explained by the
effect of insulin, as this hormone is a potent activator of lipoprotein lipase, which promotes the
catabolism of triglyceride-rich lipoproteins and reduces plasma triglyceride levels [5].
It is well established that physical activity is a protective factor for cardiovascular disease
and promotes beneficial effects on lipid and lipoprotein profiles in non-diabetic subjects. For
instance, cholesterol increases in the HDL2-C subfraction have been reported [38], also in T1D
subjects [22]. Concerning levels of LDL-C as measured by conventional methods, Rigla and
cols. [22] identified a decrease in LDL-C in T2D patients when they participated in a structured
aerobic exercise program. In the present study, we found a negative association of VO2peak,
indicator of physical fitness, with large LDL-P in the T1D group (Table 4). There is evidence
that small dense LDL (sdLDL) remain in circulation longer than large LDL before being cleared
by the LDL receptor; it is hypothesized [39] that the delayed catabolism results in modifications
of the lipid composition and size of the sdLDL particles triggered by the cholesteryl ester trans-
fer protein (CETP)-mediated exchange of cholesteryl ester and triglycerides between LDL and
VLDL and/or HDL. An interesting point of debate is whether CETP activity could be altered
by the effect of physical activity. Some studies showed an increased in reverse cholesterol trans-
port in athletes [40], while others demonstrated a decrease in CETP levels after an exercise pro-
gram [41], and even more others did not evidence any changes in CEPT levels with exercise
[42].
In the present study, increased age showed a positive association with small HDL-P, but
only in the control group. It has been described that ageing may affect the composition of HDL
lipoproteins and their ability to promote cholesterol efflux via reverse cholesterol transport,
which is linked to a loss of the potentially anti-atherogenic properties of HDL particles [43,44].
Increments in body weight, waist and/or waist-hip ratio are clinical characteristics of meta-
bolic syndrome and risk factors for CVD in populations general population [45]. The BMIs of
our groups were in the normal range (23.7 ± 2.8 kg/m2 in T1D subjects, and 23.2 ± 2.4 kg/m2
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in control ones). Despite this observation, we have detected some associations with anthropo-
metric and body composition measurements. In the group with diabetes, BMI was negatively
associated to large HDL-P and conventional HDL-C; abdominal fat percentage was found posi-
tively associated to total LDL-C and small LDL-C by 1H NMR. Analyzing total body fat per-
centage, large LDL-P showed a positive correlation in the group with T1D. It has been
described that a reduction in insulin sensitivity, assessed by hyperinsulinemic-euglucemic
clamps, was observed in young people and adults with T1D. These subjects presented higher
levels of triglycerides and a higher triglyceride/HDL ratio, while the younger group also pre-
sented lower levels of HDL [46]. Based on these results, with the goal of finding correlations
with lipoprotein subclasses and certain degrees of insulin resistance in our population, we cal-
culated the estimated glucose disposal rate (eGDR). Nevertheless, we did not find any correla-
tion in the present study, which might be explained by the small number of T1D patients
affected by hypertension and by the slight variation in HbA1c and in waist/hip ratio observed,
which represent the three clinical criteria needed for calculating eGDR. Interestingly, in our
study, the methods that evidenced the correlations of body fat composition with lipoproteins
were different for T1D and control groups: BMI and DXA were the better methods for the
T1D group and waist and waist/hip ratio for the control group. The subjects that participated
in this study presented adequate waist and waist/hip ratios, but probably slight alterations were
enough to modify lipoprotein profile.
As already cited before, HDL and HDL2 (large) lipoproteins are associated to protective fac-
tors for CVD [20]. However, the exact role of HDLs still must be investigated, as the direct clin-
ical effect of cardioprotection has been recently discussed, based, for example, on drugs that
increase HDL concentrations but fail to prove CV protection [47]. In the particular case of
patients with T1D, the expected protection effect of HDLs profile on patients carrying coronary
artery calcification was not so determinant as observed in control subjects [48]; nevertheless, in
a prospective study on T1D patients, an association of coronary artery disease with lower levels
of large HDL and higher levels of medium HDL particles was identified, measured by 1H NMR
[49]. Recent evidences are shedding light on HDL functionality, concerning its components
and sizes [47,50]. In HDLs, particles of distinct molecule species of lipids have been identified,
as well as several proteins compounds, characteristics that confer antioxidative, anti-inflamma-
tory, cytoprotective, vasodilatatory, antithrombotic and anti-infection actions [50,51]. These
aspects are raising new concepts and opening new fields of research and could better explain
the association of lipoprotein profile and cardiovascular disease in patients with T1D.
Correlation networks constructed in our study helped in the integration of lipid, lipoprotein
and clinical data and in the visualization of the global interconnections among them, similar to
the way in which physical networks have helped in the understanding of the global intercon-
nections of omics variables [52]. The FinnDiane Study also used similar features to explain the
complex correlation between clinical, lipoprotein and other biochemical variables and diabetic
kidney disease [53]. Overall, CT subjects show highly coordinated modules corresponding to
the three main lipoprotein groups (VLDL, LDL and HDL) and connected to the clinical vari-
ables (mainly through HDL group components). T1D subjects, however, show a partial uncou-
pling of the LDL group and new interrelations between clinical variables and its components,
particularly in the case of large LDL-P, small LDL-C, and the absence of IDL-P correlations
(see Fig 1B). Other studies, for example, identified that, in nondiabetic subjects, lower average
HDL particle size, lower LDL size, and higher VLDL size were associated with coronary calcifi-
cation, but this association between particle size and calcification in T1D patients was not so
clear [48]. It could be speculated that a reduction in certain variables that are usually associated
with atherogenesis (small LDL-C, medium VLDL-P, large VLDL-T and TG) [48], in the case
of T1D subjects identified in our study, could lead to a perturbation in the interconnection of
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LDL lipoproteins and clinical variables, opening up new approaches to be explored in future
studies.
From the comprehensive results obtained through 1H NMR techniques, we conclude that
patients with T1D present a lipoprotein profile classically associated to cardio-protection com-
pared to control counterparts. Nevertheless, slight alterations in BMI and/or body fat composi-
tion may be enough to establish alterations in lipoprotein profile, especially concerning HDL
and its subfractions. Improved body composition, in terms of waist, waist/hip ratio, BMI and
body fat values, is a determinant for a more favorable lipoprotein profile, and prospective stud-
ies in this model of patients will help elucidate the role of this lipoprotein profile.
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S1 Fig. Clinical and lipoproteins variables correlation heatmap in control subjects. 
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S2 Fig. Clinical and lipoproteins variables correlation heatmap in subjects with type 1 
diabetes. 
doi:10.1371/journal.pone.0136348.s002 
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S1 Table.  Association of lipoproteins and dietary habits in subjects with type 1 diabetes. 
doi:10.1371/journal.pone.0136348.s003 
 
 
 
                R 
Energy 
(Kcal) 
Total 
proteins 
(g/day) 
Total 
lipids 
(g/day) 
Saturated 
fatty 
acids 
(g/day) 
Monouns. 
FA 
(g/day) 
Polyuns. 
FA 
(g/day) 
Cholesterol 
(mg/day) 
Total 
carbohydrates 
(g/day) 
Simple 
CH 
(g/day) 
Total 
fiber 
(g/day) 
Alcohol 
(g/day) 
RLP - - - - - - - - -0.640 -0.600 - 
            
LipoProfile            
   Large-VLDL-CH-P - - - - - - - - - - 0.512 
Large LDL-P - - - - - - - -0.599 -0.524 - - 
Medium HDL-P - - - - - - - - -0.562 - - 
   Small HDL-P 0.600 - 0.506 - - 0.680 - 0.556 0.518 0.540 - 
   HDL size -0.503 - - - - - - - - - - 
            
PLS regression            
   Small VLDL-TG - - - - - - - - -0.549 - - 
   Large HDL-TG - - - - - - - - -0.538 - - 
   Small  HDL-TG 0.516 - - - - - - - - - 0.615 
 
p < 0.005 and R > 0.5 
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S2 Table. Association of lipoproteins and dietary habits in control subjects. 
doi:10.1371/journal.pone.0136348.s004 
 
 
 
R 
Energy 
(Kcal) 
Total 
proteins 
(g/day) 
Total 
lipids 
(g/day) 
Saturated 
fatty 
acids 
(g/day) 
Monouns. 
FA 
(g/day) 
Polyuns. 
FA 
(g/day) 
Cholesterol 
(mg/day) 
Total 
carbohydrates 
(g/day) 
Simple 
CH 
(g/day) 
Total 
fiber 
(g/day) 
Alcohol 
(g/day) 
LipoProfile            
   T-VLDL-Chy-P - - - - - - -0.524 - - - -0.519 
   Medium VLDL-P - - - - - - -0.524 - - - - 
  Small VLDL-P - - - - - - - - - 0.529 - 
   Large HDL-P - - -0.500 - -0.530 -0.587 - - - - - 
   Medium HDL-P -0.603 -0.514 -0.563 -0.517 -0.562 - - -0.551 - - - 
  Small HDL-P 0.578 0.621 - - - - - 0.525 - - - 
   VLDL size - - - - - - - - - -0.578 - 
   HDL size -0.518 - - - -0.511 -0.549 - - - - - 
            
PLS regression            
 Total HDL-C - - - - - -0.575 - - - - - 
   Large HDL-C -0.534 - -0.509 - -0.588 -0.651 - - - - - 
    Medium HDL-C - - - -0.513 -0.600 - - - - - - 
   Small VLDL-TG - - -0.517 - - - - - - - -0.500 
   Small LDL-TG - - - - - - - - - 0.544 - 
   Total HDL-TG - - -0.592 -0.675 - -0.504 - - - - - 
   Large HDL-TG -0.671 - -0.663 -0.547 -0.679 -0.753 - -0.532 - - - 
   Medium HDL-TG -0.623 -0.529 -0.662 -0.671 -0.597 -0.643 - - - - - 
 
Conventional  
           
   HDL-C - - -0.537 - -0.601 -0.638 - - - - - 
 
p < 0.005 and R > 0.5 
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V. SUMMARY OF THE RESULTS 
  
  
Summary of the Results 
 
 
In the present work, different aspects related to physical activity in patients with 
T1D were studied.  
 
In Study 1, the clinical characteristics of the large cohort of 265 patients and 
controls were described. A total of 129 subjects with T1D with no advanced 
chronic complications and with an adequate metabolic were compared with 136 
control subjects. Women with T1D presented the same body composition and 
cardiorespiratory capacity (VO2peak) than women without diabetes. Men with 
T1D also presented similar body composition to controls, but their VO2peak was 
lower even when compared with the most active men of each group. Moreover, 
highly active men with T1D presented higher insulin sensitivity (eGDR) than the 
less active ones.  
 
In Study 2, a careful design was performed to study differences in the metabolic 
response to an acute session of exercise in men with T1D and controls. A 
comprehensive 1H-NMR and GC-MS untargeted metabolomics approach was 
applied to serum samples taken from all participants before and after 30 min of 
static bicycle at 80% of individual VO2peak. In response to exercise, both 
groups had increased concentrations of gluconeogenic precursors (alanine and 
lactate) and tricarboxylic acid cycle intermediates (citrate, malate, fumarate and 
succinate). The T1D group, however, showed attenuation in the response of 
these metabolites to exercise. Conversely to T1D, the control group also 
presented increases in α-ketoglutarate, alpha-ketoisocaproic acid, and lipolysis 
products (glycerol and oleic and linoleic acids), as well as a reduction in 
branched chain amino acid (valine and leucine) determinations. In this sense, 
an attenuated response in lipolysis, proteolysis, glycogenolysis, and oxidative 
metabolism in subjects with T1D patients following exercise was found. 
Exogenous insulin might play a role in these alterations. 
 
In Study 3, an analysis of muscular components determined by 1H MRS in 
three different muscles was performed in T1D men and controls; each group 
included both athletes and sedentary subjects. The study showed that men with 
T1D presented similar amounts of IMCL, unsaturated ratios, carnosine and 
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creatine than men without diabetes. Also, athletes and sedentary subgroups did 
not present muscle component differences. The networks showed associations 
between IMCL (saturated methylene protons) and higher BMI or body fat 
composition in soleus muscle, the most oxidative one. Moreover, some 
repeated clusters of IMCL and carnosine (an intramyocellular buffer) were 
identified. Physical fitness was associated with body composition, but not with 
the muscular components featured in this study. Despite the normal weight 
range of the subjects, small alterations in BMI and/or body fat composition may 
have been enough to establish alterations in IMCL deposits.  
 
In Study 4, an accurate lipid and lipoprotein analysis was performed using two 
different NMR platforms to characterize lipoprotein sizes and components in 
carefully matched T1D and control groups. It was possible to identify lower 
concentrations of small LDL cholesterol, medium VLDL particles, large VLDL-
triglycerides and total triglycerides in subjects with T1D when compared with 
control subjects. Networks were constructed and different arrangements were 
identified in both groups. Patients with T1D with adequate glycemic control, 
normal BMI and without advanced chronic complications presented a more 
favorable lipoprotein profile as compared to their control counterparts. Physical 
fitness did not have effect on the lipoprotein profile in this study. In addition, 
slight alterations in BMI and/or body fat composition were relevant in promoting 
alterations in lipoproteins profiles.  
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Final Discussion 
 
 
Nowadays, the pursuit of optimal glycemic control in T1D is essential, given its 
known benefits of delaying and/or avoiding chronic complications (Nathan et al., 
2005; The Diabetes Control and Complications Trial Research Group, 1993). 
Nevertheless, the delicate balance of the requirements of external insulin is 
complex, with the dual goal of, on the one hand, preventing hyper- and 
hypoglycemic episodes, and, on the other, constantly adjusting to carbohydrate 
intake and physical activity expenditure. So, continuously fluctuations in insulin 
doses are required.  
 
Some studies are identifying different degrees of insulin resistance in patients 
with T1D (Chillarón et al., 2011; Llauradó et al., 2012), although such 
occurrence is more typical of T2D and/or obesity cases. In one example, 
hyperinsulinemic-euglycemic clamps were performed in patients with T1D and 
controls for the study of lipoprotein subfractions (David M Maahs et al., 2010). 
As expected, the authors identified that subjects with T1D had a higher 
preclamp fasting glucose and insulin level than non-diabetic subjects, but there 
were no differences at the end of the clamp. However, subjects with T1D, in 
response to the test, were more insulin resistant than non-diabetic subjects.  
 
The high prevalence and the growing incidence of T2D in these last decades, 
as well as the less than optimistic predictions for the future (International 
Diabetes Federation, 2013) represent a concern for public healthcare 
nowadays. The genetic factors in association with the increase in the obesity 
and sedentary lifestyle rates are the main causes for the increments in the 
cases of metabolic syndrome and T2D (International Diabetes Federation, 
2006). It has been recognized that patients with T1D are also exposed to these 
factors (de Ferranti et al., 2014) and, in these subjects, insulin resistance may 
furthermore be aggravated by exogenous insulin administration, which may be 
associated with some degrees of hyperinsulinemia. 
 
The subjects with T1D who participated in our studies presented no advanced 
chronic complications related to diabetes. Moreover, with different methods for 
the determination of body fat composition, most of them presented generally 
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good body fat composition, as well as few variations in eGDR index. To recall, 
eGDR is calculated using the waist/hip ratio, the presence of hypertension and 
glycated hemoglobin (HbA1c), variables that are similar for determining 
metabolic syndrome in the general population (International Diabetes 
Federation, 2006), that are obesity or increased waist circumference, 
hypertension, hyperglycemia and dyslipidemia. Few of our patients presented 
hypertension, and many of them presented adequate glycemic control. These 
observations make us believe that the patients that were evaluated might have 
fewer possibilities of developing insulin resistance, but this would probably be 
present to some degree.  
 
Study 1 showed that women with or without T1D presented the same 
characteristics in body composition and physical fitness. Men with T1D, 
however, presented similar clinical characteristics to their control counterparts 
but with lower cardiorespiratory capacity (VO2peak). As previously commented 
in the corresponding section, distinct causes could be involved in this reduction 
of cardiorespiratory capacity, such as metabolic control (Nguyen et al., 2014), 
reduced lung function (William Ricardo Komatsu et al., 2005; Niranjan et al., 
1997) and even small differences in personal fitness trainings that were not 
registered in the studies. Other studies did not confirm this difference in 
VO2peak (Stettler et al., 2006), shedding light on the need for a better 
understanding of this result. Another aspect of our study was that highly active 
men with T1D presented higher indicators of insulin sensitivity than less active 
ones (by eGDR), indicating a beneficial association of physical activity on 
insulin sensitivity. Other studies also addressed this topic by performing clamps 
before and after an exercise interventional study and identifying improvements 
in insulin sensitivity (Wallberg-Henriksson et al., 1982). However, another study 
did not confirm this finding (Ebeling et al., 1995), thus, further investigation is 
required. 
 
Study 2 indicated an attenuated metabolic response to acute exercise in 
patients with T1D. We hypothesized that this response was an effect of insulin. 
It is known that the normal physiological response to exercise is a decrease of 
insulin levels (Powers & Howley, 2015). The identification of an increase in 
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insulin released into the blood stream after acute exercise in T1D was identified 
in Study 2, and it was also observed in a recent study by Mallad and colleagues 
(Mallad et al., 2015). In that study, subjects with T1D treated with insulin pump 
infusion presented plasma insulin concentrations that increased during 
exercise, despite no changes in insulin pump infusion rates; this phenomenon 
may be attributed to an increased mobilization of insulin from subcutaneous 
depots. A similar hypothesis was formulated in our study, and we suggest that 
this increase in insulin release might explain the observed attenuation in 
lipolysis, proteolysis, glycogenolysis, and oxidative metabolism response. 
Whether the attenuation of metabolic response to acute and intense exercise 
might interfere in the training performance of subjects with T1D remains to be 
elucidated.  
 
Study 3 showed that subjects with T1D presented similar muscle components 
than their non-diabetic counterparts. Results from Study 1, as well as other 
studies (Bergman et al., 2012; Liu et al., 2009), suggested that subjects with 
T1D may present different degrees of insulin resistance. This insulin resistance 
may be reflected in muscle components, such as IMCL, and/or mitochondrial 
dysfunction (Stephan Jacob et al., 1999; Gianluca Perseghin et al., 1999; White 
et al., 2006). Study 3 was not able to demonstrate differences in the parameters 
studied in the muscles, probably because our subjects presented body 
composition in normal range and no other comorbidities. However, we were 
able to demonstrate that, in soleus muscle, IMCL was related to body fat 
composition and carnosine, an intramyocellular buffer. In our study, the 
cardiorespiratory capacity had no direct association with IMCL, as was the case 
in other studies (Coen & Goodpaster, 2012). However, it did have a negative 
association of cardiorespiratory fitness (VO2peak) with body composition, and 
also a negative association of VO2peak with carnosine in the soleus muscle of 
control subjects, suggesting some association of better fitness and less 
carnosine amount and/or expression. 
 
In Study 4, we found that subjects with T1D presented a lipoprotein profile 
classically associated with cardio-protection as compared with the control 
group. Some studies described that subjects with T1D that present an adequate 
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glycemic control may present more cardioprotective aspects than the ones with 
inadequate control (Jenkins et al., 2003; Lehmann et al., 1997), which is 
probably related to the effects of insulin (Vergès, 2009). In our study, we were 
able to improve the knowledge about lipoprotein profile using 1H NMR 
techniques to achieve more information about its particles and sub-fractions. In 
this cross-sectional study, we were not able to identify lipoprotein association 
with cardiorespiratory capacity (VO2peak), except for one single negative 
correlation with large LDL particles in T1D. Some clinical trials demonstrated 
reductions in LDL-C and Apo-B (Laaksonen et al., 2000) and increases in HDL-
C (Rigla et al., 2000) after a 3 month program of aerobic exercise. Nonetheless, 
we found that the increase in body fat composition was associated with a less 
cardioprotective lipoprotein profile, especially related to LDL and HDL particles 
and subfractions (cholesterol components) in T1D and HDL particles and 
subfractions (cholesterol and triglyceride components) in controls, despite the 
normal body mass composition (BMI) of the subjects. Such worsening in 
cardioprotective lipid profile was observed in studies like EURODIAB (Ferriss et 
al., 2006) and DCCT (Purnell et al., 1998). In the EURODIAB study, 
cardioprotective lipid profile worsened in patients whose weight increased by 5 
kg or more. In the DCCT study, this worsening occurred in patients undergoing 
intensive treatment who were in the fourth quartile of weight gain and whose 
BMI increased from 24 to 31 kg/m2 by the end of the study. We again highlight 
that our patients with T1D presented normal BMI, but even their slightly higher 
values in weight and/or body fat composition were enough to change their 
lipoprotein profile. 
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VII. CONCLUSIONS 
  
  
Conclusions 
 
 
 
- The metabolic responses of lipolysis, proteolysis, glycogenolysis and oxidative 
metabolism to acute exercise in patients with T1D are attenuated. This 
phenomenon may be attributed to the exogenous administration of insulin.  
 
 
- Subjects with T1D with good glycemic control and body fat composition 
presented a lipoprotein profile classically associated with cardio-protection.  
 
 
- Small increases in BMI and/or body fat composition were enough to establish 
alterations in lipoprotein serum profiles and muscular lipid content. 
 
 
- Subjects with highly active physical habits had better body fat composition, 
although physical activity did not correlate with lipoprotein profile or muscular 
lipid content. 
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Annex 1 
 
 
Spanish version 
CUESTIONARIO INTERNACIONAL DE ACTIVIDAD FÍSICA 
 
Estamos interesados en saber acerca de la clase de actividad física que la gente hace 
como parte de su vida diaria. Las preguntas se referirán acerca del tiempo que usted 
utilizó siendo físicamente activo(a) en los últimos 7 días. Por favor responda cada 
pregunta aún si usted no se considera una persona activa. Por favor piense en 
aquellas actividades que usted hace como parte del trabajo, en el jardín y en la casa, 
para ir de un sitio a otro, y en su tiempo libre de descanso, ejercicio o deporte. 
 
Piense acerca de todas aquellas actividades vigorosas que usted realizó en los 
últimos 7 días. Actividades vigorosas son las que requieren un esfuerzo físico fuerte 
y le hacen respirar mucho más fuerte que lo normal. Piense solamente en esas 
actividades que usted hizo por lo menos 10 minutos continuos. 
 
1. Durante los últimos 7 días, ¿Cuántos días realizó usted actividades físicas 
vigorosas como levantar objetos pesados, excavar, aeróbicos, o pedalear 
rápido en bicicleta?  
 
_____ días por semana  
 
   Ninguna actividad física vigorosa  Pase a la pregunta 3 
 
 
2. ¿Cuánto tiempo en total usualmente le tomó realizar actividades físicas 
vigorosas en uno de esos días que las realizó? 
 
_____ horas por día  
_____ minutos por día  
 
  No sabe/No está seguro(a)  
 
 
Piense acerca de todas aquellas actividades moderadas que usted realizo en los 
últimos 7 días.  Actividades moderadas son aquellas que requieren un esfuerzo 
físico moderado y le hace respirar algo más fuerte que lo normal. Piense solamente en 
esas actividades que usted hizo por lo menos 10 minutos continuos.  
 
 
3. Durante los últimos 7 días, ¿Cuántos días hizo usted actividades físicas 
moderadas tal como cargar objetos livianos, pedalear en bicicleta a paso 
regular, o jugar dobles de tenis? No incluya caminatas. 
 
_____ días por semana 
 
   Ninguna actividad física moderada         Pase a la pregunta 5 
 
 
4. Usualmente, ¿Cuánto tiempo dedica usted en uno de esos días haciendo 
actividades físicas moderadas? 
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_____ horas por día 
_____ minutos por día 
 
  No sabe/No está seguro(a)  
 
 
Piense acerca del tiempo que usted dedicó a caminar en los últimos 7 días.  Esto 
incluye trabajo en la casa, caminatas para ir de un sitio a otro, o cualquier otra 
caminata que usted hizo únicamente por recreación, deporte, ejercicio, o placer. 
 
5. Durante los últimos 7 días, ¿Cuántos días caminó usted por al menos 10 
minutos continuos?   
 
_____ días por semana 
  
   No caminó     Pase a la pregunta 7 
 
 
6. Usualmente, ¿Cuánto tiempo gastó usted en uno de esos días caminando? 
 
_____ horas por día 
_____ minutos por día  
 
  No sabe/No está seguro(a)  
 
 
La última pregunta se refiere al tiempo que usted permaneció sentado(a) en la 
semana en los últimos 7 días. Incluya el tiempo sentado(a) en el trabajo, la casa, 
estudiando, y en su tiempo libre. Esto puede incluir tiempo sentado(a) en un escritorio, 
visitando amigos(as), leyendo o permanecer sentado(a) o acostado(a) mirando 
televisión. 
 
7. Durante los últimos 7 días, ¿Cuánto tiempo permaneció sentado(a) en un día 
en la semana? 
  
_____ horas por día  
_____ minutos por día  
 
  No sabe/No está seguro(a)  
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- English version 
 
INTERNATIONAL PHYSICAL ACTIVITY QUESTIONNAIRE 
 
We are interested in finding out about the kinds of physical activities that people 
do as part of their everyday lives.  The questions will ask you about the time you 
spent being physically active in the last 7 days.  Please answer each question 
even if you do not consider yourself to be an active person.  Please think about 
the activities you do at work, as part of your house and yard work, to get from 
place to place, and in your spare time for recreation, exercise or sport. 
 
Think about all the vigorous activities that you did in the last 7 days.  
Vigorous physical activities refer to activities that take hard physical effort and 
make you breathe much harder than normal.  Think only about those physical 
activities that you did for at least 10 minutes at a time. 
 
1. During the last 7 days, on how many days did you do vigorous physical 
activities like heavy lifting, digging, aerobics, or fast bicycling?  
 
_____ days per week  
 
   No vigorous physical activities  Skip to question 3 
 
 
2. How much time did you usually spend doing vigorous physical activities on 
one of those days? 
 
_____ hours per day  
_____ minutes per day  
 
  Don’t know/Not sure  
 
 
Think about all the moderate activities that you did in the last 7 days.  
Moderate activities refer to activities that take moderate physical effort and 
make you breathe somewhat harder than normal.  Think only about those 
physical activities that you did for at least 10 minutes at a time. 
 
 
3. During the last 7 days, on how many days did you do moderate physical 
activities like carrying light loads, bicycling at a regular pace, or doubles tennis?  
Do not include walking. 
 
_____ days per week 
 
   No moderate physical activities  Skip to question 5 
 
 
4. How much time did you usually spend doing moderate physical activities on 
one of those days? 
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_____ hours per day 
_____ minutes per day 
 
  Don’t know/Not sure  
 
 
Think about the time you spent walking in the last 7 days.  This includes at 
work and at home, walking to travel from place to place, and any other walking 
that you have done solely for recreation, sport, exercise, or leisure. 
 
5. During the last 7 days, on how many days did you walk for at least 10 
minutes at a time?   
 
_____ days per week 
  
   No walking     Skip to question 7 
 
 
6. How much time did you usually spend walking on one of those days? 
 
_____ hours per day 
_____ minutes per day  
 
  Don’t know/Not sure  
 
 
The last question is about the time you spent sitting on weekdays during the 
last 7 days.  Include time spent at work, at home, while doing course work and 
during leisure time.  This may include time spent sitting at a desk, visiting 
friends, reading, or sitting or lying down to watch television. 
 
7. During the last 7 days, how much time did you spend sitting on a week 
day? 
 
_____ hours per day  
_____ minutes per day  
 
  Don’t know/Not sure  
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